{
  "title": "Actualización sobre medicamentos anticonvulsivos 2025",
  "guid": "3DFBC87737B335503A3E79C1",
  "filepath": "/sessions/bold-jolly-cerf/mnt/Dropbox/- Esquemas/- Entidades clínicas/Neurología/Continuum. Actualización sobre medicamentos anticonvulsivos-2025.smmx",
  "root": {
    "id": "0",
    "parent": "-1",
    "text": "Actualización sobre medicamentos\nanticonvulsivos 2025",
    "guid": "QcXrIDhW31pCAGrXSxYcuQ",
    "children": [
      {
        "id": "1",
        "parent": "0",
        "text": "## INTRODUCCIÓN",
        "guid": "",
        "children": [
          {
            "id": "2",
            "parent": "1",
            "text": "- Medicamentos antiepilépticos son la base de la terapia para epilepsia",
            "guid": "BaZtwBmdjfQ4Uj4sIZUVew",
            "children": []
          },
          {
            "id": "3",
            "parent": "1",
            "text": "- Hasta 1993 la elección estaba limitada a 7-8 agentes principales",
            "guid": "wnfJKspd1d3qxdbaY6ygmg",
            "children": []
          },
          {
            "id": "4",
            "parent": "1",
            "text": "- Más de 20 nuevos medicamentos antiepilépticos aprobados y comercializados desde entonces",
            "guid": "RN8hP01kN2AJyyBRzLObaQ",
            "children": []
          },
          {
            "id": "5",
            "parent": "1",
            "text": "- Gran variedad requiere\norientación para:",
            "guid": "oA3isUWxGRBSXZCbjB4DFA",
            "children": [
              {
                "id": "6",
                "parent": "5",
                "text": "- Terapia inicial",
                "guid": "bOmA1RV_KJAkOSIYhMMDhQ",
                "children": []
              },
              {
                "id": "7",
                "parent": "5",
                "text": "- Monoterapia de reemplazo posterior",
                "guid": "D9ToXcDrS4iwufl4eVzpZQ",
                "children": []
              },
              {
                "id": "8",
                "parent": "5",
                "text": "- Terapia adyuvante",
                "guid": "ZjLBjsdO68ztwgoU0nZmAg",
                "children": []
              }
            ]
          },
          {
            "id": "9",
            "parent": "1",
            "text": "## CONSIDERACIONES EN LA\nELECCIÓN DE MEDICAMENTOS",
            "guid": "3Sd1zlurjiYwiIeiznWJ8g",
            "children": [
              {
                "id": "10",
                "parent": "9",
                "text": "- Espectro de eficacia",
                "guid": "ebnxTUF6oRs6x5MXQvNuAg",
                "children": []
              },
              {
                "id": "11",
                "parent": "9",
                "text": "- Propiedades farmacocinéticas",
                "guid": "RMJr7ZGPStIONqP81g0p3A",
                "children": []
              },
              {
                "id": "12",
                "parent": "9",
                "text": "- Perfil de seguridad y tolerabilidad",
                "guid": "06SxJmQByRBcMuwb49AiYw",
                "children": []
              },
              {
                "id": "13",
                "parent": "9",
                "text": "- Eficacia contra comorbilidades relevantes para el paciente",
                "guid": "kbvoU1ac-45zv68-2QlkMg",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "14",
        "parent": "0",
        "text": "## MEDICAMENTOS\nY SU EFICACIA",
        "guid": "WyDnkOoP09BK3KZAmgvCkQ",
        "children": [
          {
            "id": "15",
            "parent": "14",
            "text": "### Brivaracetam",
            "guid": "tN42_MW2BG7kgMp-leQGdg",
            "children": [
              {
                "id": "16",
                "parent": "15",
                "text": "- Focal: Class I trials",
                "guid": "3WQvJruWpCBpV5eyOOgVWQ",
                "children": []
              },
              {
                "id": "17",
                "parent": "15",
                "text": "- Tónico-clónicas generalizadas: Unknown",
                "guid": "OLwpJXUew5SZFQHB1c65tw",
                "children": []
              },
              {
                "id": "18",
                "parent": "15",
                "text": "- Ausencias generalizadas: Unknown",
                "guid": "wo7_jxVV2hbnsAHzNuPBbw",
                "children": []
              },
              {
                "id": "19",
                "parent": "15",
                "text": "- Mioclónicas generalizadas: Unknown",
                "guid": "EV4uqa0BfyypsUI7BEDltg",
                "children": []
              }
            ]
          },
          {
            "id": "20",
            "parent": "14",
            "text": "### Carbamazepina",
            "guid": "gjEV9HsW7vP2PNH9qlD7HA",
            "children": [
              {
                "id": "21",
                "parent": "20",
                "text": "- Focal: Class I trials",
                "guid": "Wp9bVFCeQkmDk8f0x0c6Dg",
                "children": []
              },
              {
                "id": "22",
                "parent": "20",
                "text": "- Tónico-clónicas generalizadas: Suggested, but not proven in Class I trials",
                "guid": "nx1Ccb2Obm_BrO0kO-jqeg",
                "children": []
              },
              {
                "id": "23",
                "parent": "20",
                "text": "- Ausencias generalizadas: Not effective",
                "guid": "s13066aj-Z1MzoabhkrO5A",
                "children": []
              },
              {
                "id": "24",
                "parent": "20",
                "text": "- Mioclónicas generalizadas: Not effective",
                "guid": "P4y8RyMWmSflqTbMGvK8lw",
                "children": []
              }
            ]
          },
          {
            "id": "25",
            "parent": "14",
            "text": "### Cannabidiol",
            "guid": "3vRv25FkFynI7ZZrR0mLwg",
            "children": [
              {
                "id": "26",
                "parent": "25",
                "text": "- Focal: Class IV evidence",
                "guid": "IxQDPT17Y3AJo6RW73VpOA",
                "children": []
              },
              {
                "id": "27",
                "parent": "25",
                "text": "- Tónico-clónicas generalizadas: Unknown",
                "guid": "SizWDij8q-1wIlTIu4t4OQ",
                "children": []
              },
              {
                "id": "28",
                "parent": "25",
                "text": "- Ausencias generalizadas: Unknown",
                "guid": "j4xIN0VafjQcaT9iKNs39w",
                "children": []
              },
              {
                "id": "29",
                "parent": "25",
                "text": "- Mioclónicas generalizadas: Unknown",
                "guid": "aELJvSmrChl_OYeDDueq2g",
                "children": []
              },
              {
                "id": "30",
                "parent": "25",
                "text": "- Otros: Class I trials in Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis",
                "guid": "xmnZ7T0KIJWAiH9c9cvwiQ",
                "children": []
              }
            ]
          },
          {
            "id": "31",
            "parent": "14",
            "text": "### Cenobamate",
            "guid": "M76CGPwD4-r7usa5Sobczg",
            "children": [
              {
                "id": "32",
                "parent": "31",
                "text": "- Focal: Class I trials",
                "guid": "h1f-bnWS35_apjTqV6KMLg",
                "children": []
              },
              {
                "id": "33",
                "parent": "31",
                "text": "- Tónico-clónicas generalizadas: Unknown",
                "guid": "biOc_wu7OmhUgTk-fREbGQ",
                "children": []
              },
              {
                "id": "34",
                "parent": "31",
                "text": "- Ausencias generalizadas: Unknown",
                "guid": "QS5iXeft52hapV_tpns06w",
                "children": []
              },
              {
                "id": "35",
                "parent": "31",
                "text": "- Mioclónicas generalizadas: Unknown",
                "guid": "5xdEzEG58UIFDPNh5CcM4A",
                "children": []
              }
            ]
          },
          {
            "id": "36",
            "parent": "14",
            "text": "### Clobazam",
            "guid": "0pvI-xvfsQPfdGC1y9QoMw",
            "children": [
              {
                "id": "37",
                "parent": "36",
                "text": "- Focal: Suggested, but not proven in Class I trials",
                "guid": "3-MJ9FMMg-5OyiFNcYMGUg",
                "children": []
              },
              {
                "id": "38",
                "parent": "36",
                "text": "- Tónico-clónicas generalizadas: Suggested, but not proven in Class I trials",
                "guid": "qDOmj03QS7tHLC6k3QUw2Q",
                "children": []
              },
              {
                "id": "39",
                "parent": "36",
                "text": "- Ausencias generalizadas: Suggested, but not proven in Class I trials",
                "guid": "lbcArlYPHrGKPQWuQ5N1EQ",
                "children": []
              },
              {
                "id": "40",
                "parent": "36",
                "text": "- Mioclónicas generalizadas: Suggested, but not proven in Class I trials",
                "guid": "uKocAAImKb4IN2iXGSKzog",
                "children": []
              },
              {
                "id": "41",
                "parent": "36",
                "text": "- Otros: Class I trials in Lennox-Gastaut syndrome",
                "guid": "gfLvP48NDRJi0A8sqF9PBg",
                "children": []
              }
            ]
          },
          {
            "id": "42",
            "parent": "14",
            "text": "### Eslicarbazepina\nacetato",
            "guid": "AuJusBJ13aP3OGTZKCCa5g",
            "children": [
              {
                "id": "43",
                "parent": "42",
                "text": "- Focal: Class I trials",
                "guid": "B8nrfbQ-aM5c52nDk7Uj4g",
                "children": []
              },
              {
                "id": "44",
                "parent": "42",
                "text": "- Tónico-clónicas generalizadas: Unknown",
                "guid": "ZiyF-bytjzIB064UTeGouQ",
                "children": []
              },
              {
                "id": "45",
                "parent": "42",
                "text": "- Ausencias generalizadas: Not effective",
                "guid": "Tj3ASpPXMhte7LImoyhgOA",
                "children": []
              },
              {
                "id": "46",
                "parent": "42",
                "text": "- Mioclónicas generalizadas: Not effective",
                "guid": "y54Gi20RRHlnuChZyjASxg",
                "children": []
              }
            ]
          },
          {
            "id": "47",
            "parent": "14",
            "text": "### Etosuximida",
            "guid": "okaykbo39sC-ZCkMsKd9kQ",
            "children": [
              {
                "id": "48",
                "parent": "47",
                "text": "- Focal: Not effective",
                "guid": "xOD4eXFUASY_VDYTIEY6eQ",
                "children": []
              },
              {
                "id": "49",
                "parent": "47",
                "text": "- Tónico-clónicas generalizadas: Not effective",
                "guid": "ma9VGa-YRHP42PLNic5ASA",
                "children": []
              },
              {
                "id": "50",
                "parent": "47",
                "text": "- Ausencias generalizadas: Class I trials",
                "guid": "w5tiJqQflEZcKYmZGB0ogA",
                "children": []
              },
              {
                "id": "51",
                "parent": "47",
                "text": "- Mioclónicas generalizadas: Not effective",
                "guid": "V3b2clLJMy_X0MbA6lWh7Q",
                "children": []
              }
            ]
          },
          {
            "id": "52",
            "parent": "14",
            "text": "### Felbamato",
            "guid": "qT-Z-Froxnf8QTUKAgX-VQ",
            "children": [
              {
                "id": "53",
                "parent": "52",
                "text": "- Focal: Class I trials",
                "guid": "sbHBfl559oSwiUPyCVzmOg",
                "children": []
              },
              {
                "id": "54",
                "parent": "52",
                "text": "- Tónico-clónicas generalizadas: Suggested, but not proven in Class I trials",
                "guid": "u9o_8_vs50Itbmnd9Px23A",
                "children": []
              },
              {
                "id": "55",
                "parent": "52",
                "text": "- Ausencias generalizadas: Unknown",
                "guid": "6OekkzGD48_UHqiXuIJeug",
                "children": []
              },
              {
                "id": "56",
                "parent": "52",
                "text": "- Mioclónicas generalizadas: Unknown",
                "guid": "8i0pzJSIbsvHniEJHFO2qw",
                "children": []
              },
              {
                "id": "57",
                "parent": "52",
                "text": "- Otros: Class I trial in Lennox-Gastaut syndrome",
                "guid": "D1Gyf66SqZH_bl4M3iwmPA",
                "children": []
              }
            ]
          },
          {
            "id": "58",
            "parent": "14",
            "text": "### Fenfluramina",
            "guid": "wiCaHTvJ1z8oLUFX-x3w9g",
            "children": [
              {
                "id": "59",
                "parent": "58",
                "text": "- Focal: Unknown",
                "guid": "7OQJTboFrd746k2Wh2ORGw",
                "children": []
              },
              {
                "id": "60",
                "parent": "58",
                "text": "- Tónico-clónicas generalizadas: Unknown",
                "guid": "RjfhkUFmsLdTOBG_ZOl6pQ",
                "children": []
              },
              {
                "id": "61",
                "parent": "58",
                "text": "- Ausencias generalizadas: Unknown",
                "guid": "BkluscosKElVFzsHr4vx5g",
                "children": []
              },
              {
                "id": "62",
                "parent": "58",
                "text": "- Mioclónicas generalizadas: Unknown",
                "guid": "7p63Oi1oGuCtqkVjr9IG8w",
                "children": []
              },
              {
                "id": "63",
                "parent": "58",
                "text": "- Otros: Class I trial in Dravet syndrome and Lennox-Gastaut syndrome",
                "guid": "Bmt6uvRaUug75hB0SvuYVw",
                "children": []
              }
            ]
          },
          {
            "id": "64",
            "parent": "14",
            "text": "### Gabapentina",
            "guid": "SnNwO1CCHp2TvnMDFQ6IIA",
            "children": [
              {
                "id": "65",
                "parent": "64",
                "text": "- Focal: Class I trials",
                "guid": "yunX_oCeuzpWtSD9x3blDw",
                "children": []
              },
              {
                "id": "66",
                "parent": "64",
                "text": "- Tónico-clónicas generalizadas: Not effective",
                "guid": "yfEP2e4ypdta0KmVhvWgUg",
                "children": []
              },
              {
                "id": "67",
                "parent": "64",
                "text": "- Ausencias generalizadas: Not effective",
                "guid": "O44pDPNTCRibnj2grlX-gw",
                "children": []
              },
              {
                "id": "68",
                "parent": "64",
                "text": "- Mioclónicas generalizadas: Not effective",
                "guid": "tBfKCcv9Mshabi5_mOjs5Q",
                "children": []
              }
            ]
          },
          {
            "id": "69",
            "parent": "14",
            "text": "### Ganaxolona",
            "guid": "XAYCAjfxmj4yzgsZPspGLw",
            "children": [
              {
                "id": "70",
                "parent": "69",
                "text": "- Focal: Unknown",
                "guid": "b0kwk9K7SkYKkKgjjdr4_w",
                "children": []
              },
              {
                "id": "71",
                "parent": "69",
                "text": "- Tónico-clónicas generalizadas: Unknown",
                "guid": "aL2gC5n905wy88fLmBE25g",
                "children": []
              },
              {
                "id": "72",
                "parent": "69",
                "text": "- Ausencias generalizadas: Unknown",
                "guid": "qVPM85lKcne-FrkwS9I3IQ",
                "children": []
              },
              {
                "id": "73",
                "parent": "69",
                "text": "- Mioclónicas generalizadas: Unknown",
                "guid": "vfH6YHcuqt-0q3-INPYouQ",
                "children": []
              },
              {
                "id": "74",
                "parent": "69",
                "text": "- Otros: Class I trial in cyclin-dependent kinase-like 5 deficiency disorder",
                "guid": "V2EEEHbrpBVhUWOvv6c_Pw",
                "children": []
              }
            ]
          },
          {
            "id": "75",
            "parent": "14",
            "text": "### Lacosamida",
            "guid": "yzaxMZhraEbg4aPfJErofQ",
            "children": [
              {
                "id": "76",
                "parent": "75",
                "text": "- Focal: Class I trials",
                "guid": "RmkLjDvQuLqH2SfRHaojkA",
                "children": []
              },
              {
                "id": "77",
                "parent": "75",
                "text": "- Tónico-clónicas generalizadas: Class I trials",
                "guid": "UMPL-ZrcFLW-9OgVmS-DXw",
                "children": []
              },
              {
                "id": "78",
                "parent": "75",
                "text": "- Ausencias generalizadas: Not effective",
                "guid": "ROaiPwYYTT0mMAbGgz9UQA",
                "children": []
              },
              {
                "id": "79",
                "parent": "75",
                "text": "- Mioclónicas generalizadas: Not effective",
                "guid": "g0DMHGJOa3oLdIvzbnmF_g",
                "children": []
              }
            ]
          },
          {
            "id": "80",
            "parent": "14",
            "text": "### Lamotrigina",
            "guid": "Goj_1iCa9vGKAi1a1ciNAQ",
            "children": [
              {
                "id": "81",
                "parent": "80",
                "text": "- Focal: Class I trials",
                "guid": "N2Wz8-ug43iNjzFk0crT1A",
                "children": []
              },
              {
                "id": "82",
                "parent": "80",
                "text": "- Tónico-clónicas generalizadas: Class I trials",
                "guid": "npnp6Nuw8puUeSya46TReA",
                "children": []
              },
              {
                "id": "83",
                "parent": "80",
                "text": "- Ausencias generalizadas: Suggested, but not proven in Class I trials",
                "guid": "J8bFt7zhWLsv2Lci_6f7lg",
                "children": []
              },
              {
                "id": "84",
                "parent": "80",
                "text": "- Mioclónicas generalizadas: Variable",
                "guid": "7WwnC5pku5nq9ZEaJoMBWQ",
                "children": []
              },
              {
                "id": "85",
                "parent": "80",
                "text": "- Otros: Class I trial in Lennox-Gastaut syndrome",
                "guid": "r3sRsWt5hJbqnBFSEXfh_Q",
                "children": []
              }
            ]
          },
          {
            "id": "86",
            "parent": "14",
            "text": "### Levetiracetam",
            "guid": "7Zb5w2v0RqS_aGIpW6ttJQ",
            "children": [
              {
                "id": "87",
                "parent": "86",
                "text": "- Focal: Class I trials",
                "guid": "IrWnfAK9PCrG6mnYBDT0_g",
                "children": []
              },
              {
                "id": "88",
                "parent": "86",
                "text": "- Tónico-clónicas generalizadas: Class I trials",
                "guid": "eg8F7vjQdv3tW_cO-qb_bg",
                "children": []
              },
              {
                "id": "89",
                "parent": "86",
                "text": "- Ausencias generalizadas: Suggested, but not proven in Class I trials",
                "guid": "84uZkRY_C1MzHinezSPeqw",
                "children": []
              },
              {
                "id": "90",
                "parent": "86",
                "text": "- Mioclónicas generalizadas: Class I trials",
                "guid": "Znff6vDl6slvdy-m3eNA4A",
                "children": []
              }
            ]
          },
          {
            "id": "91",
            "parent": "14",
            "text": "### Oxcarbazepina",
            "guid": "fPpxaUNmWeAKszxzxdAmiQ",
            "children": [
              {
                "id": "92",
                "parent": "91",
                "text": "- Focal: Class I trials",
                "guid": "1jPFPtIUAfHUYr2U-Y2RdA",
                "children": []
              },
              {
                "id": "93",
                "parent": "91",
                "text": "- Tónico-clónicas generalizadas: Unknown",
                "guid": "1xH4xpHF5r1A_gJmoxF4wQ",
                "children": []
              },
              {
                "id": "94",
                "parent": "91",
                "text": "- Ausencias generalizadas: Not effective",
                "guid": "Y_lB80RpprfPKmriBYAJrg",
                "children": []
              },
              {
                "id": "95",
                "parent": "91",
                "text": "- Mioclónicas generalizadas: Not effective",
                "guid": "ToFlBAQaaj9TIV3l4xYYDg",
                "children": []
              }
            ]
          },
          {
            "id": "96",
            "parent": "14",
            "text": "### Perampanel",
            "guid": "ukcOX4ATR75DU51gqSKPxA",
            "children": [
              {
                "id": "97",
                "parent": "96",
                "text": "- Focal: Class I trials",
                "guid": "Oob1D31kzCydTun246TWsw",
                "children": []
              },
              {
                "id": "98",
                "parent": "96",
                "text": "- Tónico-clónicas generalizadas: Class I trials",
                "guid": "RrZNvDJA9mVxf2prq296_A",
                "children": []
              },
              {
                "id": "99",
                "parent": "96",
                "text": "- Ausencias generalizadas: Unknown",
                "guid": "xXaBcWxp_ixqUogYdHoNaQ",
                "children": []
              },
              {
                "id": "100",
                "parent": "96",
                "text": "- Mioclónicas generalizadas: Class IV evidence",
                "guid": "34cJw5cGw4OmwWXLe3ROHg",
                "children": []
              }
            ]
          },
          {
            "id": "101",
            "parent": "14",
            "text": "### Fenobarbital",
            "guid": "hne4wvCWTFFqGh0Nqtt5Nw",
            "children": [
              {
                "id": "102",
                "parent": "101",
                "text": "- Focal: Class I trials",
                "guid": "iAIq9a5jDydSmAXL1_fOMg",
                "children": []
              },
              {
                "id": "103",
                "parent": "101",
                "text": "- Tónico-clónicas generalizadas: Suggested, but not proven in Class I trials",
                "guid": "32nDbMci1yVcuoYYSs-DQQ",
                "children": []
              },
              {
                "id": "104",
                "parent": "101",
                "text": "- Ausencias generalizadas: Not effective",
                "guid": "VfKcbOtHWVMcSLAt1YYTYA",
                "children": []
              },
              {
                "id": "105",
                "parent": "101",
                "text": "- Mioclónicas generalizadas: Class IV evidence",
                "guid": "zt9ikro45sTb0HXaf9Mv0Q",
                "children": []
              }
            ]
          },
          {
            "id": "106",
            "parent": "14",
            "text": "### Fenitoína",
            "guid": "SA4gWaU_Qd71ee9Oa2AQTg",
            "children": [
              {
                "id": "107",
                "parent": "106",
                "text": "- Focal: Class I trials",
                "guid": "22UDq2ff8Y4HE-PScqmJrg",
                "children": []
              },
              {
                "id": "108",
                "parent": "106",
                "text": "- Tónico-clónicas generalizadas: Suggested, but not proven in Class I trials",
                "guid": "-7QtloS07E2JVN7x2xZfFg",
                "children": []
              },
              {
                "id": "109",
                "parent": "106",
                "text": "- Ausencias generalizadas: Not effective",
                "guid": "fW_4hf3q38ewJsGpqcc_yA",
                "children": []
              },
              {
                "id": "110",
                "parent": "106",
                "text": "- Mioclónicas generalizadas: Not effective",
                "guid": "_jaYBkMJ6yjg2HPW3o-CxA",
                "children": []
              }
            ]
          },
          {
            "id": "111",
            "parent": "14",
            "text": "### Pregabalina",
            "guid": "osObfSFrVXwWI72UjtSF2g",
            "children": [
              {
                "id": "112",
                "parent": "111",
                "text": "- Focal: Class I trials",
                "guid": "N24NrbmGmcWaZOGxSs5M0A",
                "children": []
              },
              {
                "id": "113",
                "parent": "111",
                "text": "- Tónico-clónicas generalizadas: Not effective",
                "guid": "Kp0u1B3qnxLV3lNMseeqWA",
                "children": []
              },
              {
                "id": "114",
                "parent": "111",
                "text": "- Ausencias generalizadas: Not effective",
                "guid": "kjXA-FyQlucKz2Ci5yPK_g",
                "children": []
              },
              {
                "id": "115",
                "parent": "111",
                "text": "- Mioclónicas generalizadas: Not effective",
                "guid": "KGR6ibgfCP10U-kO6Ripcw",
                "children": []
              }
            ]
          },
          {
            "id": "116",
            "parent": "14",
            "text": "### Rufinamida",
            "guid": "ujmiqI_dT7feoVZNvZfl-w",
            "children": [
              {
                "id": "117",
                "parent": "116",
                "text": "- Focal: Class I trials, but not FDA approved",
                "guid": "TknANZ-PqFaewidn_K5LNw",
                "children": []
              },
              {
                "id": "118",
                "parent": "116",
                "text": "- Tónico-clónicas generalizadas: Suggested, but not proven in Class I trials",
                "guid": "LqmLq7hx-c_TzTgIvUQ_XA",
                "children": []
              },
              {
                "id": "119",
                "parent": "116",
                "text": "- Ausencias generalizadas: Unknown",
                "guid": "FUbnWvAC_QSiXnZp9G13NQ",
                "children": []
              },
              {
                "id": "120",
                "parent": "116",
                "text": "- Mioclónicas generalizadas: Unknown",
                "guid": "OdvXkw21yFCxOMj4AdfdPw",
                "children": []
              },
              {
                "id": "121",
                "parent": "116",
                "text": "- Otros: Class I trial in Lennox-Gastaut syndrome",
                "guid": "o8pMb89QtEuBwjtWZLoSLQ",
                "children": []
              }
            ]
          },
          {
            "id": "122",
            "parent": "14",
            "text": "### Stiripentol",
            "guid": "qHBEBjp4f8dPh8ocbaftZg",
            "children": [
              {
                "id": "123",
                "parent": "122",
                "text": "- Focal: Unknown",
                "guid": "BuaaFBkNPGJYwH7470UVnQ",
                "children": []
              },
              {
                "id": "124",
                "parent": "122",
                "text": "- Tónico-clónicas generalizadas: Unknown",
                "guid": "d5UTOuXuefBXzjf8vBzqbw",
                "children": []
              },
              {
                "id": "125",
                "parent": "122",
                "text": "- Ausencias generalizadas: Unknown",
                "guid": "0dJqVIxXajkjh6SX_k8rng",
                "children": []
              },
              {
                "id": "126",
                "parent": "122",
                "text": "- Mioclónicas generalizadas: Unknown",
                "guid": "mTeIv-w5mR8bWRva6ndRyw",
                "children": []
              },
              {
                "id": "127",
                "parent": "122",
                "text": "- Otros: Class I trials in Dravet syndrome",
                "guid": "IF14P3ELnBf7qMz9wZ77ew",
                "children": []
              }
            ]
          },
          {
            "id": "128",
            "parent": "14",
            "text": "### Tiagabina",
            "guid": "PgPyurk_arlTV8diZRjuSA",
            "children": [
              {
                "id": "129",
                "parent": "128",
                "text": "- Focal: Class I trials",
                "guid": "U4_jad8Erg948AgtR2Gw2Q",
                "children": []
              },
              {
                "id": "130",
                "parent": "128",
                "text": "- Tónico-clónicas generalizadas: Not effective",
                "guid": "lorHZ3zxJmkgvoMRFsJBmQ",
                "children": []
              },
              {
                "id": "131",
                "parent": "128",
                "text": "- Ausencias generalizadas: Not effective",
                "guid": "XeJoS35_STCgPI-X87SofA",
                "children": []
              },
              {
                "id": "132",
                "parent": "128",
                "text": "- Mioclónicas generalizadas: Not effective",
                "guid": "spMrBPK12LwjNXPR0BlZRg",
                "children": []
              }
            ]
          },
          {
            "id": "133",
            "parent": "14",
            "text": "### Topiramato",
            "guid": "i2Gio_Tbv-Dsun2g2yUEzg",
            "children": [
              {
                "id": "134",
                "parent": "133",
                "text": "- Focal: Class I trials",
                "guid": "GgU6sw9hedMl4HL9KsI6Sg",
                "children": []
              },
              {
                "id": "135",
                "parent": "133",
                "text": "- Tónico-clónicas generalizadas: Class I trials",
                "guid": "Ckkiwn_VSfNE-QYvkEGt3Q",
                "children": []
              },
              {
                "id": "136",
                "parent": "133",
                "text": "- Ausencias generalizadas: Not effective in one Class I trial",
                "guid": "ai1Mtz2CgeaLJRj2jXwEdQ",
                "children": []
              },
              {
                "id": "137",
                "parent": "133",
                "text": "- Mioclónicas generalizadas: Unknown",
                "guid": "IhIYp-ZFzh5se2VKw4ZBDw",
                "children": []
              },
              {
                "id": "138",
                "parent": "133",
                "text": "- Otros: Class I trial in Lennox-Gastaut syndrome",
                "guid": "4iLrFbMku2W5rew_HDT23w",
                "children": []
              }
            ]
          },
          {
            "id": "139",
            "parent": "14",
            "text": "### Valproato",
            "guid": "U-Mv0aBn9tmM3-2UBKoZ0A",
            "children": [
              {
                "id": "140",
                "parent": "139",
                "text": "- Focal: Class I trials",
                "guid": "vOa0VT2VMD3YzbTBu9QtGA",
                "children": []
              },
              {
                "id": "141",
                "parent": "139",
                "text": "- Tónico-clónicas generalizadas: Suggested, but not proven in Class I trials",
                "guid": "r_gDFRjOnzkQ_X0_QV5Sgg",
                "children": []
              },
              {
                "id": "142",
                "parent": "139",
                "text": "- Ausencias generalizadas: Class I trials",
                "guid": "VcUVhgD7VXNrhtfmjwMpnA",
                "children": []
              },
              {
                "id": "143",
                "parent": "139",
                "text": "- Mioclónicas generalizadas: Suggested, but not proven in Class I trials",
                "guid": "jQh9f4VRwPQjxV6KA-cfQA",
                "children": []
              },
              {
                "id": "144",
                "parent": "139",
                "text": "- Otros: Suggested, but not proven in Class I trials",
                "guid": "o2Aeajmyk7eDVa0NASw9Vg",
                "children": []
              }
            ]
          },
          {
            "id": "145",
            "parent": "14",
            "text": "### Vigabatrina",
            "guid": "k4nj9UgjV8Cum4Peyd5mzg",
            "children": [
              {
                "id": "146",
                "parent": "145",
                "text": "- Focal: Class I trials",
                "guid": "BPwv5BbCK2Hcq1ggwv1IWA",
                "children": []
              },
              {
                "id": "147",
                "parent": "145",
                "text": "- Tónico-clónicas generalizadas: Not effective",
                "guid": "hZGitmHmLpwZd3f3Mp3YdA",
                "children": []
              },
              {
                "id": "148",
                "parent": "145",
                "text": "- Ausencias generalizadas: Not effective",
                "guid": "_UID1hXmJbb-ZaLGeCG9iA",
                "children": []
              },
              {
                "id": "149",
                "parent": "145",
                "text": "- Mioclónicas generalizadas: Not effective",
                "guid": "mDsZXtDg48v_LC8V-7a0fw",
                "children": []
              },
              {
                "id": "150",
                "parent": "145",
                "text": "- Otros: Class I trial in infantile spasms",
                "guid": "1Kvlovk_xYaNMd9UF4LSCQ",
                "children": []
              }
            ]
          },
          {
            "id": "151",
            "parent": "14",
            "text": "### Zonisamida",
            "guid": "S6SLfvIgEEPMIAj8-8HrEg",
            "children": [
              {
                "id": "152",
                "parent": "151",
                "text": "- Focal: Class I trials",
                "guid": "MiFcugr2CprFlv6OSZUjhg",
                "children": []
              },
              {
                "id": "153",
                "parent": "151",
                "text": "- Tónico-clónicas generalizadas: Suggested, but not proven in Class I trials",
                "guid": "vdmVi-qKC7vBqJ-GIsSdog",
                "children": []
              },
              {
                "id": "154",
                "parent": "151",
                "text": "- Ausencias generalizadas: Suggested, but not proven in Class I trials",
                "guid": "L6KRPbAT9pKjQ5H4jzUWSw",
                "children": []
              },
              {
                "id": "155",
                "parent": "151",
                "text": "- Mioclónicas generalizadas: Suggested, but not proven in Class I trials",
                "guid": "wS6euYsGhUTHyCjjMJavuw",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "156",
        "parent": "0",
        "text": "# PROPIEDADES FARMACOCINÉTICAS\nDE MEDICAMENTOS ANTIEPILÉPTICOS",
        "guid": "EhP370IHdTlspTTnPpxL6A",
        "children": [
          {
            "id": "157",
            "parent": "156",
            "text": "## BRIVARACETAM",
            "guid": "6E05fWZZAlRxt-SXr0oXkg",
            "children": [
              {
                "id": "158",
                "parent": "157",
                "text": "- Mecanismos clave: Binding SV2A",
                "guid": "ZsQLyBLpAIcwQL_MO0CugA",
                "children": []
              },
              {
                "id": "159",
                "parent": "157",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "8sWJNlRz0g78z_xbnWZ-uA",
                "children": []
              },
              {
                "id": "160",
                "parent": "157",
                "text": "- Unión a proteínas: Low",
                "guid": "8QPDNiQ9-ayzO9mbei_71Q",
                "children": []
              },
              {
                "id": "161",
                "parent": "157",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "ewHKIlXxlLRToIEiVQC19A",
                "children": []
              },
              {
                "id": "162",
                "parent": "157",
                "text": "- Vida media en adultos: Approximately 7-8 hours",
                "guid": "d7G5DBWfb-hG2S3tTqdHnw",
                "children": []
              },
              {
                "id": "163",
                "parent": "157",
                "text": "- Potencial para inductores o inhibidores: Moderate",
                "guid": "tdja0W_MrAliJtaQdLOd3g",
                "children": []
              }
            ]
          },
          {
            "id": "164",
            "parent": "156",
            "text": "## CARBAMAZEPINA",
            "guid": "bwkymAKO098T8ynwceKW8w",
            "children": [
              {
                "id": "165",
                "parent": "164",
                "text": "- Mecanismos clave: Blocking sodium channels",
                "guid": "R8Ue7Qf3XO5_nfD9kLTbHA",
                "children": []
              },
              {
                "id": "166",
                "parent": "164",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "-WB9GijOkwRMeM3uKDW_Pg",
                "children": []
              },
              {
                "id": "167",
                "parent": "164",
                "text": "- Unión a proteínas: Intermediate",
                "guid": "7rA8vKIs3_d-wug2OdzFNg",
                "children": []
              },
              {
                "id": "168",
                "parent": "164",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "xMGAp_pcB420JrHsbOx9YA",
                "children": []
              },
              {
                "id": "169",
                "parent": "164",
                "text": "- Vida media en adultos: 12-17 hours (after autoinduction is complete)",
                "guid": "_aKFw74UrCFvsHNOD5JPtw",
                "children": []
              },
              {
                "id": "170",
                "parent": "164",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "Exr0aHT_-d_8LPNsTE2euw",
                "children": []
              }
            ]
          },
          {
            "id": "171",
            "parent": "156",
            "text": "## CANNABIDIOL",
            "guid": "J60Ka7f3S5IYvn_T9BufpQ",
            "children": [
              {
                "id": "172",
                "parent": "171",
                "text": "- Mecanismos clave: Enhancing GABA, modulation of intracellular calcium",
                "guid": "2stP6fSWykc9UISl6Fci9Q",
                "children": []
              },
              {
                "id": "173",
                "parent": "171",
                "text": "- Biodisponibilidad oral: Low",
                "guid": "yU7SkLaq-exAH4iO6xBnwA",
                "children": []
              },
              {
                "id": "174",
                "parent": "171",
                "text": "- Unión a proteínas: High",
                "guid": "yjMlFoNXjpbSEbiE-1jTuw",
                "children": []
              },
              {
                "id": "175",
                "parent": "171",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "X3UQW5rdTSNtZ_xd4NMW3Q",
                "children": []
              },
              {
                "id": "176",
                "parent": "171",
                "text": "- Vida media en adultos: 56-61 hours",
                "guid": "3HKyCv0bRplo2Ez0K7V_Tw",
                "children": []
              },
              {
                "id": "177",
                "parent": "171",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "prxuKN03SF1uyJqfGgCJZg",
                "children": []
              }
            ]
          },
          {
            "id": "178",
            "parent": "156",
            "text": "## CENOBAMATE",
            "guid": "6gOPV2xMKk0uFHtgvjhOug",
            "children": [
              {
                "id": "179",
                "parent": "178",
                "text": "- Mecanismos clave: Blocking sodium channels, enhancing GABA",
                "guid": "1MPGms1Bon2H7jrKW8kxaA",
                "children": []
              },
              {
                "id": "180",
                "parent": "178",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "vW87AHWBzXeHz0LNk2VomQ",
                "children": []
              },
              {
                "id": "181",
                "parent": "178",
                "text": "- Unión a proteínas: Intermediate",
                "guid": "GU43gJPTRyCIuyboZig68Q",
                "children": []
              },
              {
                "id": "182",
                "parent": "178",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "A_X_vqGL305Pdiac4jImpA",
                "children": []
              },
              {
                "id": "183",
                "parent": "178",
                "text": "- Vida media en adultos: 50-60 hours",
                "guid": "oYG0uY-Qu6NvKjLWXlX_jw",
                "children": []
              },
              {
                "id": "184",
                "parent": "178",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "W2lZz_VHdr_9PCEG3cBM_w",
                "children": []
              }
            ]
          },
          {
            "id": "185",
            "parent": "156",
            "text": "## CLOBAZAM",
            "guid": "8jiLqqNaGpMyb23tBEaWAQ",
            "children": [
              {
                "id": "186",
                "parent": "185",
                "text": "- Mecanismos clave: Enhancing GABA",
                "guid": "I_DewfxhiKCdBMhzOQ-ixw",
                "children": []
              },
              {
                "id": "187",
                "parent": "185",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "Sdg8WXc0kdWOLs1GCFYsmA",
                "children": []
              },
              {
                "id": "188",
                "parent": "185",
                "text": "- Unión a proteínas: High",
                "guid": "VeHufoKE8sq8MjlogG1pIA",
                "children": []
              },
              {
                "id": "189",
                "parent": "185",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "sL2nqu2cOymAkX00jV_t8g",
                "children": []
              },
              {
                "id": "190",
                "parent": "185",
                "text": "- Vida media en adultos: 10-30 hours, 36-46 hours for active N-desmethylclobazam metabolite",
                "guid": "Xfcs7jMZ1RhAKTCF2UYNZA",
                "children": []
              },
              {
                "id": "191",
                "parent": "185",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "yDtBwLKSdlOJCDa9cJYPJA",
                "children": []
              }
            ]
          },
          {
            "id": "192",
            "parent": "156",
            "text": "## ESLICARBAZEPINA\nACETATO",
            "guid": "nwkUmmhNwMc2CPsPBD-RWA",
            "children": [
              {
                "id": "193",
                "parent": "192",
                "text": "- Mecanismos clave: Blocking sodium channels",
                "guid": "Q3DoBudMlZRuSZ25QMbphQ",
                "children": []
              },
              {
                "id": "194",
                "parent": "192",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "wMsQIhVsmfxtZJzj-UkdHA",
                "children": []
              },
              {
                "id": "195",
                "parent": "192",
                "text": "- Unión a proteínas: Low",
                "guid": "NU1sCRSk7BJpVih_Akhn6Q",
                "children": []
              },
              {
                "id": "196",
                "parent": "192",
                "text": "- Metabolismo/Excreción: Approximately 40% hepatic, 60% renal unchanged",
                "guid": "MimA0KbXF74eqkoCIIXj5A",
                "children": []
              },
              {
                "id": "197",
                "parent": "192",
                "text": "- Vida media en adultos: 13-20 hours",
                "guid": "a_mTcionRpm6u-_svElA7Q",
                "children": []
              },
              {
                "id": "198",
                "parent": "192",
                "text": "- Potencial para inductores o inhibidores: Moderate",
                "guid": "akVjhUSlen3sfRPJLlSKFw",
                "children": []
              }
            ]
          },
          {
            "id": "199",
            "parent": "156",
            "text": "## ETOSUXIMIDA",
            "guid": "fGzKFMlP7Qw44d18gbtVSQ",
            "children": [
              {
                "id": "200",
                "parent": "199",
                "text": "- Mecanismos clave: Blocking T-type calcium channels",
                "guid": "94fDWUI0kCiHKBcrcKQEYA",
                "children": []
              },
              {
                "id": "201",
                "parent": "199",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "bcR0GWIKMeof95z3UyKCKg",
                "children": []
              },
              {
                "id": "202",
                "parent": "199",
                "text": "- Unión a proteínas: Low",
                "guid": "FslHKE-Fwz49uYHCgyrrqQ",
                "children": []
              },
              {
                "id": "203",
                "parent": "199",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "wcn9izs_jZxpAGYH_xN8Rg",
                "children": []
              },
              {
                "id": "204",
                "parent": "199",
                "text": "- Vida media en adultos: 30-60 hours",
                "guid": "v9OG1RkC_6bUxxkjWwZlPg",
                "children": []
              },
              {
                "id": "205",
                "parent": "199",
                "text": "- Potencial para inductores o inhibidores: Moderate",
                "guid": "p3FSltctuGgkr8D8Ex-FXg",
                "children": []
              }
            ]
          },
          {
            "id": "206",
            "parent": "156",
            "text": "## FELBAMATO",
            "guid": "312AKk9QO4WnX8RVShBY5A",
            "children": [
              {
                "id": "207",
                "parent": "206",
                "text": "- Mecanismos clave: NMDA antagonism, blocking sodium channels, enhancing GABA",
                "guid": "HPU5zqT_KaYdLblJayXdxQ",
                "children": []
              },
              {
                "id": "208",
                "parent": "206",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "yb1dvprt6cGkZ72aGw4FKQ",
                "children": []
              },
              {
                "id": "209",
                "parent": "206",
                "text": "- Unión a proteínas: Low",
                "guid": "v1xnDD16wnlsF17ypInjvA",
                "children": []
              },
              {
                "id": "210",
                "parent": "206",
                "text": "- Metabolismo/Excreción: Approximately 50% hepatic, 40-50% unchanged in urine",
                "guid": "7JVOuNlbzPU0E-sNcdDVIg",
                "children": []
              },
              {
                "id": "211",
                "parent": "206",
                "text": "- Vida media en adultos: 20-23 hours",
                "guid": "bA34_pFnjCe0u1hZnilFOA",
                "children": []
              },
              {
                "id": "212",
                "parent": "206",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "HAoPj0a9jMI33wKTZoZvTg",
                "children": []
              }
            ]
          },
          {
            "id": "213",
            "parent": "156",
            "text": "## FENFLURAMINA",
            "guid": "7nsAE6he2hWb9Yyrgbvk6g",
            "children": [
              {
                "id": "214",
                "parent": "213",
                "text": "- Mecanismos clave: Enhancing serotonin",
                "guid": "SxRBjfhqEO54lxnWojPvcw",
                "children": []
              },
              {
                "id": "215",
                "parent": "213",
                "text": "- Biodisponibilidad oral: Low",
                "guid": "mXhAQp4bevF3nqsl8fH6GQ",
                "children": []
              },
              {
                "id": "216",
                "parent": "213",
                "text": "- Unión a proteínas: Intermediate",
                "guid": "hrq8wmTH1i2OSdwvVaS4ZQ",
                "children": []
              },
              {
                "id": "217",
                "parent": "213",
                "text": "- Metabolismo/Excreción: >75% hepatic, <25% unchanged or minor metabolite in urine",
                "guid": "XF1KnKI0SKA9_boOhXrjYQ",
                "children": []
              },
              {
                "id": "218",
                "parent": "213",
                "text": "- Vida media en adultos: Approximately 20 hours",
                "guid": "W9DH8qcZstNaUeaRTMc1MQ",
                "children": []
              },
              {
                "id": "219",
                "parent": "213",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "ZbLokP9k-rndI5PkPVToxQ",
                "children": []
              }
            ]
          },
          {
            "id": "220",
            "parent": "156",
            "text": "## GABAPENTINA",
            "guid": "afEcAN23PMbfF0IiG8swwg",
            "children": [
              {
                "id": "221",
                "parent": "220",
                "text": "- Mecanismos clave: Binding α2δ calcium channel subunit",
                "guid": "m7ldrSMm2xjQA9CGZAQKIA",
                "children": []
              },
              {
                "id": "222",
                "parent": "220",
                "text": "- Biodisponibilidad oral: Low",
                "guid": "WCchT_YmrtsnJ8Xsnper-g",
                "children": []
              },
              {
                "id": "223",
                "parent": "220",
                "text": "- Unión a proteínas: Low",
                "guid": "R6GtJF_SSNvNltJzcSQgaA",
                "children": []
              },
              {
                "id": "224",
                "parent": "220",
                "text": "- Metabolismo/Excreción: None",
                "guid": "si4Yp4uOutM022cAz9tO2g",
                "children": []
              },
              {
                "id": "225",
                "parent": "220",
                "text": "- Vida media en adultos: 5-7 hours",
                "guid": "MbdAHSRpl5k1KKHDZ9LzEQ",
                "children": []
              },
              {
                "id": "226",
                "parent": "220",
                "text": "- Potencial para inductores o inhibidores: None or minimal",
                "guid": "qD_RaiDqBsKDv5O5DBX7GQ",
                "children": []
              }
            ]
          },
          {
            "id": "227",
            "parent": "156",
            "text": "## GANAXOLONA",
            "guid": "x5Mc8qquf0RHaqSRiY2zdA",
            "children": [
              {
                "id": "228",
                "parent": "227",
                "text": "- Mecanismos clave: Enhancing GABA",
                "guid": "Q_4c3BovuXPx-5qhFEfI4Q",
                "children": []
              },
              {
                "id": "229",
                "parent": "227",
                "text": "- Biodisponibilidad oral: Low",
                "guid": "P5H46YnmvfojKXT2o0zMxg",
                "children": []
              },
              {
                "id": "230",
                "parent": "227",
                "text": "- Unión a proteínas: High",
                "guid": "JRi2igXyW_suNvJmt-XhGg",
                "children": []
              },
              {
                "id": "231",
                "parent": "227",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "Ngft3_9HFVP9BzL8Z-7bbQ",
                "children": []
              },
              {
                "id": "232",
                "parent": "227",
                "text": "- Vida media en adultos: Approximately 24 hours",
                "guid": "Ce5M49nPB4VjdVg7WWhWWg",
                "children": []
              },
              {
                "id": "233",
                "parent": "227",
                "text": "- Potencial para inductores o inhibidores: Moderate",
                "guid": "_is8cglio6FFTCN2azpWnw",
                "children": []
              }
            ]
          },
          {
            "id": "234",
            "parent": "156",
            "text": "## LACOSAMIDA",
            "guid": "lRBAd1yIgESdRWAT70D5TA",
            "children": [
              {
                "id": "235",
                "parent": "234",
                "text": "- Mecanismos clave: Blocking sodium channels",
                "guid": "lEJW7M1Rl7gMFeonUZkaFg",
                "children": []
              },
              {
                "id": "236",
                "parent": "234",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "M3oMFWh9PC5e4h7_O9jMzg",
                "children": []
              },
              {
                "id": "237",
                "parent": "234",
                "text": "- Unión a proteínas: Low",
                "guid": "DeI38-xDpUivU9J2FYwP1A",
                "children": []
              },
              {
                "id": "238",
                "parent": "234",
                "text": "- Metabolismo/Excreción: Approximately 60% hepatic, 40% unchanged in urine",
                "guid": "UhHpT5uDQppMcpfIY48PTg",
                "children": []
              },
              {
                "id": "239",
                "parent": "234",
                "text": "- Vida media en adultos: Approximately 13 hours",
                "guid": "BAzp6varWurroz0f0A6vqA",
                "children": []
              },
              {
                "id": "240",
                "parent": "234",
                "text": "- Potencial para inductores o inhibidores: None or minimal",
                "guid": "8g97P1ZWMOvTJHq9eLVfHw",
                "children": []
              }
            ]
          },
          {
            "id": "241",
            "parent": "156",
            "text": "## LAMOTRIGINA",
            "guid": "uY5c0GeqE11qpwMY8n29gw",
            "children": [
              {
                "id": "242",
                "parent": "241",
                "text": "- Mecanismos clave: Blocking sodium channels",
                "guid": "YpdN5mlviLeDCIpK3KhGqg",
                "children": []
              },
              {
                "id": "243",
                "parent": "241",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "Xq_zQEX0y8bIGc6AfJYtgw",
                "children": []
              },
              {
                "id": "244",
                "parent": "241",
                "text": "- Unión a proteínas: Intermediate",
                "guid": "J3t_f9YlDdI744Qc1o_MPQ",
                "children": []
              },
              {
                "id": "245",
                "parent": "241",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "9z0OfPapThRTmIis004KwQ",
                "children": []
              },
              {
                "id": "246",
                "parent": "241",
                "text": "- Vida media en adultos: Approximately 24 hours",
                "guid": "7XMGjUKKEkUheXr6VBjhgA",
                "children": []
              },
              {
                "id": "247",
                "parent": "241",
                "text": "- Potencial para inductores o inhibidores: Moderate",
                "guid": "YCn9_ANAOePpDazxO7pw1w",
                "children": []
              }
            ]
          },
          {
            "id": "248",
            "parent": "156",
            "text": "## LEVETIRACETAM",
            "guid": "7No9sN1k98CntTONMyzBKw",
            "children": [
              {
                "id": "249",
                "parent": "248",
                "text": "- Mecanismos clave: Binding SV2A",
                "guid": "Ijs6gYnbe7sma-ek-dGSUg",
                "children": []
              },
              {
                "id": "250",
                "parent": "248",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "_VHoK3gtoy79BNAH1MZosQ",
                "children": []
              },
              {
                "id": "251",
                "parent": "248",
                "text": "- Unión a proteínas: Low",
                "guid": "8B3TdTmyo2zN5ynuIWuAPg",
                "children": []
              },
              {
                "id": "252",
                "parent": "248",
                "text": "- Metabolismo/Excreción: Approximately 34% hepatic, 66% unchanged renal",
                "guid": "ORTIZ2wsZxtaxd7W7LnMlw",
                "children": []
              },
              {
                "id": "253",
                "parent": "248",
                "text": "- Vida media en adultos: 6-8 hours",
                "guid": "uWu73mVpH7KgetThzLR1Kg",
                "children": []
              },
              {
                "id": "254",
                "parent": "248",
                "text": "- Potencial para inductores o inhibidores: None or minimal",
                "guid": "wDSoJ2llVabAXXW8BxH4tA",
                "children": []
              }
            ]
          },
          {
            "id": "255",
            "parent": "156",
            "text": "## OXCARBAZEPINA",
            "guid": "Or7jLWxMQyhQZFbyCLibVA",
            "children": [
              {
                "id": "256",
                "parent": "255",
                "text": "- Mecanismos clave: Blocking sodium channels",
                "guid": "JS1e7UUxUbSA5RhU3bBqpQ",
                "children": []
              },
              {
                "id": "257",
                "parent": "255",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "wZOmQIcoFDYI3BwX7VytwA",
                "children": []
              },
              {
                "id": "258",
                "parent": "255",
                "text": "- Unión a proteínas: Low",
                "guid": "jStZfh3HNWXYAQUfbPyW2Q",
                "children": []
              },
              {
                "id": "259",
                "parent": "255",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "JhpySaiX8QIU8F8OcOb2pA",
                "children": []
              },
              {
                "id": "260",
                "parent": "255",
                "text": "- Vida media en adultos: 8-10 hours (for active metabolite)",
                "guid": "0txhu0mWOrbhMnODkiMZYw",
                "children": []
              },
              {
                "id": "261",
                "parent": "255",
                "text": "- Potencial para inductores o inhibidores: Moderate",
                "guid": "MnlGg-UvZNq6T4Oy9IaUTg",
                "children": []
              }
            ]
          },
          {
            "id": "262",
            "parent": "156",
            "text": "## PERAMPANEL",
            "guid": "QW1w2coMEYaaQ6u6iJwB3Q",
            "children": [
              {
                "id": "263",
                "parent": "262",
                "text": "- Mecanismos clave: AMPA antagonism",
                "guid": "T70iwgNqyg2l6P5q320VJg",
                "children": []
              },
              {
                "id": "264",
                "parent": "262",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "IVDmhtf_nEhGBJpZ9I83VQ",
                "children": []
              },
              {
                "id": "265",
                "parent": "262",
                "text": "- Unión a proteínas: High",
                "guid": "eh4He4PLAEveZoi6vy6-QQ",
                "children": []
              },
              {
                "id": "266",
                "parent": "262",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "nKw7ZVtdb3HL70i7Kv16EQ",
                "children": []
              },
              {
                "id": "267",
                "parent": "262",
                "text": "- Vida media en adultos: Approximately 105 hours",
                "guid": "BLueyI1qPneGVy3ElJWkew",
                "children": []
              },
              {
                "id": "268",
                "parent": "262",
                "text": "- Potencial para inductores o inhibidores: Moderate",
                "guid": "LFzkuOvVjkTj_MUtQsHOXA",
                "children": []
              }
            ]
          },
          {
            "id": "269",
            "parent": "156",
            "text": "## FENOBARBITAL",
            "guid": "w18sN4eYye-neQY_SIjqnw",
            "children": [
              {
                "id": "270",
                "parent": "269",
                "text": "- Mecanismos clave: Enhancing GABA",
                "guid": "FfiEseygICTqib2GAB6Wjw",
                "children": []
              },
              {
                "id": "271",
                "parent": "269",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "swI-0W6H_odV56OwEeCD7g",
                "children": []
              },
              {
                "id": "272",
                "parent": "269",
                "text": "- Unión a proteínas: Low",
                "guid": "VxbFcTpKtB_Ldknv5lkDeQ",
                "children": []
              },
              {
                "id": "273",
                "parent": "269",
                "text": "- Metabolismo/Excreción: >70% metabolized in liver, 20-30% eliminated unchanged",
                "guid": "hEbYAKomecsBUZ1SreTeWg",
                "children": []
              },
              {
                "id": "274",
                "parent": "269",
                "text": "- Vida media en adultos: 80-100 hours",
                "guid": "9W_Ul9dI7xUTtDbDORgDuw",
                "children": []
              },
              {
                "id": "275",
                "parent": "269",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "D48lfJ3SsjvvBG9eRTwruA",
                "children": []
              }
            ]
          },
          {
            "id": "276",
            "parent": "156",
            "text": "## FENITOÍNA",
            "guid": "vhbulnIRnU7GWhNiDNJKKQ",
            "children": [
              {
                "id": "277",
                "parent": "276",
                "text": "- Mecanismos clave: Blocking sodium channels",
                "guid": "RMOeI9Hn1rHOdCmKoLUrHw",
                "children": []
              },
              {
                "id": "278",
                "parent": "276",
                "text": "- Biodisponibilidad oral: Variable",
                "guid": "l14L_1YlvfjN8oAC3V8O5Q",
                "children": []
              },
              {
                "id": "279",
                "parent": "276",
                "text": "- Unión a proteínas: High",
                "guid": "DcjE1qHPwLD2DqZKVV19KQ",
                "children": []
              },
              {
                "id": "280",
                "parent": "276",
                "text": "- Metabolismo/Excreción: Extensive hepatic, nonlinear",
                "guid": "i_TA4ty1WLytS2cnhe_XXQ",
                "children": []
              },
              {
                "id": "281",
                "parent": "276",
                "text": "- Vida media en adultos: Average 22 hours (longer with toxicity)",
                "guid": "C2pygmeCApcMbACpzF533Q",
                "children": []
              },
              {
                "id": "282",
                "parent": "276",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "Njms1wMBHxyRfopxT-Q5LA",
                "children": []
              }
            ]
          },
          {
            "id": "283",
            "parent": "156",
            "text": "## PREGABALINA",
            "guid": "yqZSvgNbSApR285bPVGRdw",
            "children": [
              {
                "id": "284",
                "parent": "283",
                "text": "- Mecanismos clave: Binding α2δ calcium channel subunit",
                "guid": "K9CCzMbt7yhNnEiXgvjE2w",
                "children": []
              },
              {
                "id": "285",
                "parent": "283",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "anrdbp_TmFTJFRiUN7nD_Q",
                "children": []
              },
              {
                "id": "286",
                "parent": "283",
                "text": "- Unión a proteínas: Low",
                "guid": "G0E6qAp5RGZVwjDFNhev5Q",
                "children": []
              },
              {
                "id": "287",
                "parent": "283",
                "text": "- Metabolismo/Excreción: None",
                "guid": "oaxWI15EjNloQ41DDhZqMA",
                "children": []
              },
              {
                "id": "288",
                "parent": "283",
                "text": "- Vida media en adultos: Approximately 6 hours",
                "guid": "IqNBru-BECdFA6tmt6KFOg",
                "children": []
              },
              {
                "id": "289",
                "parent": "283",
                "text": "- Potencial para inductores o inhibidores: None or minimal",
                "guid": "ZI9LCzocmz2_9EpWw4RTOw",
                "children": []
              }
            ]
          },
          {
            "id": "290",
            "parent": "156",
            "text": "## PRIMIDONA",
            "guid": "JFeceIh0QGu1sUWh9tDQtA",
            "children": [
              {
                "id": "291",
                "parent": "290",
                "text": "- Mecanismos clave: Enhancing GABA",
                "guid": "K7QCeVtcK5MrPcXty7Jdog",
                "children": []
              },
              {
                "id": "292",
                "parent": "290",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "NRJ5xwFdcR3e1Gufuq7tSQ",
                "children": []
              },
              {
                "id": "293",
                "parent": "290",
                "text": "- Unión a proteínas: Low",
                "guid": "h-99_zkR1hWEfEhn05QZwQ",
                "children": []
              },
              {
                "id": "294",
                "parent": "290",
                "text": "- Metabolismo/Excreción: 25% converted to phenobarbital, 40% excreted unchanged in urine",
                "guid": "Lk9O6I9na6egH3i7MS6Plw",
                "children": []
              },
              {
                "id": "295",
                "parent": "290",
                "text": "- Vida media en adultos: 10-15 hours",
                "guid": "Aui-S9fzNlh-QVmLyit0Ew",
                "children": []
              },
              {
                "id": "296",
                "parent": "290",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "GhikHOgQcJsw8W5l-TLxuA",
                "children": []
              }
            ]
          },
          {
            "id": "297",
            "parent": "156",
            "text": "## RUFINAMIDA",
            "guid": "Gcc74Em7q-EYeuvenBze7w",
            "children": [
              {
                "id": "298",
                "parent": "297",
                "text": "- Mecanismos clave: Blocking sodium channels",
                "guid": "DuWu-vQJsDAHpcq80ih9iw",
                "children": []
              },
              {
                "id": "299",
                "parent": "297",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "yT8Jj9uHy1XhOLAGs1bp9w",
                "children": []
              },
              {
                "id": "300",
                "parent": "297",
                "text": "- Unión a proteínas: Intermediate",
                "guid": "i5GUjGP6ELzXmfFl6a83Rw",
                "children": []
              },
              {
                "id": "301",
                "parent": "297",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "nwLLLlCvuXUM_IWyoxJyaQ",
                "children": []
              },
              {
                "id": "302",
                "parent": "297",
                "text": "- Vida media en adultos: 6-10 hours",
                "guid": "cZcTIHl3V7O26NE7YwSb5g",
                "children": []
              },
              {
                "id": "303",
                "parent": "297",
                "text": "- Potencial para inductores o inhibidores: Moderate",
                "guid": "4Gqom60cghm42GFZ8M6JIQ",
                "children": []
              }
            ]
          },
          {
            "id": "304",
            "parent": "156",
            "text": "## STIRIPENTOL",
            "guid": "C2aLSuyC0qrbBJtXy2RqdQ",
            "children": [
              {
                "id": "305",
                "parent": "304",
                "text": "- Mecanismos clave: Enhancing GABA",
                "guid": "GKDDmdOi1fcjSpmBXmyQKQ",
                "children": []
              },
              {
                "id": "306",
                "parent": "304",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "ka4KiQdl1MASgh2Lntnc5g",
                "children": []
              },
              {
                "id": "307",
                "parent": "304",
                "text": "- Unión a proteínas: High",
                "guid": "njvGR5u0LehLSgD9Mp5ZUA",
                "children": []
              },
              {
                "id": "308",
                "parent": "304",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "FaiKl2FkfokcFK7J3WD31w",
                "children": []
              },
              {
                "id": "309",
                "parent": "304",
                "text": "- Vida media en adultos: 4.5-13 hours",
                "guid": "Ob2EI4VPqwS9w6hxX1Tg1w",
                "children": []
              },
              {
                "id": "310",
                "parent": "304",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "fnAJoPcv6z8rTtQQx6iWaQ",
                "children": []
              }
            ]
          },
          {
            "id": "311",
            "parent": "156",
            "text": "## TIAGABINA",
            "guid": "lnAaCn-k5KvCQtmYojMa0Q",
            "children": [
              {
                "id": "312",
                "parent": "311",
                "text": "- Mecanismos clave: Enhancing GABA",
                "guid": "Ul82oyPfPJ0dKkHKdRvboQ",
                "children": []
              },
              {
                "id": "313",
                "parent": "311",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "64SHdZ7NTqo0mDoNgcVsXA",
                "children": []
              },
              {
                "id": "314",
                "parent": "311",
                "text": "- Unión a proteínas: High",
                "guid": "iJRGup_DzyFXpc7e045TBA",
                "children": []
              },
              {
                "id": "315",
                "parent": "311",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "1ZAyo7OOqRKCSRHDsWn1bA",
                "children": []
              },
              {
                "id": "316",
                "parent": "311",
                "text": "- Vida media en adultos: 7-9 hours",
                "guid": "6SG6Mt2mpil57cokgsUuyA",
                "children": []
              },
              {
                "id": "317",
                "parent": "311",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "OazAo0mw1WsE2__CZmMenQ",
                "children": []
              }
            ]
          },
          {
            "id": "318",
            "parent": "156",
            "text": "## TOPIRAMATO",
            "guid": "GDRVRe_6JGsmgupmkDteWQ",
            "children": [
              {
                "id": "319",
                "parent": "318",
                "text": "- Mecanismos clave: Blocking sodium channels, AMPA/kainate antagonism, enhancing GABA",
                "guid": "jNb62wCf-N1sZ2Mt0oKLEw",
                "children": []
              },
              {
                "id": "320",
                "parent": "318",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "koA6S4nv39Xh9HSA59qcEA",
                "children": []
              },
              {
                "id": "321",
                "parent": "318",
                "text": "- Unión a proteínas: Low",
                "guid": "eNU0JhjU07rRPobeC_VyDg",
                "children": []
              },
              {
                "id": "322",
                "parent": "318",
                "text": "- Metabolismo/Excreción: Approximately 30% hepatic, 70% unchanged in urine",
                "guid": "vlpX-us6kWHeKV0vJDAgtg",
                "children": []
              },
              {
                "id": "323",
                "parent": "318",
                "text": "- Vida media en adultos: Approximately 21 hours",
                "guid": "QVI4aj3gio2LsC4YPtDZUw",
                "children": []
              },
              {
                "id": "324",
                "parent": "318",
                "text": "- Potencial para inductores o inhibidores: None or minimal",
                "guid": "INrHK13fnLyXR_YbHuX92w",
                "children": []
              }
            ]
          },
          {
            "id": "325",
            "parent": "156",
            "text": "## VALPROATO",
            "guid": "ghFY-AT2gx_CM2oEkj4SiA",
            "children": [
              {
                "id": "326",
                "parent": "325",
                "text": "- Mecanismos clave: Blocking sodium channels, enhancing GABA, blocking T-type calcium channels",
                "guid": "8vWPqx7OA4TmDJ87t7VNFQ",
                "children": []
              },
              {
                "id": "327",
                "parent": "325",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "ozXwDEuNANoRQdZFFZFzSA",
                "children": []
              },
              {
                "id": "328",
                "parent": "325",
                "text": "- Unión a proteínas: High",
                "guid": "yRqAq-c8gtQY4zs0HKPm_A",
                "children": []
              },
              {
                "id": "329",
                "parent": "325",
                "text": "- Metabolismo/Excreción: Extensive hepatic",
                "guid": "12hpsaoOHN3mFLjCc71IUQ",
                "children": []
              },
              {
                "id": "330",
                "parent": "325",
                "text": "- Vida media en adultos: 13-16 hours",
                "guid": "Q1E2EWevzjP4KsMtujwpmg",
                "children": []
              },
              {
                "id": "331",
                "parent": "325",
                "text": "- Potencial para inductores o inhibidores: High",
                "guid": "zyGGo5y7RC3YX7JNsgI16g",
                "children": []
              }
            ]
          },
          {
            "id": "332",
            "parent": "156",
            "text": "## VIGABATRINA",
            "guid": "7nRrY9KLhlEaLLdQCpMB4g",
            "children": [
              {
                "id": "333",
                "parent": "332",
                "text": "- Mecanismos clave: Enhancing GABA",
                "guid": "5X5uOrMvJmwc9B-wurLgQQ",
                "children": []
              },
              {
                "id": "334",
                "parent": "332",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "Dzj6P9DJs-AlUqsFVvuhNQ",
                "children": []
              },
              {
                "id": "335",
                "parent": "332",
                "text": "- Unión a proteínas: Low",
                "guid": "qayc8NVWiYXOIKveY0UuLA",
                "children": []
              },
              {
                "id": "336",
                "parent": "332",
                "text": "- Metabolismo/Excreción: None",
                "guid": "IDDU4YjipwIaBZ4X4UTGJw",
                "children": []
              },
              {
                "id": "337",
                "parent": "332",
                "text": "- Vida media en adultos: Approximately 10.5 hours",
                "guid": "X12aLG4Pf15e11H2zXXeQA",
                "children": []
              },
              {
                "id": "338",
                "parent": "332",
                "text": "- Potencial para inductores o inhibidores: None or minimal",
                "guid": "GXv9zLGSla-jb_3UnWXTKQ",
                "children": []
              }
            ]
          },
          {
            "id": "339",
            "parent": "156",
            "text": "## ZONISAMIDA",
            "guid": "_TMGyowcSHt6nnOPvQ2u_A",
            "children": [
              {
                "id": "340",
                "parent": "339",
                "text": "- Mecanismos clave: Blocking sodium channels, blocking T-type calcium channels",
                "guid": "dJrtnVFj63fJUc6BIdkNUg",
                "children": []
              },
              {
                "id": "341",
                "parent": "339",
                "text": "- Biodisponibilidad oral: Good",
                "guid": "Qq_B9I9xb4DO1H4oM48WNw",
                "children": []
              },
              {
                "id": "342",
                "parent": "339",
                "text": "- Unión a proteínas: Low",
                "guid": "zsrqhM2SXP7t6DNJZT2Efg",
                "children": []
              },
              {
                "id": "343",
                "parent": "339",
                "text": "- Metabolismo/Excreción: Approximately 65% renal",
                "guid": "qz7lTMvf3zOQXsamc4-iWw",
                "children": []
              },
              {
                "id": "344",
                "parent": "339",
                "text": "- Vida media en adultos: Approximately 60 hours",
                "guid": "JZ52KWmuc5t3xeFxzfovhA",
                "children": []
              },
              {
                "id": "345",
                "parent": "339",
                "text": "- Potencial para inductores o inhibidores: Moderate",
                "guid": "fEBX6L86B6PIYKi0XcJHJg",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "346",
        "parent": "0",
        "text": "# DOSIFICACIÓN DE\nMEDICAMENTOS ANTIEPILÉPTICOS\nEN ADULTOS",
        "guid": "AAM9sSRYajh42sWpQcko0Q",
        "children": [
          {
            "id": "347",
            "parent": "346",
            "text": "## BRIVARACETAM",
            "guid": "2Y5nbopUauq4YWDKnHwXHw",
            "children": [
              {
                "id": "348",
                "parent": "347",
                "text": "- Dosis diaria inicial: 50-100 mg",
                "guid": "Rw6MB1u1Jh9VOdD4LwYpyQ",
                "children": []
              },
              {
                "id": "349",
                "parent": "347",
                "text": "- Titulación: 50 mg según necesidad",
                "guid": "ovHYhXNxwa6NgcNuQRSO3g",
                "children": []
              },
              {
                "id": "350",
                "parent": "347",
                "text": "- Dosis objetivo/máxima: 100 mg; máximo 200 mg",
                "guid": "b1DZjhOdNn1va0jWgfupSQ",
                "children": []
              }
            ]
          },
          {
            "id": "351",
            "parent": "346",
            "text": "## CARBAMAZEPINA",
            "guid": "qgBJGElHzf2zpfyUbkbHzg",
            "children": []
          }
        ]
      },
      {
        "id": "352",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 200 mg",
        "guid": "rheIFzqrNK1uKMbjk9ogmA",
        "children": []
      },
      {
        "id": "353",
        "parent": "0",
        "text": "- Titulación: 200\nmg cada 3 días",
        "guid": "6MtXBTvEnuxt2qT5JIGGFQ",
        "children": []
      },
      {
        "id": "354",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima:\n400-800 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "355",
        "parent": "0",
        "text": "## CANNABIDIOL",
        "guid": "",
        "children": []
      },
      {
        "id": "356",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 5 mg/kg",
        "guid": "",
        "children": []
      },
      {
        "id": "357",
        "parent": "0",
        "text": "- Titulación: Incremento de 5 mg/kg\ncada semana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "358",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 10\nmg/kg; máximo 20 mg/kg",
        "guid": "",
        "children": []
      },
      {
        "id": "359",
        "parent": "0",
        "text": "## CENOBAMATE",
        "guid": "",
        "children": []
      },
      {
        "id": "360",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 12.5 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "361",
        "parent": "0",
        "text": "- Titulación: Incremento a 25 mg después de 2\nsemanas, 50 mg 2 semanas después, luego\nincrementos de 50 mg cada 2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "362",
        "parent": "0",
        "text": "- Dosis objetivo/máxima:\n100-200 mg; máximo 400 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "363",
        "parent": "0",
        "text": "## CLOBAZAM",
        "guid": "",
        "children": []
      },
      {
        "id": "364",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 10 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "365",
        "parent": "0",
        "text": "- Titulación: 10 mg cada 2\nsemanas según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "366",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima:\n20-40 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "367",
        "parent": "0",
        "text": "##\nESLICARBAZEPINA\nACETATO",
        "guid": "",
        "children": []
      },
      {
        "id": "368",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 400 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "369",
        "parent": "0",
        "text": "- Titulación: 400\nmg/semana según\nnecesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "370",
        "parent": "0",
        "text": "- Dosis objetivo/máxima:\n800-1200 mg; máximo 1600 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "371",
        "parent": "0",
        "text": "## ETOSUXIMIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "372",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 500 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "373",
        "parent": "0",
        "text": "- Titulación: 250\nmg/semana según\nnecesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "374",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 750\nmg; máximo 1500 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "375",
        "parent": "0",
        "text": "## FELBAMATO",
        "guid": "",
        "children": []
      },
      {
        "id": "376",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 1200 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "377",
        "parent": "0",
        "text": "- Titulación:\n600-1200\nmg/semana",
        "guid": "",
        "children": []
      },
      {
        "id": "378",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima:\n3600 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "379",
        "parent": "0",
        "text": "## GABAPENTINA",
        "guid": "",
        "children": []
      },
      {
        "id": "380",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 300-400 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "381",
        "parent": "0",
        "text": "- Titulación:\n300-400 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "382",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 1200\nmg; máximo 4800 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "383",
        "parent": "0",
        "text": "## GANAXOLONA",
        "guid": "",
        "children": []
      },
      {
        "id": "384",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 450 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "385",
        "parent": "0",
        "text": "- Titulación: 450\nmg/semana",
        "guid": "",
        "children": []
      },
      {
        "id": "386",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima:\n1800 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "387",
        "parent": "0",
        "text": "## LACOSAMIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "388",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 100 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "389",
        "parent": "0",
        "text": "- Titulación: 100\nmg/semana según\nnecesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "390",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 200\nmg; máximo 600 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "391",
        "parent": "0",
        "text": "## LAMOTRIGINA",
        "guid": "",
        "children": []
      },
      {
        "id": "392",
        "parent": "0",
        "text": "- Dosis diaria inicial: Monoterapia\npara semanas 1 y 2: 25 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "393",
        "parent": "0",
        "text": "- Titulación: Monoterapia para semanas\n3 y 4: 50 mg; luego incremento de 50\nmg cada 1-2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "394",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima:\n200-300 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "395",
        "parent": "0",
        "text": "## LEVETIRACETAM",
        "guid": "",
        "children": []
      },
      {
        "id": "396",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 500 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "397",
        "parent": "0",
        "text": "- Titulación: 500\nmg/semana según\nnecesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "398",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 1000\nmg; máximo 4000 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "399",
        "parent": "0",
        "text": "## OXCARBAZEPINA",
        "guid": "",
        "children": []
      },
      {
        "id": "400",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 300-600 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "401",
        "parent": "0",
        "text": "- Titulación: 300\nmg/semana según\nnecesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "402",
        "parent": "0",
        "text": "- Dosis objetivo/máxima:\n600-1200 mg; máximo 2400 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "403",
        "parent": "0",
        "text": "## PERAMPANEL",
        "guid": "",
        "children": []
      },
      {
        "id": "404",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 2 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "405",
        "parent": "0",
        "text": "- Titulación: 2 mg\ncada 3 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "406",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 4\nmg; máximo 8 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "407",
        "parent": "0",
        "text": "## FENOBARBITAL",
        "guid": "",
        "children": []
      },
      {
        "id": "408",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 30-60 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "409",
        "parent": "0",
        "text": "- Titulación: 30-60 mg cada 1-2\nsemanas según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "410",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima:\n120-180 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "411",
        "parent": "0",
        "text": "## FENITOÍNA",
        "guid": "",
        "children": []
      },
      {
        "id": "412",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 200-400 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "413",
        "parent": "0",
        "text": "- Titulación: No requiere titulación, ajuste de\ndosis con incrementos de 30-60 mg según\nnecesidad para control de crisis",
        "guid": "",
        "children": []
      },
      {
        "id": "414",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima:\n200-400 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "415",
        "parent": "0",
        "text": "## PREGABALINA",
        "guid": "",
        "children": []
      },
      {
        "id": "416",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 75-150 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "417",
        "parent": "0",
        "text": "- Titulación: 75-150\nmg/semana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "418",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 300\nmg; máximo 600 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "419",
        "parent": "0",
        "text": "## PRIMIDONA",
        "guid": "",
        "children": []
      },
      {
        "id": "420",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 50-125 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "421",
        "parent": "0",
        "text": "- Titulación: 50-125\nmg cada 3-7 días",
        "guid": "",
        "children": []
      },
      {
        "id": "422",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima:\n750-1000 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "423",
        "parent": "0",
        "text": "## RUFINAMIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "424",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 400 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "425",
        "parent": "0",
        "text": "- Titulación: 400\nmg cada 2 días",
        "guid": "",
        "children": []
      },
      {
        "id": "426",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima:\n3200 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "427",
        "parent": "0",
        "text": "## TIAGABINA",
        "guid": "",
        "children": []
      },
      {
        "id": "428",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 4 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "429",
        "parent": "0",
        "text": "- Titulación: 4\nmg/semana",
        "guid": "",
        "children": []
      },
      {
        "id": "430",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 24\nmg; máximo 56 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "431",
        "parent": "0",
        "text": "## TOPIRAMATO",
        "guid": "",
        "children": []
      },
      {
        "id": "432",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 25 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "433",
        "parent": "0",
        "text": "- Titulación: 25\nmg/semana",
        "guid": "",
        "children": []
      },
      {
        "id": "434",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 100\nmg; máximo 400 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "435",
        "parent": "0",
        "text": "## VALPROATO",
        "guid": "",
        "children": []
      },
      {
        "id": "436",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 500 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "437",
        "parent": "0",
        "text": "- Titulación: 250-500\nmg/semana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "438",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima:\n1000-2000 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "439",
        "parent": "0",
        "text": "## VIGABATRINA",
        "guid": "",
        "children": []
      },
      {
        "id": "440",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 1000 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "441",
        "parent": "0",
        "text": "- Titulación: 500\nmg/semana según\nnecesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "442",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 3000\nmg; máximo 6000 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "443",
        "parent": "0",
        "text": "## ZONISAMIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "444",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 100 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "445",
        "parent": "0",
        "text": "- Titulación: 100 mg cada 1-2\nsemanas según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "446",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 200\nmg; máximo 600 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "447",
        "parent": "0",
        "text": "## NOTA",
        "guid": "",
        "children": []
      },
      {
        "id": "448",
        "parent": "0",
        "text": "- El esquema depende de la\nformulación utilizada y de la vida media\ndel medicamento antiepiléptico.",
        "guid": "",
        "children": []
      },
      {
        "id": "449",
        "parent": "0",
        "text": "# DOSIFICACIÓN DE\nMEDICAMENTOS\nANTIEPILÉPTICOS EN\nNIÑOS",
        "guid": "XK9JkjrbMIAM30WKAC1V7w",
        "children": []
      },
      {
        "id": "450",
        "parent": "0",
        "text": "## BRIVARACETAM",
        "guid": "",
        "children": []
      },
      {
        "id": "451",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n1-2 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "452",
        "parent": "0",
        "text": "- Titulación: Ajuste de dosis\nbasado en respuesta",
        "guid": "",
        "children": []
      },
      {
        "id": "453",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 1-5 mg/kg/día (pacientes\npediátricos >50 kg [110 lb]); dosis inicial de 50-100\nmg/día con máximo de 200 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "454",
        "parent": "0",
        "text": "## CARBAMAZEPINA",
        "guid": "",
        "children": []
      },
      {
        "id": "455",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n10-20 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "456",
        "parent": "0",
        "text": "- Titulación: Incremento semanal\nusando aumentos de 100 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "457",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 20 mg/kg/día;\nusualmente <35 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "458",
        "parent": "0",
        "text": "## CANNABIDIOL",
        "guid": "",
        "children": []
      },
      {
        "id": "459",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 5 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "460",
        "parent": "0",
        "text": "- Titulación: Incremento de 5 mg/kg/día\ncada semana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "461",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima: 20\nmg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "462",
        "parent": "0",
        "text": "## CLOBAZAM",
        "guid": "",
        "children": []
      },
      {
        "id": "463",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n0.1 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "464",
        "parent": "0",
        "text": "- Titulación: Incremento de 0.1 mg/kg/día\ncada semana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "465",
        "parent": "0",
        "text": "- Dosis objetivo/máxima:\n0.5-1.0 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "466",
        "parent": "0",
        "text": "##\nESLICARBAZEPINA\nACETATO",
        "guid": "",
        "children": []
      },
      {
        "id": "467",
        "parent": "0",
        "text": "- Dosis diaria inicial: 10-20\nmg/kg/día (200-400 mg/día\ndependiendo del peso)",
        "guid": "",
        "children": []
      },
      {
        "id": "468",
        "parent": "0",
        "text": "- Titulación: 200-400\nmg/semana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "469",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 20-60\nmg/kg/día (400-1200 mg/día\ndependiendo del peso)",
        "guid": "",
        "children": []
      },
      {
        "id": "470",
        "parent": "0",
        "text": "## ETOSUXIMIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "471",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n10-15 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "472",
        "parent": "0",
        "text": "- Titulación: 5 mg/kg/día cada\nsemana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "473",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 20-30\nmg/kg/día; hasta 40 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "474",
        "parent": "0",
        "text": "## FELBAMATO",
        "guid": "",
        "children": []
      },
      {
        "id": "475",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n15 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "476",
        "parent": "0",
        "text": "- Titulación: 15\nmg/kg/día cada\nsemana",
        "guid": "",
        "children": []
      },
      {
        "id": "477",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima: 45\nmg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "478",
        "parent": "0",
        "text": "## FENFLURAMINA",
        "guid": "",
        "children": []
      },
      {
        "id": "479",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n0.2 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "480",
        "parent": "0",
        "text": "- Titulación: Incremento\nsemanal según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "481",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 0.7\nmg/kg/día; máximo 26 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "482",
        "parent": "0",
        "text": "- 0.4 mg/kg/día en presencia\nde stiripentol y clobazam;\nmáximo 17 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "483",
        "parent": "0",
        "text": "## GABAPENTINA",
        "guid": "",
        "children": []
      },
      {
        "id": "484",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n10-15 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "485",
        "parent": "0",
        "text": "- Titulación: 10\nmg/kg/día cada día",
        "guid": "",
        "children": []
      },
      {
        "id": "486",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 40\nmg/kg/día; hasta 50 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "487",
        "parent": "0",
        "text": "## GANAXOLONA",
        "guid": "",
        "children": []
      },
      {
        "id": "488",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n18 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "489",
        "parent": "0",
        "text": "- Titulación: 5\nmg/kg/día cada\nsemana",
        "guid": "",
        "children": []
      },
      {
        "id": "490",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima: 63\nmg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "491",
        "parent": "0",
        "text": "## LACOSAMIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "492",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 2 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "493",
        "parent": "0",
        "text": "- Titulación: 2\nmg/kg/día cada\nsemana",
        "guid": "",
        "children": []
      },
      {
        "id": "494",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima: 4-8\nmg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "495",
        "parent": "0",
        "text": "- 6-12 mg/kg/día para\npacientes <30 kg (66 lb)",
        "guid": "",
        "children": []
      },
      {
        "id": "496",
        "parent": "0",
        "text": "## LAMOTRIGINA",
        "guid": "",
        "children": []
      },
      {
        "id": "497",
        "parent": "0",
        "text": "- Dosis diaria inicial:",
        "guid": "",
        "children": []
      },
      {
        "id": "498",
        "parent": "0",
        "text": "- Monoterapia, semanas 1\ny 2: 0.3 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "499",
        "parent": "0",
        "text": "- Con valproato, semanas 1\ny 2: 0.15 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "500",
        "parent": "0",
        "text": "- Con inductor enzimático,\nsemanas 1 y 2: 0.6 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "501",
        "parent": "0",
        "text": "- Titulación:",
        "guid": "",
        "children": []
      },
      {
        "id": "502",
        "parent": "0",
        "text": "- Monoterapia, semanas 3 y 4: 0.6 mg/kg/día;\nsemana 5 y posteriores: incremento de 0.6\nmg/kg/día cada 1-2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "503",
        "parent": "0",
        "text": "- Con valproato, semanas 3 y 4: 0.3 mg/kg/día;\nsemana 5 y posteriores: incremento de 0.3\nmg/kg/día cada 1-2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "504",
        "parent": "0",
        "text": "- Con inductor enzimático, semanas 3 y 4: 1.2\nmg/kg/día; semana 5 y posteriores: incremento de\n1.2 mg/kg/día cada 1-2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "505",
        "parent": "0",
        "text": "- Dosis objetivo/máxima:",
        "guid": "",
        "children": []
      },
      {
        "id": "506",
        "parent": "0",
        "text": "- Monoterapia: 4.\n5-7.5 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "507",
        "parent": "0",
        "text": "- Con valproato:\n1-5 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "508",
        "parent": "0",
        "text": "- Con inductores\nenzimáticos: 5-15\nmg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "509",
        "parent": "0",
        "text": "## LEVETIRACETAM",
        "guid": "",
        "children": []
      },
      {
        "id": "510",
        "parent": "0",
        "text": "- Dosis diaria inicial: 20\nmg/kg/día (infantes 1 mes a\n<6 meses: 14 mg/kg/día)",
        "guid": "",
        "children": []
      },
      {
        "id": "511",
        "parent": "0",
        "text": "- Titulación: 10 mg/kg/día\ncada 1-2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "512",
        "parent": "0",
        "text": "- Dosis objetivo/máxima:",
        "guid": "",
        "children": []
      },
      {
        "id": "513",
        "parent": "0",
        "text": "- Niños 4 años a <16\naños: 60 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "514",
        "parent": "0",
        "text": "- Niños 6 meses a <4\naños: 50 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "515",
        "parent": "0",
        "text": "- Infantes 1 mes a <6\nmeses: 42 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "516",
        "parent": "0",
        "text": "## OXCARBAZEPINA",
        "guid": "",
        "children": []
      },
      {
        "id": "517",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n8-10 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "518",
        "parent": "0",
        "text": "- Titulación: 5-10 mg/kg/día cada\n3-7 días según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "519",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 30-50\nmg/kg/día; usualmente <60 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "520",
        "parent": "0",
        "text": "## PERAMPANEL",
        "guid": "",
        "children": []
      },
      {
        "id": "521",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 2 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "522",
        "parent": "0",
        "text": "- Titulación: Incremento de 2 mg\nsegún necesidad, no más\nfrecuente que semanalmente",
        "guid": "",
        "children": []
      },
      {
        "id": "523",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima: 8-12\nmg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "524",
        "parent": "0",
        "text": "## FENOBARBITAL",
        "guid": "",
        "children": []
      },
      {
        "id": "525",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n1-3 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "526",
        "parent": "0",
        "text": "- Titulación: 1 mg/kg/día\ncada 1-2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "527",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 3\nmg/kg/día; hasta 8 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "528",
        "parent": "0",
        "text": "## FENITOÍNA",
        "guid": "",
        "children": []
      },
      {
        "id": "529",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n5-7 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "530",
        "parent": "0",
        "text": "- Titulación: No\nrequiere titulación",
        "guid": "",
        "children": []
      },
      {
        "id": "531",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 6-8 mg/kg/día;\nhasta 10 mg/kg/día (puede guiarse por\nconcentración sérica)",
        "guid": "",
        "children": []
      },
      {
        "id": "532",
        "parent": "0",
        "text": "## PREGABALINA",
        "guid": "",
        "children": []
      },
      {
        "id": "533",
        "parent": "0",
        "text": "- Dosis diaria inicial:",
        "guid": "",
        "children": []
      },
      {
        "id": "534",
        "parent": "0",
        "text": "- 2.5 mg/kg/día si paciente\npesa ≥30 kg (66 lb)",
        "guid": "",
        "children": []
      },
      {
        "id": "535",
        "parent": "0",
        "text": "- 3.5 mg/kg/día si paciente\npesa <30 kg (66 lb)",
        "guid": "",
        "children": []
      },
      {
        "id": "536",
        "parent": "0",
        "text": "- Titulación: Incremento de 2.\n5 mg/kg/día semanalmente\nsegún necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "537",
        "parent": "0",
        "text": "- Dosis objetivo/máxima:",
        "guid": "",
        "children": []
      },
      {
        "id": "538",
        "parent": "0",
        "text": "- 10 mg/kg si paciente\npesa ≥30 kg (66 lb)",
        "guid": "",
        "children": []
      },
      {
        "id": "539",
        "parent": "0",
        "text": "- 14 mg/kg si paciente\npesa <30 kg (66 lb)",
        "guid": "",
        "children": []
      },
      {
        "id": "540",
        "parent": "0",
        "text": "## RUFINAMIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "541",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n10 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "542",
        "parent": "0",
        "text": "- Con valproato, dosis inicial\naproximadamente 5 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "543",
        "parent": "0",
        "text": "- Titulación:",
        "guid": "",
        "children": []
      },
      {
        "id": "544",
        "parent": "0",
        "text": "- Incremento de 10\nmg/kg/día cada dos días",
        "guid": "",
        "children": []
      },
      {
        "id": "545",
        "parent": "0",
        "text": "- Con valproato, titulación\naproximadamente 5 mg/kg/día cada dos\ndías",
        "guid": "",
        "children": []
      },
      {
        "id": "546",
        "parent": "0",
        "text": "- Dosis objetivo/máxima:",
        "guid": "",
        "children": []
      },
      {
        "id": "547",
        "parent": "0",
        "text": "- 45 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "548",
        "parent": "0",
        "text": "- Con valproato, dosis\nobjetivo 20-30 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "549",
        "parent": "0",
        "text": "## STIRIPENTOL",
        "guid": "",
        "children": []
      },
      {
        "id": "550",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n50 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "551",
        "parent": "0",
        "text": "- Titulación: No\nespecificada",
        "guid": "",
        "children": []
      },
      {
        "id": "552",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima: 3000\nmg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "553",
        "parent": "0",
        "text": "## TOPIRAMATO",
        "guid": "",
        "children": []
      },
      {
        "id": "554",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n1-3 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "555",
        "parent": "0",
        "text": "- Titulación: 1-3 mg/kg/día\ncada 1-2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "556",
        "parent": "0",
        "text": "- Dosis\nobjetivo/máxima: 5-9\nmg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "557",
        "parent": "0",
        "text": "## VALPROATO",
        "guid": "",
        "children": []
      },
      {
        "id": "558",
        "parent": "0",
        "text": "- Dosis diaria inicial:\n15 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "559",
        "parent": "0",
        "text": "- Titulación: 5-10\nmg/kg/día cada semana",
        "guid": "",
        "children": []
      },
      {
        "id": "560",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: 30 mg/kg/día; hasta\n60 mg/kg/día con medicamentos\nantiepilépticos inductores enzimáticos",
        "guid": "",
        "children": []
      },
      {
        "id": "561",
        "parent": "0",
        "text": "## VIGABATRINA",
        "guid": "",
        "children": []
      },
      {
        "id": "562",
        "parent": "0",
        "text": "- Dosis diaria inicial:",
        "guid": "",
        "children": []
      },
      {
        "id": "563",
        "parent": "0",
        "text": "- 20 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "564",
        "parent": "0",
        "text": "- Espasmos\ninfantiles: 50\nmg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "565",
        "parent": "0",
        "text": "- Titulación:",
        "guid": "",
        "children": []
      },
      {
        "id": "566",
        "parent": "0",
        "text": "- 20 mg/kg/día cada\nsemana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "567",
        "parent": "0",
        "text": "- Espasmos infantiles: incremento a 100\nmg/kg/día después de 5 días",
        "guid": "",
        "children": []
      },
      {
        "id": "568",
        "parent": "0",
        "text": "- Dosis objetivo/máxima:",
        "guid": "",
        "children": []
      },
      {
        "id": "569",
        "parent": "0",
        "text": "- 40-60 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "570",
        "parent": "0",
        "text": "- Espasmos infantiles: 100\nmg/kg/día; máximo 150 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "571",
        "parent": "0",
        "text": "## ZONISAMIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "572",
        "parent": "0",
        "text": "- Dosis diaria\ninicial: 1 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "573",
        "parent": "0",
        "text": "- Titulación: 2 mg/kg/día cada 2\nsemanas según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "574",
        "parent": "0",
        "text": "- Dosis objetivo/máxima: Dosis\nusual de 4-8 mg/kg/día; con dosis\nmáxima de 12 mg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "575",
        "parent": "0",
        "text": "## NOTAS",
        "guid": "",
        "children": []
      },
      {
        "id": "576",
        "parent": "0",
        "text": "- Generalmente aplicable a niños menores\nde 12 años. La dosificación es para\nmedicamentos antiepilépticos que han sido al\nmenos probados en niños.",
        "guid": "",
        "children": []
      },
      {
        "id": "577",
        "parent": "0",
        "text": "- Aplicable a niños que pesan\n11-50 kg (24-110 lb).",
        "guid": "",
        "children": []
      },
      {
        "id": "578",
        "parent": "0",
        "text": "- No aprobado por la\nFDA para niños.",
        "guid": "",
        "children": []
      },
      {
        "id": "579",
        "parent": "0",
        "text": "# TERATOGENICIDAD DE\nMEDICAMENTOS ANTIEPILÉPTICOS",
        "guid": "VUUqsArraVgQuLXUfJBSeg",
        "children": []
      },
      {
        "id": "580",
        "parent": "0",
        "text": "## TASA DE MALFORMACIONES\nMAYORES EN MONOTERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "581",
        "parent": "0",
        "text": "### RIESGO MUY\nALTO (>8%)",
        "guid": "",
        "children": []
      },
      {
        "id": "582",
        "parent": "0",
        "text": "- Valproato: >2900\nexposiciones",
        "guid": "",
        "children": []
      },
      {
        "id": "583",
        "parent": "0",
        "text": "### RIESGO ALTO\n(6.1% a 8%)",
        "guid": "",
        "children": []
      },
      {
        "id": "584",
        "parent": "0",
        "text": "- Fenobarbital: >500\nexposiciones",
        "guid": "",
        "children": []
      },
      {
        "id": "585",
        "parent": "0",
        "text": "- Efecto negativo adicional:\ndisminución del CI en\ndescendencia masculina",
        "guid": "",
        "children": []
      },
      {
        "id": "586",
        "parent": "0",
        "text": "### RIESGO\nINTERMEDIO (3.1% a\n6%)",
        "guid": "",
        "children": []
      },
      {
        "id": "587",
        "parent": "0",
        "text": "- Carbamazepina:\n>4800 exposiciones",
        "guid": "",
        "children": []
      },
      {
        "id": "588",
        "parent": "0",
        "text": "- Fenitoína: >600\nexposiciones",
        "guid": "",
        "children": []
      },
      {
        "id": "589",
        "parent": "0",
        "text": "- Topiramato: >700\nexposiciones",
        "guid": "",
        "children": []
      },
      {
        "id": "590",
        "parent": "0",
        "text": "### RIESGO\nBAJO (≤3%)",
        "guid": "",
        "children": []
      },
      {
        "id": "591",
        "parent": "0",
        "text": "- Clonazepam: >100\nexposiciones",
        "guid": "",
        "children": []
      },
      {
        "id": "592",
        "parent": "0",
        "text": "- Gabapentina:\n>200 exposiciones",
        "guid": "",
        "children": []
      },
      {
        "id": "593",
        "parent": "0",
        "text": "- Lamotrigina:\n>7000 exposiciones",
        "guid": "",
        "children": []
      },
      {
        "id": "594",
        "parent": "0",
        "text": "- Levetiracetam:\n>2100 exposiciones",
        "guid": "",
        "children": []
      },
      {
        "id": "595",
        "parent": "0",
        "text": "- Oxcarbazepina:\n>600 exposiciones",
        "guid": "",
        "children": []
      },
      {
        "id": "596",
        "parent": "0",
        "text": "- Zonisamida: >200\nexposiciones",
        "guid": "",
        "children": []
      },
      {
        "id": "597",
        "parent": "0",
        "text": "### RIESGO DESCONOCIDO\n(EXPOSICIÓN INSUFICIENTE)",
        "guid": "",
        "children": []
      },
      {
        "id": "598",
        "parent": "0",
        "text": "- Brivaracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "599",
        "parent": "0",
        "text": "- Cannabidiol",
        "guid": "",
        "children": []
      },
      {
        "id": "600",
        "parent": "0",
        "text": "- Cenobamate",
        "guid": "",
        "children": []
      },
      {
        "id": "601",
        "parent": "0",
        "text": "- Clobazam",
        "guid": "",
        "children": []
      },
      {
        "id": "602",
        "parent": "0",
        "text": "- Eslicarbazepina\nacetato",
        "guid": "",
        "children": []
      },
      {
        "id": "603",
        "parent": "0",
        "text": "- Etosuximida",
        "guid": "",
        "children": []
      },
      {
        "id": "604",
        "parent": "0",
        "text": "- Felbamato",
        "guid": "",
        "children": []
      },
      {
        "id": "605",
        "parent": "0",
        "text": "- Fenfluramina",
        "guid": "",
        "children": []
      },
      {
        "id": "606",
        "parent": "0",
        "text": "- Ganaxolona",
        "guid": "",
        "children": []
      },
      {
        "id": "607",
        "parent": "0",
        "text": "- Lacosamida",
        "guid": "",
        "children": []
      },
      {
        "id": "608",
        "parent": "0",
        "text": "- Perampanel",
        "guid": "",
        "children": []
      },
      {
        "id": "609",
        "parent": "0",
        "text": "- Pregabalina",
        "guid": "",
        "children": []
      },
      {
        "id": "610",
        "parent": "0",
        "text": "- Primidona",
        "guid": "",
        "children": []
      },
      {
        "id": "611",
        "parent": "0",
        "text": "- Rufinamida",
        "guid": "",
        "children": []
      },
      {
        "id": "612",
        "parent": "0",
        "text": "- Stiripentol",
        "guid": "",
        "children": []
      },
      {
        "id": "613",
        "parent": "0",
        "text": "- Tiagabina",
        "guid": "",
        "children": []
      },
      {
        "id": "614",
        "parent": "0",
        "text": "- Vigabatrina",
        "guid": "",
        "children": []
      },
      {
        "id": "615",
        "parent": "0",
        "text": "## NOTAS",
        "guid": "",
        "children": []
      },
      {
        "id": "616",
        "parent": "0",
        "text": "- Datos extraídos de registros de\nNorteamérica, Europa y Reino Unido",
        "guid": "",
        "children": []
      },
      {
        "id": "617",
        "parent": "0",
        "text": "- Se utilizó un\npromedio ponderado",
        "guid": "",
        "children": []
      },
      {
        "id": "618",
        "parent": "0",
        "text": "- Datos reportados solo para\nmedicamentos antiepilépticos con\n>100 exposiciones en monoterapia",
        "guid": "",
        "children": []
      },
      {
        "id": "619",
        "parent": "0",
        "text": "- Para valproato, los efectos\nnegativos adicionales son\ndisminución del CI verbal y autismo",
        "guid": "",
        "children": []
      },
      {
        "id": "620",
        "parent": "0",
        "text": "# FENOBARBITAL",
        "guid": "crRlHFMYj-B5QBFleFrS3A",
        "children": []
      },
      {
        "id": "621",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "622",
        "parent": "0",
        "text": "- En uso clínico desde 1912 (inicialmente\ncomo sedante y somnífero)",
        "guid": "",
        "children": []
      },
      {
        "id": "623",
        "parent": "0",
        "text": "- Mecanismo principal: Unión\nal receptor GABA-A",
        "guid": "",
        "children": []
      },
      {
        "id": "624",
        "parent": "0",
        "text": "- Prolonga la apertura del\ncanal de cloruro asociado",
        "guid": "",
        "children": []
      },
      {
        "id": "625",
        "parent": "0",
        "text": "- Disponible en preparación oral\ny solución parenteral",
        "guid": "",
        "children": []
      },
      {
        "id": "626",
        "parent": "0",
        "text": "- Propiedades\nfarmacocinéticas:",
        "guid": "",
        "children": []
      },
      {
        "id": "627",
        "parent": "0",
        "text": "- Excelente\nbiodisponibilidad\noral",
        "guid": "",
        "children": []
      },
      {
        "id": "628",
        "parent": "0",
        "text": "- Baja unión a proteínas",
        "guid": "",
        "children": []
      },
      {
        "id": "629",
        "parent": "0",
        "text": "- Metabolismo\nprincipalmente\nhepático",
        "guid": "",
        "children": []
      },
      {
        "id": "630",
        "parent": "0",
        "text": "- Aproximadamente 25%\neliminado sin cambios en orina",
        "guid": "",
        "children": []
      },
      {
        "id": "631",
        "parent": "0",
        "text": "- Vida media larga:\n80-100 horas",
        "guid": "",
        "children": []
      },
      {
        "id": "632",
        "parent": "0",
        "text": "- Potente inductor\nenzimático hepático P450",
        "guid": "",
        "children": []
      },
      {
        "id": "633",
        "parent": "0",
        "text": "- Acelera el metabolismo de\notros medicamentos",
        "guid": "",
        "children": []
      },
      {
        "id": "634",
        "parent": "0",
        "text": "- Reduce concentraciones plasmáticas\nde fármacos concomitantes",
        "guid": "",
        "children": []
      },
      {
        "id": "635",
        "parent": "0",
        "text": "- Puede reducir eficacia de\notros antiepilépticos\nmetabolizados por hígado",
        "guid": "",
        "children": []
      },
      {
        "id": "636",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "637",
        "parent": "0",
        "text": "- Efectivo contra:",
        "guid": "",
        "children": []
      },
      {
        "id": "638",
        "parent": "0",
        "text": "- Crisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "639",
        "parent": "0",
        "text": "- Crisis\ntónico-clónicas\ngeneralizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "640",
        "parent": "0",
        "text": "- No efectivo contra crisis de\nausencia generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "641",
        "parent": "0",
        "text": "- Solución parenteral efectiva\npara estatus epiléptico",
        "guid": "",
        "children": []
      },
      {
        "id": "642",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "643",
        "parent": "0",
        "text": "- Dosis de\nmantenimiento: 1-2.5\nmg/kg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "644",
        "parent": "0",
        "text": "- Dosis inicial recomendada:\n30-60 mg al acostarse",
        "guid": "",
        "children": []
      },
      {
        "id": "645",
        "parent": "0",
        "text": "- Ajuste: Incrementos de 30-60 mg cada\n1-2 semanas según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "646",
        "parent": "0",
        "text": "- Administración una vez al día\n(preferiblemente al acostarse)",
        "guid": "",
        "children": []
      },
      {
        "id": "647",
        "parent": "0",
        "text": "- Reduce sedación",
        "guid": "",
        "children": []
      },
      {
        "id": "648",
        "parent": "0",
        "text": "- Adecuado por su\nlarga vida media",
        "guid": "",
        "children": []
      },
      {
        "id": "649",
        "parent": "0",
        "text": "- Concentración sérica\nrecomendada: 15-40 μg/mL",
        "guid": "",
        "children": []
      },
      {
        "id": "650",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "651",
        "parent": "0",
        "text": "- Principales:",
        "guid": "",
        "children": []
      },
      {
        "id": "652",
        "parent": "0",
        "text": "- Sedación",
        "guid": "",
        "children": []
      },
      {
        "id": "653",
        "parent": "0",
        "text": "- Disminución de\nconcentración",
        "guid": "",
        "children": []
      },
      {
        "id": "654",
        "parent": "0",
        "text": "- Cambios de humor,\nparticularmente depresión",
        "guid": "",
        "children": []
      },
      {
        "id": "655",
        "parent": "0",
        "text": "- Hiperactividad\n(en niños)",
        "guid": "",
        "children": []
      },
      {
        "id": "656",
        "parent": "0",
        "text": "- Uso a largo plazo\nasociado con:",
        "guid": "",
        "children": []
      },
      {
        "id": "657",
        "parent": "0",
        "text": "- Disminución de\ndensidad ósea",
        "guid": "",
        "children": []
      },
      {
        "id": "658",
        "parent": "0",
        "text": "- Contracturas\nde Dupuytren",
        "guid": "",
        "children": []
      },
      {
        "id": "659",
        "parent": "0",
        "text": "- Fibromatosis plantar",
        "guid": "",
        "children": []
      },
      {
        "id": "660",
        "parent": "0",
        "text": "- Hombro congelado",
        "guid": "",
        "children": []
      },
      {
        "id": "661",
        "parent": "0",
        "text": "- Teratogenicidad:",
        "guid": "",
        "children": []
      },
      {
        "id": "662",
        "parent": "0",
        "text": "- No recomendado\nen embarazo",
        "guid": "",
        "children": []
      },
      {
        "id": "663",
        "parent": "0",
        "text": "- Mayor riesgo de malformaciones\ncardíacas en feto expuesto",
        "guid": "",
        "children": []
      },
      {
        "id": "664",
        "parent": "0",
        "text": "- Evidencia de disminución de\ncapacidades cognitivas en\nvarones expuestos in utero",
        "guid": "",
        "children": []
      },
      {
        "id": "665",
        "parent": "0",
        "text": "- Es una\nsustancia\ncontrolada",
        "guid": "",
        "children": []
      },
      {
        "id": "666",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "667",
        "parent": "0",
        "text": "- Uso infrecuente como\nterapia de primera línea en\npaíses de altos ingresos",
        "guid": "",
        "children": []
      },
      {
        "id": "668",
        "parent": "0",
        "text": "- Excepción: tratamiento\nde crisis neonatales",
        "guid": "",
        "children": []
      },
      {
        "id": "669",
        "parent": "0",
        "text": "- Ampliamente utilizado en\npaíses en desarrollo por:",
        "guid": "",
        "children": []
      },
      {
        "id": "670",
        "parent": "0",
        "text": "- Bajo costo",
        "guid": "",
        "children": []
      },
      {
        "id": "671",
        "parent": "0",
        "text": "- Amplia disponibilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "672",
        "parent": "0",
        "text": "- Debate sobre efectos\ncognitivos adversos:",
        "guid": "",
        "children": []
      },
      {
        "id": "673",
        "parent": "0",
        "text": "- Un estudio en China rural no\nreportó efectos cognitivos\nnegativos importantes",
        "guid": "",
        "children": []
      },
      {
        "id": "674",
        "parent": "0",
        "text": "- Algunas ganancias cognitivas,\nprobablemente relacionadas con\nmejor control de crisis",
        "guid": "",
        "children": []
      },
      {
        "id": "675",
        "parent": "0",
        "text": "# PRIMIDONA",
        "guid": "bLYd1DGST5EZ7-hXBrlOew",
        "children": []
      },
      {
        "id": "676",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "677",
        "parent": "0",
        "text": "- Metabolismo:",
        "guid": "",
        "children": []
      },
      {
        "id": "678",
        "parent": "0",
        "text": "- Convertida en el hígado a\nfenobarbital y\nfeniletilamalonamida (metabolito\nactivo)",
        "guid": "",
        "children": []
      },
      {
        "id": "679",
        "parent": "0",
        "text": "- En monoterapia, aproximadamente\n25% se convierte a fenobarbital",
        "guid": "",
        "children": []
      },
      {
        "id": "680",
        "parent": "0",
        "text": "- Disponible solo en\npreparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "681",
        "parent": "0",
        "text": "- Vida media:",
        "guid": "",
        "children": []
      },
      {
        "id": "682",
        "parent": "0",
        "text": "- 10-15 horas en\nmonoterapia",
        "guid": "",
        "children": []
      },
      {
        "id": "683",
        "parent": "0",
        "text": "- 6.5-8.3 horas con\ninductores enzimáticos",
        "guid": "",
        "children": []
      },
      {
        "id": "684",
        "parent": "0",
        "text": "- Potente\ninductor\nenzimático",
        "guid": "",
        "children": []
      },
      {
        "id": "685",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "686",
        "parent": "0",
        "text": "- Efectiva contra:",
        "guid": "",
        "children": []
      },
      {
        "id": "687",
        "parent": "0",
        "text": "- Crisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "688",
        "parent": "0",
        "text": "- Crisis\ntónico-clónicas\ngeneralizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "689",
        "parent": "0",
        "text": "- Evidencia anecdótica de eficacia\ncontra crisis mioclónicas en\nepilepsia mioclónica juvenil",
        "guid": "",
        "children": []
      },
      {
        "id": "690",
        "parent": "0",
        "text": "- También efectiva para\ncontrolar temblor esencial",
        "guid": "",
        "children": []
      },
      {
        "id": "691",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "692",
        "parent": "0",
        "text": "- Incluye todos los efectos del\nfenobarbital (sedación, etc.)",
        "guid": "",
        "children": []
      },
      {
        "id": "693",
        "parent": "0",
        "text": "- Puede asociarse con\nreacción tóxica aguda no\nrelacionada con fenobarbital:",
        "guid": "",
        "children": []
      },
      {
        "id": "694",
        "parent": "0",
        "text": "- Somnolencia\npotencialmente\ndebilitante",
        "guid": "",
        "children": []
      },
      {
        "id": "695",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "696",
        "parent": "0",
        "text": "- Ataxia",
        "guid": "",
        "children": []
      },
      {
        "id": "697",
        "parent": "0",
        "text": "- Náuseas",
        "guid": "",
        "children": []
      },
      {
        "id": "698",
        "parent": "0",
        "text": "- Vómitos",
        "guid": "",
        "children": []
      },
      {
        "id": "699",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "700",
        "parent": "0",
        "text": "- Inicio a dosis baja:\n50-125 mg al acostarse",
        "guid": "",
        "children": []
      },
      {
        "id": "701",
        "parent": "0",
        "text": "- Incremento gradual:\n50-125 mg cada 3-7 días",
        "guid": "",
        "children": []
      },
      {
        "id": "702",
        "parent": "0",
        "text": "- Objetivo: 250 mg\n3 veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "703",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "704",
        "parent": "0",
        "text": "- Uso infrecuente en la\npráctica actual",
        "guid": "",
        "children": []
      },
      {
        "id": "705",
        "parent": "0",
        "text": "- Fue el agente menos tolerado en el gran\nensayo cooperativo del Departamento de\nAsuntos de Veteranos de EE.UU.",
        "guid": "",
        "children": []
      },
      {
        "id": "706",
        "parent": "0",
        "text": "- Ensayo comparó eficacia y\ntolerabilidad de carbamazepina,\nfenobarbital, fenitoína y primidona",
        "guid": "",
        "children": []
      },
      {
        "id": "707",
        "parent": "0",
        "text": "- Pacientes adultos con\nepilepsia focal no tratada o\nsubtratada previamente",
        "guid": "",
        "children": []
      },
      {
        "id": "708",
        "parent": "0",
        "text": "# FENITOÍNA",
        "guid": "RqUn-zFgT5FXywvBBDsJfw",
        "children": []
      },
      {
        "id": "709",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "710",
        "parent": "0",
        "text": "- En uso clínico\ndesde 1938",
        "guid": "",
        "children": []
      },
      {
        "id": "711",
        "parent": "0",
        "text": "- Descubierta por su eficacia\nen modelo animal de\nelectrochoque máximo",
        "guid": "",
        "children": []
      },
      {
        "id": "712",
        "parent": "0",
        "text": "- Mecanismo de acción:",
        "guid": "",
        "children": []
      },
      {
        "id": "713",
        "parent": "0",
        "text": "- Se une al estado activo\ndel canal de sodio",
        "guid": "",
        "children": []
      },
      {
        "id": "714",
        "parent": "0",
        "text": "- Prolonga su estado de\ninactivación rápida",
        "guid": "",
        "children": []
      },
      {
        "id": "715",
        "parent": "0",
        "text": "- Reduce disparos de alta frecuencia\n(como en crisis epilépticas)",
        "guid": "",
        "children": []
      },
      {
        "id": "716",
        "parent": "0",
        "text": "- Permite potenciales de\nacción normales",
        "guid": "",
        "children": []
      },
      {
        "id": "717",
        "parent": "0",
        "text": "- Disponibilidad:",
        "guid": "",
        "children": []
      },
      {
        "id": "718",
        "parent": "0",
        "text": "- Preparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "719",
        "parent": "0",
        "text": "- Solución parenteral",
        "guid": "",
        "children": []
      },
      {
        "id": "720",
        "parent": "0",
        "text": "- Fosfenitoína (profármaco) para\nadministración IV e IM",
        "guid": "",
        "children": []
      },
      {
        "id": "721",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "722",
        "parent": "0",
        "text": "- Biodisponibilidad:",
        "guid": "",
        "children": []
      },
      {
        "id": "723",
        "parent": "0",
        "text": "- Reducida con coadministración\nde calcio, antiácidos y\nalimentación nasogástrica",
        "guid": "",
        "children": []
      },
      {
        "id": "724",
        "parent": "0",
        "text": "- Alta unión a\nproteínas (~90%)",
        "guid": "",
        "children": []
      },
      {
        "id": "725",
        "parent": "0",
        "text": "- Metabolismo hepático:",
        "guid": "",
        "children": []
      },
      {
        "id": "726",
        "parent": "0",
        "text": "- Principalmente\npor CYP2C9",
        "guid": "",
        "children": []
      },
      {
        "id": "727",
        "parent": "0",
        "text": "- En menor medida\npor CYP2C19",
        "guid": "",
        "children": []
      },
      {
        "id": "728",
        "parent": "0",
        "text": "- Cinética no lineal:",
        "guid": "",
        "children": []
      },
      {
        "id": "729",
        "parent": "0",
        "text": "- Metabolismo saturable",
        "guid": "",
        "children": []
      },
      {
        "id": "730",
        "parent": "0",
        "text": "- Al aumentar concentración\nsérica, aumenta vida media",
        "guid": "",
        "children": []
      },
      {
        "id": "731",
        "parent": "0",
        "text": "- Incrementos de dosis producen\naumentos desproporcionados en\nniveles plasmáticos",
        "guid": "",
        "children": []
      },
      {
        "id": "732",
        "parent": "0",
        "text": "- Potente inductor\nenzimático:",
        "guid": "",
        "children": []
      },
      {
        "id": "733",
        "parent": "0",
        "text": "- Reduce eficacia de fármacos\nmetabolizados por sistema P450",
        "guid": "",
        "children": []
      },
      {
        "id": "734",
        "parent": "0",
        "text": "- Afectado por agentes que\nreducen su metabolismo:",
        "guid": "",
        "children": []
      },
      {
        "id": "735",
        "parent": "0",
        "text": "- Amiodarona, fluoxetina, fluvoxamina,\nisoniazida, antifúngicos azólicos",
        "guid": "",
        "children": []
      },
      {
        "id": "736",
        "parent": "0",
        "text": "- Fracción libre de\nproteínas aumenta en:",
        "guid": "",
        "children": []
      },
      {
        "id": "737",
        "parent": "0",
        "text": "- Insuficiencia\nhepática y renal",
        "guid": "",
        "children": []
      },
      {
        "id": "738",
        "parent": "0",
        "text": "- Estados de\nbaja proteína",
        "guid": "",
        "children": []
      },
      {
        "id": "739",
        "parent": "0",
        "text": "- Embarazo",
        "guid": "",
        "children": []
      },
      {
        "id": "740",
        "parent": "0",
        "text": "- Personas >50 años",
        "guid": "",
        "children": []
      },
      {
        "id": "741",
        "parent": "0",
        "text": "- Presencia de fármacos altamente\nunidos a proteínas (ej. valproato)",
        "guid": "",
        "children": []
      },
      {
        "id": "742",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "743",
        "parent": "0",
        "text": "- Efectiva contra:",
        "guid": "",
        "children": []
      },
      {
        "id": "744",
        "parent": "0",
        "text": "- Crisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "745",
        "parent": "0",
        "text": "- Crisis\ntónico-clónicas\ngeneralizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "746",
        "parent": "0",
        "text": "- No efectiva contra:",
        "guid": "",
        "children": []
      },
      {
        "id": "747",
        "parent": "0",
        "text": "- Crisis mioclónicas\ngeneralizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "748",
        "parent": "0",
        "text": "- Crisis de ausencia\ngeneralizadas (puede\nexacerbarlas)",
        "guid": "",
        "children": []
      },
      {
        "id": "749",
        "parent": "0",
        "text": "- No es fármaco de elección en\nepilepsia generalizada idiopática",
        "guid": "",
        "children": []
      },
      {
        "id": "750",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "751",
        "parent": "0",
        "text": "- Dosis inicial: 200-400 mg/día\n(inicialmente en dosis nocturna)",
        "guid": "",
        "children": []
      },
      {
        "id": "752",
        "parent": "0",
        "text": "- Titulación basada en:",
        "guid": "",
        "children": []
      },
      {
        "id": "753",
        "parent": "0",
        "text": "- Respuesta clínica",
        "guid": "",
        "children": []
      },
      {
        "id": "754",
        "parent": "0",
        "text": "- Concentración sérica",
        "guid": "",
        "children": []
      },
      {
        "id": "755",
        "parent": "0",
        "text": "- Concentración sérica\n\"terapéutica\" recomendada:",
        "guid": "",
        "children": []
      },
      {
        "id": "756",
        "parent": "0",
        "text": "- Total: 10-20 μg/mL",
        "guid": "",
        "children": []
      },
      {
        "id": "757",
        "parent": "0",
        "text": "- Libre: 1-2 μg/mL (verificar en\nsituaciones donde se espera\naumento de fracción libre)",
        "guid": "",
        "children": []
      },
      {
        "id": "758",
        "parent": "0",
        "text": "- Debido a\ncinética no\nlineal:",
        "guid": "",
        "children": []
      },
      {
        "id": "759",
        "parent": "0",
        "text": "- Usar incrementos pequeños\n(30-60 mg) cuando nivel está en\nrango \"terapéutico\"",
        "guid": "",
        "children": []
      },
      {
        "id": "760",
        "parent": "0",
        "text": "- Preferencia por cápsulas de\nliberación prolongada",
        "guid": "",
        "children": []
      },
      {
        "id": "761",
        "parent": "0",
        "text": "- Dosificación 2 veces al día\nen crisis resistentes",
        "guid": "",
        "children": []
      },
      {
        "id": "762",
        "parent": "0",
        "text": "- Carga oral: 18 mg/kg divididos en\n3 dosis cada 2-3 horas (o dosis\núnica si es necesario)",
        "guid": "",
        "children": []
      },
      {
        "id": "763",
        "parent": "0",
        "text": "## ADMINISTRACIÓN\nPARENTERAL",
        "guid": "",
        "children": []
      },
      {
        "id": "764",
        "parent": "0",
        "text": "- Preparación IV\nde fenitoína:",
        "guid": "",
        "children": []
      },
      {
        "id": "765",
        "parent": "0",
        "text": "- Asociada con reacciones locales:\ndolor, flebitis, celulitis, síndrome\ndel guante púrpura",
        "guid": "",
        "children": []
      },
      {
        "id": "766",
        "parent": "0",
        "text": "- Administración IM\ncontraindicada:",
        "guid": "",
        "children": []
      },
      {
        "id": "767",
        "parent": "0",
        "text": "- Absorción errática",
        "guid": "",
        "children": []
      },
      {
        "id": "768",
        "parent": "0",
        "text": "- Formación de\nabscesos estériles",
        "guid": "",
        "children": []
      },
      {
        "id": "769",
        "parent": "0",
        "text": "- Fosfenitoína (profármaco)\npreferida para uso parenteral:",
        "guid": "",
        "children": []
      },
      {
        "id": "770",
        "parent": "0",
        "text": "- Menor incidencia de\nreacciones locales IV",
        "guid": "",
        "children": []
      },
      {
        "id": "771",
        "parent": "0",
        "text": "- Buena absorción IM\n(opción sin acceso IV)",
        "guid": "",
        "children": []
      },
      {
        "id": "772",
        "parent": "0",
        "text": "- Puede causar parestesias y prurito\n(mayormente en región inguinal)",
        "guid": "",
        "children": []
      },
      {
        "id": "773",
        "parent": "0",
        "text": "- Monitorización durante\nadministración IV:",
        "guid": "",
        "children": []
      },
      {
        "id": "774",
        "parent": "0",
        "text": "- ECG y presión\narterial recomendados",
        "guid": "",
        "children": []
      },
      {
        "id": "775",
        "parent": "0",
        "text": "- Velocidad no debe exceder: 50\nmg/min para fenitoína, 150\nmg/min para fosfenitoína",
        "guid": "",
        "children": []
      },
      {
        "id": "776",
        "parent": "0",
        "text": "- Riesgo de\nhipotensión y\narritmias",
        "guid": "",
        "children": []
      },
      {
        "id": "777",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "778",
        "parent": "0",
        "text": "- Menos sedante\nque fenobarbital",
        "guid": "",
        "children": []
      },
      {
        "id": "779",
        "parent": "0",
        "text": "- Efectos cognitivos adversos posibles\nincluso en rango terapéutico",
        "guid": "",
        "children": []
      },
      {
        "id": "780",
        "parent": "0",
        "text": "- Con\nconcentraciones\nelevadas:",
        "guid": "",
        "children": []
      },
      {
        "id": "781",
        "parent": "0",
        "text": "- Ataxia, incoordinación,\ndisartria, nistagmo, diplopía",
        "guid": "",
        "children": []
      },
      {
        "id": "782",
        "parent": "0",
        "text": "- Aumento paradójico de crisis con\nconcentraciones >30 μg/mL",
        "guid": "",
        "children": []
      },
      {
        "id": "783",
        "parent": "0",
        "text": "- Reacciones\nidiosincráticas:",
        "guid": "",
        "children": []
      },
      {
        "id": "784",
        "parent": "0",
        "text": "- Erupción alérgica (~6%\nen práctica clínica)",
        "guid": "",
        "children": []
      },
      {
        "id": "785",
        "parent": "0",
        "text": "- Raramente: síndrome de\nStevens-Johnson, necrólisis\nepidérmica tóxica",
        "guid": "",
        "children": []
      },
      {
        "id": "786",
        "parent": "0",
        "text": "- Síndrome de hipersensibilidad con fiebre,\nerupción, linfadenopatía, eosinofilia,\nalteraciones hepáticas y renales",
        "guid": "",
        "children": []
      },
      {
        "id": "787",
        "parent": "0",
        "text": "- Efectos adversos por\nuso prolongado:",
        "guid": "",
        "children": []
      },
      {
        "id": "788",
        "parent": "0",
        "text": "- Hiperplasia gingival",
        "guid": "",
        "children": []
      },
      {
        "id": "789",
        "parent": "0",
        "text": "- Acné",
        "guid": "",
        "children": []
      },
      {
        "id": "790",
        "parent": "0",
        "text": "- Hirsutismo",
        "guid": "",
        "children": []
      },
      {
        "id": "791",
        "parent": "0",
        "text": "- Atrofia cerebelosa",
        "guid": "",
        "children": []
      },
      {
        "id": "792",
        "parent": "0",
        "text": "- Disminución de\ndensidad ósea",
        "guid": "",
        "children": []
      },
      {
        "id": "793",
        "parent": "0",
        "text": "- Anemia",
        "guid": "",
        "children": []
      },
      {
        "id": "794",
        "parent": "0",
        "text": "- Neuropatía periférica",
        "guid": "",
        "children": []
      },
      {
        "id": "795",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "796",
        "parent": "0",
        "text": "- Fue el antiepiléptico más\nutilizado durante muchos años",
        "guid": "",
        "children": []
      },
      {
        "id": "797",
        "parent": "0",
        "text": "- Uso ha disminuido\nconsiderablemente con\naparición de nuevos\nantiepilépticos",
        "guid": "",
        "children": []
      },
      {
        "id": "798",
        "parent": "0",
        "text": "- Factores que\nlimitan su uso:",
        "guid": "",
        "children": []
      },
      {
        "id": "799",
        "parent": "0",
        "text": "- Ventana\nterapéutica\nestrecha",
        "guid": "",
        "children": []
      },
      {
        "id": "800",
        "parent": "0",
        "text": "- Dificultad para mantener\nconcentraciones recomendadas sin\ntoxicidad o infradosificación",
        "guid": "",
        "children": []
      },
      {
        "id": "801",
        "parent": "0",
        "text": "- Cinética no lineal",
        "guid": "",
        "children": []
      },
      {
        "id": "802",
        "parent": "0",
        "text": "- Absorción variable",
        "guid": "",
        "children": []
      },
      {
        "id": "803",
        "parent": "0",
        "text": "# CARBAMAZEPINA",
        "guid": "b4ccZ2K0Zw0L_7RYAZsUVg",
        "children": []
      },
      {
        "id": "804",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "805",
        "parent": "0",
        "text": "- Mecanismo de acción\nsimilar a fenitoína:",
        "guid": "",
        "children": []
      },
      {
        "id": "806",
        "parent": "0",
        "text": "- Bloquea el canal de sodio de forma\ndependiente de voltaje y uso",
        "guid": "",
        "children": []
      },
      {
        "id": "807",
        "parent": "0",
        "text": "- Reduce disparos\nneuronales de alta\nfrecuencia",
        "guid": "",
        "children": []
      },
      {
        "id": "808",
        "parent": "0",
        "text": "- Disponibilidad:",
        "guid": "",
        "children": []
      },
      {
        "id": "809",
        "parent": "0",
        "text": "- Tradicionalmente solo\npreparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "810",
        "parent": "0",
        "text": "- Preparación parenteral\naprobada en 2016 como terapia\nde reemplazo temporal",
        "guid": "",
        "children": []
      },
      {
        "id": "811",
        "parent": "0",
        "text": "- Buena\nbiodisponibilidad\noral",
        "guid": "",
        "children": []
      },
      {
        "id": "812",
        "parent": "0",
        "text": "- Unión a proteínas\naproximadamente 75% (no\nclínicamente significativa)",
        "guid": "",
        "children": []
      },
      {
        "id": "813",
        "parent": "0",
        "text": "- Metabolismo:",
        "guid": "",
        "children": []
      },
      {
        "id": "814",
        "parent": "0",
        "text": "- Hepático,\nprincipalmente por\nCYP3A4",
        "guid": "",
        "children": []
      },
      {
        "id": "815",
        "parent": "0",
        "text": "- Metabolito principal:\ncarbamazepina-10,11-epóxido (activo,\nresponsable de algunos efectos\nadversos)",
        "guid": "",
        "children": []
      },
      {
        "id": "816",
        "parent": "0",
        "text": "- Potente inductor\nenzimático:",
        "guid": "",
        "children": []
      },
      {
        "id": "817",
        "parent": "0",
        "text": "- Reduce niveles de fármacos y\nsustancias endógenas\nmetabolizadas por sistema CYP",
        "guid": "",
        "children": []
      },
      {
        "id": "818",
        "parent": "0",
        "text": "- Induce su propio\nmetabolismo\n(autoinducción)",
        "guid": "",
        "children": []
      },
      {
        "id": "819",
        "parent": "0",
        "text": "- Aumenta aclaramiento\nen 2-4 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "820",
        "parent": "0",
        "text": "- Acorta vida media",
        "guid": "",
        "children": []
      },
      {
        "id": "821",
        "parent": "0",
        "text": "- Disminuye\nconcentración\nsérica",
        "guid": "",
        "children": []
      },
      {
        "id": "822",
        "parent": "0",
        "text": "- Interacciones:",
        "guid": "",
        "children": []
      },
      {
        "id": "823",
        "parent": "0",
        "text": "- Puede acumularse con\ninhibidores de CYP3A4:",
        "guid": "",
        "children": []
      },
      {
        "id": "824",
        "parent": "0",
        "text": "- Eritromicina y otros antibióticos\nmacrólidos (excepto azitromicina)",
        "guid": "",
        "children": []
      },
      {
        "id": "825",
        "parent": "0",
        "text": "- Fluoxetina",
        "guid": "",
        "children": []
      },
      {
        "id": "826",
        "parent": "0",
        "text": "- Propoxifeno",
        "guid": "",
        "children": []
      },
      {
        "id": "827",
        "parent": "0",
        "text": "- Zumo de pomelo",
        "guid": "",
        "children": []
      },
      {
        "id": "828",
        "parent": "0",
        "text": "- Niveles de epóxido\naumentan con:",
        "guid": "",
        "children": []
      },
      {
        "id": "829",
        "parent": "0",
        "text": "- Valproato",
        "guid": "",
        "children": []
      },
      {
        "id": "830",
        "parent": "0",
        "text": "- Felbamato",
        "guid": "",
        "children": []
      },
      {
        "id": "831",
        "parent": "0",
        "text": "- Brivaracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "832",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "833",
        "parent": "0",
        "text": "- Efectiva contra:",
        "guid": "",
        "children": []
      },
      {
        "id": "834",
        "parent": "0",
        "text": "- Crisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "835",
        "parent": "0",
        "text": "- Crisis\ntónico-clónicas\ngeneralizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "836",
        "parent": "0",
        "text": "- Puede exacerbar:",
        "guid": "",
        "children": []
      },
      {
        "id": "837",
        "parent": "0",
        "text": "- Crisis de ausencia",
        "guid": "",
        "children": []
      },
      {
        "id": "838",
        "parent": "0",
        "text": "- Crisis mioclónicas",
        "guid": "",
        "children": []
      },
      {
        "id": "839",
        "parent": "0",
        "text": "- Crisis atónicas",
        "guid": "",
        "children": []
      },
      {
        "id": "840",
        "parent": "0",
        "text": "- No recomendada en epilepsia\ngeneralizada idiopática",
        "guid": "",
        "children": []
      },
      {
        "id": "841",
        "parent": "0",
        "text": "- Indicaciones\nFDA adicionales:",
        "guid": "",
        "children": []
      },
      {
        "id": "842",
        "parent": "0",
        "text": "- Neuralgia del trigémino",
        "guid": "",
        "children": []
      },
      {
        "id": "843",
        "parent": "0",
        "text": "- Manía aguda y\ntrastorno bipolar",
        "guid": "",
        "children": []
      },
      {
        "id": "844",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "845",
        "parent": "0",
        "text": "- Dosis inicial:",
        "guid": "",
        "children": []
      },
      {
        "id": "846",
        "parent": "0",
        "text": "- 100 mg 2\nveces al día, o",
        "guid": "",
        "children": []
      },
      {
        "id": "847",
        "parent": "0",
        "text": "- 200 mg al acostarse (preparación\nde liberación prolongada)",
        "guid": "",
        "children": []
      },
      {
        "id": "848",
        "parent": "0",
        "text": "- Incrementos: 200\nmg cada 3 días",
        "guid": "",
        "children": []
      },
      {
        "id": "849",
        "parent": "0",
        "text": "- Dosis objetivo: 400-800\nmg/día en 2 dosis divididas",
        "guid": "",
        "children": []
      },
      {
        "id": "850",
        "parent": "0",
        "text": "- Posibilidad de aumentar\ndosis si persisten crisis",
        "guid": "",
        "children": []
      },
      {
        "id": "851",
        "parent": "0",
        "text": "- Formulaciones de\nliberación inmediata:",
        "guid": "",
        "children": []
      },
      {
        "id": "852",
        "parent": "0",
        "text": "- Recomendadas en 3\ndosis divididas",
        "guid": "",
        "children": []
      },
      {
        "id": "853",
        "parent": "0",
        "text": "- Menor adherencia por\nesquema más complejo",
        "guid": "",
        "children": []
      },
      {
        "id": "854",
        "parent": "0",
        "text": "- Preparación de\nliberación prolongada:",
        "guid": "",
        "children": []
      },
      {
        "id": "855",
        "parent": "0",
        "text": "- Indicada para\ndosificación 2 veces al\ndía",
        "guid": "",
        "children": []
      },
      {
        "id": "856",
        "parent": "0",
        "text": "- Niveles más estables",
        "guid": "",
        "children": []
      },
      {
        "id": "857",
        "parent": "0",
        "text": "- Mejor\ntolerabilidad y\neficacia",
        "guid": "",
        "children": []
      },
      {
        "id": "858",
        "parent": "0",
        "text": "- Rango terapéutico\nrecomendado: 4-12 μg/mL",
        "guid": "",
        "children": []
      },
      {
        "id": "859",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "860",
        "parent": "0",
        "text": "- Comunes:",
        "guid": "",
        "children": []
      },
      {
        "id": "861",
        "parent": "0",
        "text": "- Náuseas",
        "guid": "",
        "children": []
      },
      {
        "id": "862",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "863",
        "parent": "0",
        "text": "- Sedación",
        "guid": "",
        "children": []
      },
      {
        "id": "864",
        "parent": "0",
        "text": "- Cansancio",
        "guid": "",
        "children": []
      },
      {
        "id": "865",
        "parent": "0",
        "text": "- Deterioro cognitivo documentado en\npruebas neuropsicológicas",
        "guid": "",
        "children": []
      },
      {
        "id": "866",
        "parent": "0",
        "text": "- Con niveles elevados:",
        "guid": "",
        "children": []
      },
      {
        "id": "867",
        "parent": "0",
        "text": "- Visión borrosa",
        "guid": "",
        "children": []
      },
      {
        "id": "868",
        "parent": "0",
        "text": "- Diplopía",
        "guid": "",
        "children": []
      },
      {
        "id": "869",
        "parent": "0",
        "text": "- Nistagmo",
        "guid": "",
        "children": []
      },
      {
        "id": "870",
        "parent": "0",
        "text": "- Inestabilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "871",
        "parent": "0",
        "text": "- Incoordinación",
        "guid": "",
        "children": []
      },
      {
        "id": "872",
        "parent": "0",
        "text": "- Temblor",
        "guid": "",
        "children": []
      },
      {
        "id": "873",
        "parent": "0",
        "text": "- Otros efectos:",
        "guid": "",
        "children": []
      },
      {
        "id": "874",
        "parent": "0",
        "text": "- Hiponatremia",
        "guid": "",
        "children": []
      },
      {
        "id": "875",
        "parent": "0",
        "text": "- Aumento de peso",
        "guid": "",
        "children": []
      },
      {
        "id": "876",
        "parent": "0",
        "text": "- Disminución de densidad\nósea (uso prolongado)",
        "guid": "",
        "children": []
      },
      {
        "id": "877",
        "parent": "0",
        "text": "- Leucopenia leve\n(10-20% de pacientes)",
        "guid": "",
        "children": []
      },
      {
        "id": "878",
        "parent": "0",
        "text": "- Generalmente benigna\naunque persistente",
        "guid": "",
        "children": []
      },
      {
        "id": "879",
        "parent": "0",
        "text": "- Anemia aplásica (rara,\nestimada en 1/200,000)",
        "guid": "",
        "children": []
      },
      {
        "id": "880",
        "parent": "0",
        "text": "- Seguimiento\nrecomendado:",
        "guid": "",
        "children": []
      },
      {
        "id": "881",
        "parent": "0",
        "text": "- Hemograma completo y enzimas\nhepáticas antes de iniciar terapia",
        "guid": "",
        "children": []
      },
      {
        "id": "882",
        "parent": "0",
        "text": "- Control después de 2-3\nmeses de tratamiento",
        "guid": "",
        "children": []
      },
      {
        "id": "883",
        "parent": "0",
        "text": "- Seguimiento cada 6-12 meses\nsegún necesidad clínica",
        "guid": "",
        "children": []
      },
      {
        "id": "884",
        "parent": "0",
        "text": "- Reacciones\nidiosincráticas:",
        "guid": "",
        "children": []
      },
      {
        "id": "885",
        "parent": "0",
        "text": "- Erupción cutánea (menos\ncomún que con fenitoína)",
        "guid": "",
        "children": []
      },
      {
        "id": "886",
        "parent": "0",
        "text": "- Síndrome de Stevens-Johnson y\nnecrólisis epidérmica tóxica (raros)",
        "guid": "",
        "children": []
      },
      {
        "id": "887",
        "parent": "0",
        "text": "- Mayor probabilidad con alelo\nHLA-B1502 en personas de\nascendencia asiática",
        "guid": "",
        "children": []
      },
      {
        "id": "888",
        "parent": "0",
        "text": "- Prueba genética de polimorfismos\nHLA-B indicada antes del inicio",
        "guid": "",
        "children": []
      },
      {
        "id": "889",
        "parent": "0",
        "text": "- Síndrome\nsimilar al lupus",
        "guid": "",
        "children": []
      },
      {
        "id": "890",
        "parent": "0",
        "text": "- Hepatotoxicidad",
        "guid": "",
        "children": []
      },
      {
        "id": "891",
        "parent": "0",
        "text": "- Síndrome de\nhipersensibilidad con fiebre,\nerupción y afectación\norgánica",
        "guid": "",
        "children": []
      },
      {
        "id": "892",
        "parent": "0",
        "text": "- Uso en politerapia: asociado con\nmayor riesgo de espina bífida en\nexposición durante gestación",
        "guid": "",
        "children": []
      },
      {
        "id": "893",
        "parent": "0",
        "text": "- Retirada abrupta: puede asociarse\ncon crisis de rebote graves",
        "guid": "",
        "children": []
      },
      {
        "id": "894",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "895",
        "parent": "0",
        "text": "- Mejor equilibrio de eficacia y tolerabilidad\nen estudio del Departamento de Asuntos\nde Veteranos de EE.UU.",
        "guid": "",
        "children": []
      },
      {
        "id": "896",
        "parent": "0",
        "text": "- Comparado con fenitoína,\nfenobarbital y primidona",
        "guid": "",
        "children": []
      },
      {
        "id": "897",
        "parent": "0",
        "text": "- Se convirtió en tratamiento estándar\npara crisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "898",
        "parent": "0",
        "text": "- Ningún fármaco ha\ndemostrado ser más eficaz",
        "guid": "",
        "children": []
      },
      {
        "id": "899",
        "parent": "0",
        "text": "- Uso ha disminuido con\ncomercialización de nuevos\nantiepilépticos con ventajas\nfarmacocinéticas",
        "guid": "",
        "children": []
      },
      {
        "id": "900",
        "parent": "0",
        "text": "- Lamotrigina, oxcarbazepina y gabapentina\ntienen mejor tolerabilidad que\ncarbamazepina de liberación inmediata",
        "guid": "",
        "children": []
      },
      {
        "id": "901",
        "parent": "0",
        "text": "- Ensayos comparativos con\ncarbamazepina de liberación prolongada:",
        "guid": "",
        "children": []
      },
      {
        "id": "902",
        "parent": "0",
        "text": "- No muestran tolerabilidad superior\nde lamotrigina, levetiracetam,\nzonisamida o lacosamida",
        "guid": "",
        "children": []
      },
      {
        "id": "903",
        "parent": "0",
        "text": "- Consideraciones\neconómicas favorecen\ncarbamazepina por menor\ncosto",
        "guid": "",
        "children": []
      },
      {
        "id": "904",
        "parent": "0",
        "text": "- Inducción enzimática e\ninteracciones farmacocinéticas\nfavorecen medicamentos más\nnuevos",
        "guid": "",
        "children": []
      },
      {
        "id": "905",
        "parent": "0",
        "text": "# OXCARBAZEPINA",
        "guid": "JLvcRnik6UBAN2A-JL8Z9w",
        "children": []
      },
      {
        "id": "906",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "907",
        "parent": "0",
        "text": "- Análogo estructural de\ncarbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "908",
        "parent": "0",
        "text": "- Diferencias estructurales menores resultan\nen cambios importantes en metabolismo e\ninducción de vías metabólicas",
        "guid": "",
        "children": []
      },
      {
        "id": "909",
        "parent": "0",
        "text": "- Mecanismo de acción similar a\ncarbamazepina y fenitoína:",
        "guid": "",
        "children": []
      },
      {
        "id": "910",
        "parent": "0",
        "text": "- Se une al\ncanal de sodio",
        "guid": "",
        "children": []
      },
      {
        "id": "911",
        "parent": "0",
        "text": "- Inhibe disparos neuronales\nrepetitivos de alta frecuencia",
        "guid": "",
        "children": []
      },
      {
        "id": "912",
        "parent": "0",
        "text": "- Solo disponible como\npreparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "913",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "914",
        "parent": "0",
        "text": "- Excelente\nbiodisponibilidad\noral",
        "guid": "",
        "children": []
      },
      {
        "id": "915",
        "parent": "0",
        "text": "- Conversión muy rápida al derivado\nmonohidroxi con dos enantiómeros:",
        "guid": "",
        "children": []
      },
      {
        "id": "916",
        "parent": "0",
        "text": "- S-licarbazepina (activo,\nresponsable del 80% de\nactividad anticonvulsivante)",
        "guid": "",
        "children": []
      },
      {
        "id": "917",
        "parent": "0",
        "text": "- R-licarbazepina (menos activo,\ncontribuye a efectos adversos)",
        "guid": "",
        "children": []
      },
      {
        "id": "918",
        "parent": "0",
        "text": "- Unión a proteínas no\nclínicamente significativa",
        "guid": "",
        "children": []
      },
      {
        "id": "919",
        "parent": "0",
        "text": "- Vida media:",
        "guid": "",
        "children": []
      },
      {
        "id": "920",
        "parent": "0",
        "text": "- Oxcarbazepina:\n1-3.7 horas",
        "guid": "",
        "children": []
      },
      {
        "id": "921",
        "parent": "0",
        "text": "- Derivados\nmonohidroxi: 8-10\nhoras",
        "guid": "",
        "children": []
      },
      {
        "id": "922",
        "parent": "0",
        "text": "- Interacciones:",
        "guid": "",
        "children": []
      },
      {
        "id": "923",
        "parent": "0",
        "text": "- Inductor débil de CYP3A4\n(responsable del\nmetabolismo de estrógenos)",
        "guid": "",
        "children": []
      },
      {
        "id": "924",
        "parent": "0",
        "text": "- Reduce eficacia de anticonceptivos\norales a dosis altas (>900 mg/día)",
        "guid": "",
        "children": []
      },
      {
        "id": "925",
        "parent": "0",
        "text": "- Inhibidor débil\nde CYP2C19",
        "guid": "",
        "children": []
      },
      {
        "id": "926",
        "parent": "0",
        "text": "- Aumenta nivel de\nfenitoína a dosis altas",
        "guid": "",
        "children": []
      },
      {
        "id": "927",
        "parent": "0",
        "text": "- No induce su\npropio metabolismo",
        "guid": "",
        "children": []
      },
      {
        "id": "928",
        "parent": "0",
        "text": "- No afectado por inhibidores de\nCYP3A4 (eritromicina, fluoxetina,\npropoxifeno, zumo de pomelo)",
        "guid": "",
        "children": []
      },
      {
        "id": "929",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "930",
        "parent": "0",
        "text": "- Efectiva contra\ncrisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "931",
        "parent": "0",
        "text": "- Puede exacerbar crisis de\nausencia y mioclónicas",
        "guid": "",
        "children": []
      },
      {
        "id": "932",
        "parent": "0",
        "text": "- Debe evitarse en pacientes con\nepilepsia generalizada",
        "guid": "",
        "children": []
      },
      {
        "id": "933",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "934",
        "parent": "0",
        "text": "- Inicio:",
        "guid": "",
        "children": []
      },
      {
        "id": "935",
        "parent": "0",
        "text": "- 300 mg 2\nveces al día, o",
        "guid": "",
        "children": []
      },
      {
        "id": "936",
        "parent": "0",
        "text": "- Preferiblemente 150 mg 2 veces al\ndía (ausencia de urgencia)",
        "guid": "",
        "children": []
      },
      {
        "id": "937",
        "parent": "0",
        "text": "- Titulación: 300\nmg/semana según\nnecesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "938",
        "parent": "0",
        "text": "- Dosis máxima en ensayos\nclínicos: 1200 mg 2 veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "939",
        "parent": "0",
        "text": "- Preparación de liberación\nprolongada disponible\n(dosificación una vez al día)",
        "guid": "",
        "children": []
      },
      {
        "id": "940",
        "parent": "0",
        "text": "- Rango terapéutico recomendado\n(derivado monohidroxi): 15-35 μg/mL",
        "guid": "",
        "children": []
      },
      {
        "id": "941",
        "parent": "0",
        "text": "- Conversión desde\ncarbamazepina:",
        "guid": "",
        "children": []
      },
      {
        "id": "942",
        "parent": "0",
        "text": "- 300 mg de oxcarbazepina por\ncada 200 mg de carbamazepina\n(dosis ≤800 mg)",
        "guid": "",
        "children": []
      },
      {
        "id": "943",
        "parent": "0",
        "text": "- Conversión más lenta y\nmenor proporción\nrecomendada para dosis más\naltas",
        "guid": "",
        "children": []
      },
      {
        "id": "944",
        "parent": "0",
        "text": "- Puede\nacompañarse\nde:",
        "guid": "",
        "children": []
      },
      {
        "id": "945",
        "parent": "0",
        "text": "- Reducción de\nconcentración de sodio",
        "guid": "",
        "children": []
      },
      {
        "id": "946",
        "parent": "0",
        "text": "- Aumento de niveles de\nmedicamentos concomitantes\nmetabolizados por sistema CYP",
        "guid": "",
        "children": []
      },
      {
        "id": "947",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "948",
        "parent": "0",
        "text": "- Comunes:",
        "guid": "",
        "children": []
      },
      {
        "id": "949",
        "parent": "0",
        "text": "- Somnolencia",
        "guid": "",
        "children": []
      },
      {
        "id": "950",
        "parent": "0",
        "text": "- Dolor de cabeza",
        "guid": "",
        "children": []
      },
      {
        "id": "951",
        "parent": "0",
        "text": "- Fatiga",
        "guid": "",
        "children": []
      },
      {
        "id": "952",
        "parent": "0",
        "text": "- Con dosis más altas:",
        "guid": "",
        "children": []
      },
      {
        "id": "953",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "954",
        "parent": "0",
        "text": "- Visión borrosa",
        "guid": "",
        "children": []
      },
      {
        "id": "955",
        "parent": "0",
        "text": "- Diplopía",
        "guid": "",
        "children": []
      },
      {
        "id": "956",
        "parent": "0",
        "text": "- Náuseas",
        "guid": "",
        "children": []
      },
      {
        "id": "957",
        "parent": "0",
        "text": "- Vómitos",
        "guid": "",
        "children": []
      },
      {
        "id": "958",
        "parent": "0",
        "text": "- Ataxia",
        "guid": "",
        "children": []
      },
      {
        "id": "959",
        "parent": "0",
        "text": "- Erupción cutánea\n(2-4% de individuos)",
        "guid": "",
        "children": []
      },
      {
        "id": "960",
        "parent": "0",
        "text": "- 25% de reactividad cruzada\ncon carbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "961",
        "parent": "0",
        "text": "- Mayor probabilidad de\nhiponatremia que carbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "962",
        "parent": "0",
        "text": "- Hiponatremia sintomática más\nprobable en personas mayores y\nquienes toman diuréticos",
        "guid": "",
        "children": []
      },
      {
        "id": "963",
        "parent": "0",
        "text": "- Retirada abrupta: puede asociarse\ncon crisis de rebote graves",
        "guid": "",
        "children": []
      },
      {
        "id": "964",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "965",
        "parent": "0",
        "text": "- Aprobada como monoterapia de primera\nlínea para crisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "966",
        "parent": "0",
        "text": "- Múltiples ensayos comparativos\nde monoterapia para epilepsia\nfocal de nuevo inicio:",
        "guid": "",
        "children": []
      },
      {
        "id": "967",
        "parent": "0",
        "text": "- Igual en eficacia a fenitoína y\ncarbamazepina de liberación inmediata",
        "guid": "",
        "children": []
      },
      {
        "id": "968",
        "parent": "0",
        "text": "- Posiblemente superior\nen tolerabilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "969",
        "parent": "0",
        "text": "- Combinación con otros\nbloqueadores clásicos de canales de\nsodio puede limitar tolerabilidad:",
        "guid": "",
        "children": []
      },
      {
        "id": "970",
        "parent": "0",
        "text": "- Con carbamazepina,\nlamotrigina, fenitoína",
        "guid": "",
        "children": []
      },
      {
        "id": "971",
        "parent": "0",
        "text": "- Debido a mareos,\ndiplopía y ataxia",
        "guid": "",
        "children": []
      },
      {
        "id": "972",
        "parent": "0",
        "text": "#\nESLICARBAZEPINA\nACETATO",
        "guid": "HP1TeDkSJedmiELIeaydCg",
        "children": []
      },
      {
        "id": "973",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "974",
        "parent": "0",
        "text": "- Aprobada en Estados\nUnidos en 2014",
        "guid": "",
        "children": []
      },
      {
        "id": "975",
        "parent": "0",
        "text": "- Representa tercera generación de\nderivados de carbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "976",
        "parent": "0",
        "text": "- Profármaco rápidamente\nconvertido a S-licarbazepina\n(eslicarbazepina)",
        "guid": "",
        "children": []
      },
      {
        "id": "977",
        "parent": "0",
        "text": "- Metabolito activo",
        "guid": "",
        "children": []
      },
      {
        "id": "978",
        "parent": "0",
        "text": "- Enantiómero activo del derivado\nmonohidroxi de oxcarbazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "979",
        "parent": "0",
        "text": "- Mecanismo de acción:",
        "guid": "",
        "children": []
      },
      {
        "id": "980",
        "parent": "0",
        "text": "- Bloquea\ncanales de\nsodio",
        "guid": "",
        "children": []
      },
      {
        "id": "981",
        "parent": "0",
        "text": "- Estabiliza estado inactivo del canal de\nsodio voltaje-dependiente (NaV)",
        "guid": "",
        "children": []
      },
      {
        "id": "982",
        "parent": "0",
        "text": "- A diferencia de\ncarbamazepina, puede\nmejorar inactivación lenta de\nNaVs",
        "guid": "",
        "children": []
      },
      {
        "id": "983",
        "parent": "0",
        "text": "- Solo disponible como\npreparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "984",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "985",
        "parent": "0",
        "text": "- Metabolizada a\ncompuestos inactivos",
        "guid": "",
        "children": []
      },
      {
        "id": "986",
        "parent": "0",
        "text": "- >50% excretada en orina como\neslicarbazepina sin cambios",
        "guid": "",
        "children": []
      },
      {
        "id": "987",
        "parent": "0",
        "text": "- Vida media:",
        "guid": "",
        "children": []
      },
      {
        "id": "988",
        "parent": "0",
        "text": "- 13-20 horas en plasma",
        "guid": "",
        "children": []
      },
      {
        "id": "989",
        "parent": "0",
        "text": "- 20-24 horas en LCR",
        "guid": "",
        "children": []
      },
      {
        "id": "990",
        "parent": "0",
        "text": "- Justifica dosificación\nuna vez al día",
        "guid": "",
        "children": []
      },
      {
        "id": "991",
        "parent": "0",
        "text": "- A diferencia de oxcarbazepina, no\nseguida por pico en LCR",
        "guid": "",
        "children": []
      },
      {
        "id": "992",
        "parent": "0",
        "text": "- Ausencia de pico posiblemente\nresponsable de menos efectos\nadversos agudos",
        "guid": "",
        "children": []
      },
      {
        "id": "993",
        "parent": "0",
        "text": "- Interacciones:",
        "guid": "",
        "children": []
      },
      {
        "id": "994",
        "parent": "0",
        "text": "- Inductor débil\nde CYP3A4",
        "guid": "",
        "children": []
      },
      {
        "id": "995",
        "parent": "0",
        "text": "- Potencialmente disminuye\nconcentraciones plasmáticas de\nestrógenos y otras moléculas",
        "guid": "",
        "children": []
      },
      {
        "id": "996",
        "parent": "0",
        "text": "- Inhibidor débil\nde CYP2C19",
        "guid": "",
        "children": []
      },
      {
        "id": "997",
        "parent": "0",
        "text": "- Potencialmente aumenta\nconcentración plasmática de\nfenitoína y otros fármacos",
        "guid": "",
        "children": []
      },
      {
        "id": "998",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "999",
        "parent": "0",
        "text": "- Efectiva contra\ncrisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "1000",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1001",
        "parent": "0",
        "text": "- Dosis inicial: 400\nmg una vez al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1002",
        "parent": "0",
        "text": "- Aumento a 800 mg una vez al\ndía después de 1 semana",
        "guid": "",
        "children": []
      },
      {
        "id": "1003",
        "parent": "0",
        "text": "- Si es necesario, aumento a 1200\nmg/día después de otra semana",
        "guid": "",
        "children": []
      },
      {
        "id": "1004",
        "parent": "0",
        "text": "- En estudio de conversión a monoterapia\nexitoso: dosis de 1600 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1005",
        "parent": "0",
        "text": "- En estudio inicial\nde monoterapia:",
        "guid": "",
        "children": []
      },
      {
        "id": "1006",
        "parent": "0",
        "text": "- Dos tercios de pacientes no\nrequirieron titulación más allá de\n800 mg/día durante 6 meses",
        "guid": "",
        "children": []
      },
      {
        "id": "1007",
        "parent": "0",
        "text": "- Gran mayoría mantuvo esta dosis\ndurante seguimiento a largo plazo",
        "guid": "",
        "children": []
      },
      {
        "id": "1008",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1009",
        "parent": "0",
        "text": "- Similares a oxcarbazepina\npero menos frecuentes",
        "guid": "",
        "children": []
      },
      {
        "id": "1010",
        "parent": "0",
        "text": "- Efectos adversos comunes\nrelacionados con dosis:",
        "guid": "",
        "children": []
      },
      {
        "id": "1011",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "1012",
        "parent": "0",
        "text": "- Somnolencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1013",
        "parent": "0",
        "text": "- Dolor de cabeza",
        "guid": "",
        "children": []
      },
      {
        "id": "1014",
        "parent": "0",
        "text": "- Diplopía",
        "guid": "",
        "children": []
      },
      {
        "id": "1015",
        "parent": "0",
        "text": "- Náuseas",
        "guid": "",
        "children": []
      },
      {
        "id": "1016",
        "parent": "0",
        "text": "- Vómitos",
        "guid": "",
        "children": []
      },
      {
        "id": "1017",
        "parent": "0",
        "text": "- Fatiga",
        "guid": "",
        "children": []
      },
      {
        "id": "1018",
        "parent": "0",
        "text": "- Ataxia",
        "guid": "",
        "children": []
      },
      {
        "id": "1019",
        "parent": "0",
        "text": "- Hiponatremia menos común que en\nensayos con oxcarbazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "1020",
        "parent": "0",
        "text": "- Niveles de sodio ≤125 mEq/L\nreportados en hasta 1.5% de\nindividuos tomando 1200 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1021",
        "parent": "0",
        "text": "- Erupción cutánea en hasta 3% de\nindividuos a 1200 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1022",
        "parent": "0",
        "text": "- Efectos neuropsicológicos\nadversos menos pronunciados\nque carbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "1023",
        "parent": "0",
        "text": "- Pequeño estudio prospectivo\nsugiere no efecto adverso\nsobre densidad ósea",
        "guid": "",
        "children": []
      },
      {
        "id": "1024",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1025",
        "parent": "0",
        "text": "- Inicialmente aprobada por FDA\ncomo tratamiento adyuvante para\ncrisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "1026",
        "parent": "0",
        "text": "- Mejor evitar combinación con\nfármacos clásicos de canal de sodio",
        "guid": "",
        "children": []
      },
      {
        "id": "1027",
        "parent": "0",
        "text": "- Combinación con\nlamotrigina menos\nproblemática que con\ncarbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "1028",
        "parent": "0",
        "text": "- Indicación de monoterapia tras\ncompletar con éxito ensayo de\nconversión a monoterapia",
        "guid": "",
        "children": []
      },
      {
        "id": "1029",
        "parent": "0",
        "text": "- Como oxcarbazepina, debe\nevitarse en epilepsia\ngeneralizada idiopática",
        "guid": "",
        "children": []
      },
      {
        "id": "1030",
        "parent": "0",
        "text": "- Puede considerarse\nmonoterapia de primera línea\npara crisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "1031",
        "parent": "0",
        "text": "- Ventajas de tolerabilidad sobre\noxcarbazepina de liberación inmediata",
        "guid": "",
        "children": []
      },
      {
        "id": "1032",
        "parent": "0",
        "text": "- Consideraciones financieras\npueden ser un obstáculo",
        "guid": "",
        "children": []
      },
      {
        "id": "1033",
        "parent": "0",
        "text": "# ÁCIDO VALPROICO Y\nDIVALPROEX SÓDICO\n(VALPROATO)",
        "guid": "c-1WaHNniFN52fL5STKBGA",
        "children": []
      },
      {
        "id": "1034",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1035",
        "parent": "0",
        "text": "- Múltiples\nmecanismos de\nacción:",
        "guid": "",
        "children": []
      },
      {
        "id": "1036",
        "parent": "0",
        "text": "- Potenciación de GABA",
        "guid": "",
        "children": []
      },
      {
        "id": "1037",
        "parent": "0",
        "text": "- Bloqueo de canales de calcio\ntipo T (predictivo de eficacia\ncontra crisis de ausencia)",
        "guid": "",
        "children": []
      },
      {
        "id": "1038",
        "parent": "0",
        "text": "- Bloqueo de\ncanales de sodio",
        "guid": "",
        "children": []
      },
      {
        "id": "1039",
        "parent": "0",
        "text": "- Disponibilidad:",
        "guid": "",
        "children": []
      },
      {
        "id": "1040",
        "parent": "0",
        "text": "- Preparaciones orales\n(principalmente como divalproex\nsódico)",
        "guid": "",
        "children": []
      },
      {
        "id": "1041",
        "parent": "0",
        "text": "- Complejo de ácido\nvalproico y valproato sódico",
        "guid": "",
        "children": []
      },
      {
        "id": "1042",
        "parent": "0",
        "text": "- Preparación parenteral\nde valproato sódico",
        "guid": "",
        "children": []
      },
      {
        "id": "1043",
        "parent": "0",
        "text": "- Biodisponibilidad\noral casi completa",
        "guid": "",
        "children": []
      },
      {
        "id": "1044",
        "parent": "0",
        "text": "- Ligeramente menor para\npreparación de liberación prolongada",
        "guid": "",
        "children": []
      },
      {
        "id": "1045",
        "parent": "0",
        "text": "- Alta unión a\nproteínas (~90%)",
        "guid": "",
        "children": []
      },
      {
        "id": "1046",
        "parent": "0",
        "text": "- Fracción libre\naumenta con:",
        "guid": "",
        "children": []
      },
      {
        "id": "1047",
        "parent": "0",
        "text": "- Aumento de\nconcentración total",
        "guid": "",
        "children": []
      },
      {
        "id": "1048",
        "parent": "0",
        "text": "- Coadministración de fenitoína\n(compite por unión a proteínas)",
        "guid": "",
        "children": []
      },
      {
        "id": "1049",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1050",
        "parent": "0",
        "text": "- Metabolismo extenso por\nconjugación y oxidación",
        "guid": "",
        "children": []
      },
      {
        "id": "1051",
        "parent": "0",
        "text": "- Vida media en\nadultos: 13-16 horas",
        "guid": "",
        "children": []
      },
      {
        "id": "1052",
        "parent": "0",
        "text": "- Más corta (~9 horas) con\nfármacos inductores enzimáticos",
        "guid": "",
        "children": []
      },
      {
        "id": "1053",
        "parent": "0",
        "text": "- Potente\ninhibidor\nenzimático",
        "guid": "",
        "children": []
      },
      {
        "id": "1054",
        "parent": "0",
        "text": "- Reduce aclaramiento de\nfenobarbital, lamotrigina, rufinamida\ny epóxido de carbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "1055",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1056",
        "parent": "0",
        "text": "- Amplio espectro de eficacia\ncontra todas las crisis focales\ny generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1057",
        "parent": "0",
        "text": "- Incluye crisis de ausencia\ngeneralizada y mioclónicas",
        "guid": "",
        "children": []
      },
      {
        "id": "1058",
        "parent": "0",
        "text": "- Formulación de divalproex sódico:\nindicaciones FDA adicionales",
        "guid": "",
        "children": []
      },
      {
        "id": "1059",
        "parent": "0",
        "text": "- Profilaxis de migraña",
        "guid": "",
        "children": []
      },
      {
        "id": "1060",
        "parent": "0",
        "text": "- Trastorno bipolar",
        "guid": "",
        "children": []
      },
      {
        "id": "1061",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1062",
        "parent": "0",
        "text": "- Inicio a dosis baja para\nmejorar tolerabilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1063",
        "parent": "0",
        "text": "- Preferencia por preparación de\ndivalproex sódico de liberación prolongada\n(administración una vez al día)",
        "guid": "",
        "children": []
      },
      {
        "id": "1064",
        "parent": "0",
        "text": "- Dosis inicial\nrecomendada:",
        "guid": "",
        "children": []
      },
      {
        "id": "1065",
        "parent": "0",
        "text": "- 500 mg al acostarse (divalproex\nsódico de liberación prolongada)",
        "guid": "",
        "children": []
      },
      {
        "id": "1066",
        "parent": "0",
        "text": "- 250 mg 2 veces al día\n(preparaciones de liberación\nretardada e inmediata)",
        "guid": "",
        "children": []
      },
      {
        "id": "1067",
        "parent": "0",
        "text": "- Incremento gradual según\nnecesidad para control de crisis",
        "guid": "",
        "children": []
      },
      {
        "id": "1068",
        "parent": "0",
        "text": "- Hasta\n1000-2000\nmg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1069",
        "parent": "0",
        "text": "- Evitar en pacientes femeninas en edad\nfértil por riesgo teratogénico",
        "guid": "",
        "children": []
      },
      {
        "id": "1070",
        "parent": "0",
        "text": "- Rango de concentración sérica\nterapéutica: 50-100 μg/mL",
        "guid": "",
        "children": []
      },
      {
        "id": "1071",
        "parent": "0",
        "text": "- Verificar concentración\nlibre de proteínas:",
        "guid": "",
        "children": []
      },
      {
        "id": "1072",
        "parent": "0",
        "text": "- A niveles altos",
        "guid": "",
        "children": []
      },
      {
        "id": "1073",
        "parent": "0",
        "text": "- En circunstancias donde se espera\naumento de fracción libre",
        "guid": "",
        "children": []
      },
      {
        "id": "1074",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1075",
        "parent": "0",
        "text": "- Irritación gástrica:",
        "guid": "",
        "children": []
      },
      {
        "id": "1076",
        "parent": "0",
        "text": "- Náuseas",
        "guid": "",
        "children": []
      },
      {
        "id": "1077",
        "parent": "0",
        "text": "- Vómitos",
        "guid": "",
        "children": []
      },
      {
        "id": "1078",
        "parent": "0",
        "text": "- Anorexia",
        "guid": "",
        "children": []
      },
      {
        "id": "1079",
        "parent": "0",
        "text": "- Otros posibles efectos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1080",
        "parent": "0",
        "text": "- Diarrea",
        "guid": "",
        "children": []
      },
      {
        "id": "1081",
        "parent": "0",
        "text": "- Fatiga",
        "guid": "",
        "children": []
      },
      {
        "id": "1082",
        "parent": "0",
        "text": "- Somnolencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1083",
        "parent": "0",
        "text": "- Temblor",
        "guid": "",
        "children": []
      },
      {
        "id": "1084",
        "parent": "0",
        "text": "- Aumento de peso",
        "guid": "",
        "children": []
      },
      {
        "id": "1085",
        "parent": "0",
        "text": "- Caída del cabello",
        "guid": "",
        "children": []
      },
      {
        "id": "1086",
        "parent": "0",
        "text": "- Edema periférico",
        "guid": "",
        "children": []
      },
      {
        "id": "1087",
        "parent": "0",
        "text": "- Confusión",
        "guid": "",
        "children": []
      },
      {
        "id": "1088",
        "parent": "0",
        "text": "- Mejor tolerabilidad con formulación\nde liberación prolongada",
        "guid": "",
        "children": []
      },
      {
        "id": "1089",
        "parent": "0",
        "text": "- Trombocitopenia\nrelacionada con dosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1090",
        "parent": "0",
        "text": "- Efectos endocrinos (más\nreconocidos en mujeres):",
        "guid": "",
        "children": []
      },
      {
        "id": "1091",
        "parent": "0",
        "text": "- Síndrome de\novario poliquístico",
        "guid": "",
        "children": []
      },
      {
        "id": "1092",
        "parent": "0",
        "text": "- Hiperandrogenismo",
        "guid": "",
        "children": []
      },
      {
        "id": "1093",
        "parent": "0",
        "text": "- Hiperinsulinemia",
        "guid": "",
        "children": []
      },
      {
        "id": "1094",
        "parent": "0",
        "text": "- Resistencia a insulina",
        "guid": "",
        "children": []
      },
      {
        "id": "1095",
        "parent": "0",
        "text": "- En adultos mayores\n(uso crónico):",
        "guid": "",
        "children": []
      },
      {
        "id": "1096",
        "parent": "0",
        "text": "- Parkinsonismo\nreversible",
        "guid": "",
        "children": []
      },
      {
        "id": "1097",
        "parent": "0",
        "text": "- Trastorno de la marcha",
        "guid": "",
        "children": []
      },
      {
        "id": "1098",
        "parent": "0",
        "text": "- Demencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1099",
        "parent": "0",
        "text": "- Atrofia cerebral",
        "guid": "",
        "children": []
      },
      {
        "id": "1100",
        "parent": "0",
        "text": "- En politerapia:",
        "guid": "",
        "children": []
      },
      {
        "id": "1101",
        "parent": "0",
        "text": "- Encefalopatía",
        "guid": "",
        "children": []
      },
      {
        "id": "1102",
        "parent": "0",
        "text": "- Hiperamonemia",
        "guid": "",
        "children": []
      },
      {
        "id": "1103",
        "parent": "0",
        "text": "- Efectos idiosincráticos (raros pero\npotencialmente mortales):",
        "guid": "",
        "children": []
      },
      {
        "id": "1104",
        "parent": "0",
        "text": "- Hepatotoxicidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1105",
        "parent": "0",
        "text": "- Pancreatitis",
        "guid": "",
        "children": []
      },
      {
        "id": "1106",
        "parent": "0",
        "text": "- Factores de riesgo:\npoliterapia y edad temprana",
        "guid": "",
        "children": []
      },
      {
        "id": "1107",
        "parent": "0",
        "text": "- Teratogenicidad:",
        "guid": "",
        "children": []
      },
      {
        "id": "1108",
        "parent": "0",
        "text": "- Relacionada con dosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1109",
        "parent": "0",
        "text": "- Mayor tasa que cualquier otro\nantiepiléptico comercializado",
        "guid": "",
        "children": []
      },
      {
        "id": "1110",
        "parent": "0",
        "text": "- Riesgo de malformaciones mayores\n>20% con dosis >1500 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1111",
        "parent": "0",
        "text": "- Exposición in utero\nasociada con:",
        "guid": "",
        "children": []
      },
      {
        "id": "1112",
        "parent": "0",
        "text": "- Reducción de CI verbal\ndependiente de dosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1113",
        "parent": "0",
        "text": "- Otras\ndisfunciones\ncognitivas",
        "guid": "",
        "children": []
      },
      {
        "id": "1114",
        "parent": "0",
        "text": "- Autismo",
        "guid": "",
        "children": []
      },
      {
        "id": "1115",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1116",
        "parent": "0",
        "text": "- Sigue siendo el antiepiléptico más eficaz para\nepilepsia generalizada idiopática con crisis\ntónico-clónicas generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1117",
        "parent": "0",
        "text": "- Debería seguir siendo fármaco de\nprimera elección para pacientes\nmasculinos con epilepsia generalizada",
        "guid": "",
        "children": []
      },
      {
        "id": "1118",
        "parent": "0",
        "text": "- Para crisis de ausencia\ngeneralizada en niños:",
        "guid": "",
        "children": []
      },
      {
        "id": "1119",
        "parent": "0",
        "text": "- Igual de efectivo\nque etosuximida",
        "guid": "",
        "children": []
      },
      {
        "id": "1120",
        "parent": "0",
        "text": "- Más efectos\nadversos cognitivos",
        "guid": "",
        "children": []
      },
      {
        "id": "1121",
        "parent": "0",
        "text": "- Estudio del Departamento de\nAsuntos de Veteranos de EE.UU.:",
        "guid": "",
        "children": []
      },
      {
        "id": "1122",
        "parent": "0",
        "text": "- Menos tolerado y menos efectivo que\ncarbamazepina para crisis focales con\nalteración de conciencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1123",
        "parent": "0",
        "text": "- Igualmente efectivo para crisis\nfocales con evolución a\ntónico-clónicas bilaterales",
        "guid": "",
        "children": []
      },
      {
        "id": "1124",
        "parent": "0",
        "text": "# ETOSUXIMIDA",
        "guid": "flLxqwqSqM1FwtOScQdWxw",
        "children": []
      },
      {
        "id": "1125",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1126",
        "parent": "0",
        "text": "- Bloquea corrientes\nde calcio tipo T",
        "guid": "",
        "children": []
      },
      {
        "id": "1127",
        "parent": "0",
        "text": "- Predice eficacia contra\ncrisis de ausencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1128",
        "parent": "0",
        "text": "- Excelente\nbiodisponibilidad oral\n(>90%)",
        "guid": "",
        "children": []
      },
      {
        "id": "1129",
        "parent": "0",
        "text": "- Unión a\nproteínas muy\nbaja",
        "guid": "",
        "children": []
      },
      {
        "id": "1130",
        "parent": "0",
        "text": "- Metabolismo\nextenso en hígado",
        "guid": "",
        "children": []
      },
      {
        "id": "1131",
        "parent": "0",
        "text": "- Vida media larga:\n30-60 horas",
        "guid": "",
        "children": []
      },
      {
        "id": "1132",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1133",
        "parent": "0",
        "text": "- Antiepiléptico de\nespectro estrecho",
        "guid": "",
        "children": []
      },
      {
        "id": "1134",
        "parent": "0",
        "text": "- Indicado únicamente para crisis de\nausencia generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1135",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1136",
        "parent": "0",
        "text": "- Dosis inicial:",
        "guid": "",
        "children": []
      },
      {
        "id": "1137",
        "parent": "0",
        "text": "- 250 mg/día (pacientes\nentre 3-6 años)",
        "guid": "",
        "children": []
      },
      {
        "id": "1138",
        "parent": "0",
        "text": "- 250 mg 2 veces al día\n(pacientes >6 años)",
        "guid": "",
        "children": []
      },
      {
        "id": "1139",
        "parent": "0",
        "text": "- Incrementos: 250 mg cada\nsemana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1140",
        "parent": "0",
        "text": "- Dosis máxima: 500\nmg 3 veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1141",
        "parent": "0",
        "text": "- Rango terapéutico\nrecomendado: 40-100 μg/mL",
        "guid": "",
        "children": []
      },
      {
        "id": "1142",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1143",
        "parent": "0",
        "text": "- Relacionados con dosis (mejoran\ncon administración de dosis\ndivididas con comidas):",
        "guid": "",
        "children": []
      },
      {
        "id": "1144",
        "parent": "0",
        "text": "- Náuseas",
        "guid": "",
        "children": []
      },
      {
        "id": "1145",
        "parent": "0",
        "text": "- Malestar abdominal",
        "guid": "",
        "children": []
      },
      {
        "id": "1146",
        "parent": "0",
        "text": "- Anorexia",
        "guid": "",
        "children": []
      },
      {
        "id": "1147",
        "parent": "0",
        "text": "- Vómitos",
        "guid": "",
        "children": []
      },
      {
        "id": "1148",
        "parent": "0",
        "text": "- Diarrea",
        "guid": "",
        "children": []
      },
      {
        "id": "1149",
        "parent": "0",
        "text": "- Somnolencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1150",
        "parent": "0",
        "text": "- Insomnio",
        "guid": "",
        "children": []
      },
      {
        "id": "1151",
        "parent": "0",
        "text": "- Nerviosismo",
        "guid": "",
        "children": []
      },
      {
        "id": "1152",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "1153",
        "parent": "0",
        "text": "- Fatiga",
        "guid": "",
        "children": []
      },
      {
        "id": "1154",
        "parent": "0",
        "text": "- Ataxia",
        "guid": "",
        "children": []
      },
      {
        "id": "1155",
        "parent": "0",
        "text": "- Cambios de\ncomportamiento",
        "guid": "",
        "children": []
      },
      {
        "id": "1156",
        "parent": "0",
        "text": "- No claramente\nrelacionados con dosis:",
        "guid": "",
        "children": []
      },
      {
        "id": "1157",
        "parent": "0",
        "text": "- Dolores de cabeza",
        "guid": "",
        "children": []
      },
      {
        "id": "1158",
        "parent": "0",
        "text": "- Psicosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1159",
        "parent": "0",
        "text": "- Depresión",
        "guid": "",
        "children": []
      },
      {
        "id": "1160",
        "parent": "0",
        "text": "- Alucinaciones",
        "guid": "",
        "children": []
      },
      {
        "id": "1161",
        "parent": "0",
        "text": "- Reacciones\nidiosincráticas:",
        "guid": "",
        "children": []
      },
      {
        "id": "1162",
        "parent": "0",
        "text": "- Erupción cutánea",
        "guid": "",
        "children": []
      },
      {
        "id": "1163",
        "parent": "0",
        "text": "- Síndrome de\nStevens-Johnson",
        "guid": "",
        "children": []
      },
      {
        "id": "1164",
        "parent": "0",
        "text": "- Lupus\neritematoso\nsistémico",
        "guid": "",
        "children": []
      },
      {
        "id": "1165",
        "parent": "0",
        "text": "- Anemia aplásica (rara)",
        "guid": "",
        "children": []
      },
      {
        "id": "1166",
        "parent": "0",
        "text": "- Trombocitopenia",
        "guid": "",
        "children": []
      },
      {
        "id": "1167",
        "parent": "0",
        "text": "- Agranulocitosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1168",
        "parent": "0",
        "text": "- Tiroiditis\nautoinmune\n(rara)",
        "guid": "",
        "children": []
      },
      {
        "id": "1169",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1170",
        "parent": "0",
        "text": "- Antiepiléptico de elección para epilepsia de\nausencia con crisis de ausencia generalizadas\ncomo único tipo de crisis",
        "guid": "",
        "children": []
      },
      {
        "id": "1171",
        "parent": "0",
        "text": "- Estatus respaldado por gran\nensayo multicéntrico aleatorizado\ncontrolado doble ciego",
        "guid": "",
        "children": []
      },
      {
        "id": "1172",
        "parent": "0",
        "text": "- Comparó etosuximida, ácido\nvalproico y lamotrigina",
        "guid": "",
        "children": []
      },
      {
        "id": "1173",
        "parent": "0",
        "text": "# BENZODIAZEPINAS",
        "guid": "Xas4rj8C5PhpYimjSmFWgg",
        "children": []
      },
      {
        "id": "1174",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1175",
        "parent": "0",
        "text": "- Actúan principalmente\nsobre receptor GABA-A",
        "guid": "",
        "children": []
      },
      {
        "id": "1176",
        "parent": "0",
        "text": "- Aumentan frecuencia de\napertura de canales de cloruro\nmediados por GABA",
        "guid": "",
        "children": []
      },
      {
        "id": "1177",
        "parent": "0",
        "text": "- Clonazepam y clobazam utilizados para\nmanejo crónico de epilepsia",
        "guid": "",
        "children": []
      },
      {
        "id": "1178",
        "parent": "0",
        "text": "- Clobazam: única 1,\n5-benzodiazepina (posición de\nátomos de nitrógeno en anillo\nheterocíclico)",
        "guid": "",
        "children": []
      },
      {
        "id": "1179",
        "parent": "0",
        "text": "- Otras benzodiazepinas: 1,\n4-benzodiazepinas",
        "guid": "",
        "children": []
      },
      {
        "id": "1180",
        "parent": "0",
        "text": "- En EE.UU. solo disponibles\ncomo preparaciones orales",
        "guid": "",
        "children": []
      },
      {
        "id": "1181",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1182",
        "parent": "0",
        "text": "- Ambas con buena\nbiodisponibilidad oral",
        "guid": "",
        "children": []
      },
      {
        "id": "1183",
        "parent": "0",
        "text": "- Ambas altamente\nunidas a proteínas",
        "guid": "",
        "children": []
      },
      {
        "id": "1184",
        "parent": "0",
        "text": "- Diferencias en\nmetabolismo:",
        "guid": "",
        "children": []
      },
      {
        "id": "1185",
        "parent": "0",
        "text": "- Clonazepam: convertido a\nmetabolitos inactivos",
        "guid": "",
        "children": []
      },
      {
        "id": "1186",
        "parent": "0",
        "text": "- Clobazam: metabolizado en hígado a\nN-desmetilclobazam (activo)",
        "guid": "",
        "children": []
      },
      {
        "id": "1187",
        "parent": "0",
        "text": "- Afinidad por\nsubunidades\nGABA-A:",
        "guid": "",
        "children": []
      },
      {
        "id": "1188",
        "parent": "0",
        "text": "- Clobazam y su metabolito activo:\nmayor afinidad por subunidad α2",
        "guid": "",
        "children": []
      },
      {
        "id": "1189",
        "parent": "0",
        "text": "- Media efectos\nanticonvulsivantes sin acciones\nsedantes",
        "guid": "",
        "children": []
      },
      {
        "id": "1190",
        "parent": "0",
        "text": "- Clonazepam: igual afinidad\npor subunidades α1 y α2",
        "guid": "",
        "children": []
      },
      {
        "id": "1191",
        "parent": "0",
        "text": "- Metabolito activo de clobazam\nsujeto a interacción con\ninhibidores de CYP2C19:",
        "guid": "",
        "children": []
      },
      {
        "id": "1192",
        "parent": "0",
        "text": "- Puede resultar en\nacumulación y sedación\nasociada",
        "guid": "",
        "children": []
      },
      {
        "id": "1193",
        "parent": "0",
        "text": "- Inhibidores incluyen felbamato,\ncannabidiol y cenobamate",
        "guid": "",
        "children": []
      },
      {
        "id": "1194",
        "parent": "0",
        "text": "- Ambas con vidas medias largas\n(justifica dosificación una vez al día)",
        "guid": "",
        "children": []
      },
      {
        "id": "1195",
        "parent": "0",
        "text": "- Clobazam dosificado 2 veces al\ndía en ensayos clínicos",
        "guid": "",
        "children": []
      },
      {
        "id": "1196",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1197",
        "parent": "0",
        "text": "- Ambas son agentes de\namplio espectro",
        "guid": "",
        "children": []
      },
      {
        "id": "1198",
        "parent": "0",
        "text": "- Indicación FDA limitada a tipos\nde crisis generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1199",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1200",
        "parent": "0",
        "text": "- Somnolencia: efecto adverso común\nque mejora con el tiempo",
        "guid": "",
        "children": []
      },
      {
        "id": "1201",
        "parent": "0",
        "text": "- Menos probable\ncon clobazam",
        "guid": "",
        "children": []
      },
      {
        "id": "1202",
        "parent": "0",
        "text": "- Con dosis crecientes:",
        "guid": "",
        "children": []
      },
      {
        "id": "1203",
        "parent": "0",
        "text": "- Nistagmo",
        "guid": "",
        "children": []
      },
      {
        "id": "1204",
        "parent": "0",
        "text": "- Incoordinación",
        "guid": "",
        "children": []
      },
      {
        "id": "1205",
        "parent": "0",
        "text": "- Inestabilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1206",
        "parent": "0",
        "text": "- Disartria",
        "guid": "",
        "children": []
      },
      {
        "id": "1207",
        "parent": "0",
        "text": "- Tolerancia al efecto\nterapéutico puede desarrollarse",
        "guid": "",
        "children": []
      },
      {
        "id": "1208",
        "parent": "0",
        "text": "- Menos probable\ncon clobazam",
        "guid": "",
        "children": []
      },
      {
        "id": "1209",
        "parent": "0",
        "text": "- Crisis por abstinencia posibles con\ndiscontinuación abrupta",
        "guid": "",
        "children": []
      },
      {
        "id": "1210",
        "parent": "0",
        "text": "- Todas las benzodiazepinas son\nsustancias controladas",
        "guid": "",
        "children": []
      },
      {
        "id": "1211",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1212",
        "parent": "0",
        "text": "- Típicamente usadas\ncomo terapia adyuvante",
        "guid": "",
        "children": []
      },
      {
        "id": "1213",
        "parent": "0",
        "text": "- Datos limitados para apoyar\nuso en monoterapia",
        "guid": "",
        "children": []
      },
      {
        "id": "1214",
        "parent": "0",
        "text": "- Indicación FDA\nde clobazam:",
        "guid": "",
        "children": []
      },
      {
        "id": "1215",
        "parent": "0",
        "text": "- Tratamiento adyuvante de\ncrisis asociadas con síndrome\nde Lennox-Gastaut",
        "guid": "",
        "children": []
      },
      {
        "id": "1216",
        "parent": "0",
        "text": "- Pacientes ≥2\naños de edad",
        "guid": "",
        "children": []
      },
      {
        "id": "1217",
        "parent": "0",
        "text": "- Evidencia clase IV de eficacia\ncomo tratamiento adyuvante:",
        "guid": "",
        "children": []
      },
      {
        "id": "1218",
        "parent": "0",
        "text": "- Epilepsia focal\nresistente a fármacos",
        "guid": "",
        "children": []
      },
      {
        "id": "1219",
        "parent": "0",
        "text": "- Epilepsia\ngeneralizada\nidiopática",
        "guid": "",
        "children": []
      },
      {
        "id": "1220",
        "parent": "0",
        "text": "# FELBAMATO",
        "guid": "",
        "children": []
      },
      {
        "id": "1221",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1222",
        "parent": "0",
        "text": "- Primer antiepiléptico de\nsegunda generación\naprobado en EE.UU. (1993)",
        "guid": "",
        "children": []
      },
      {
        "id": "1223",
        "parent": "0",
        "text": "- Múltiples\nmecanismos de\nacción:",
        "guid": "",
        "children": []
      },
      {
        "id": "1224",
        "parent": "0",
        "text": "- Antagonismo del receptor\nN-metil-D-aspartato (NMDA)",
        "guid": "",
        "children": []
      },
      {
        "id": "1225",
        "parent": "0",
        "text": "- Potenciación de GABA",
        "guid": "",
        "children": []
      },
      {
        "id": "1226",
        "parent": "0",
        "text": "- Bloqueo de\ncanales de sodio",
        "guid": "",
        "children": []
      },
      {
        "id": "1227",
        "parent": "0",
        "text": "- Disponible como\npreparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "1228",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1229",
        "parent": "0",
        "text": "- Excelente\nbiodisponibilidad\noral",
        "guid": "",
        "children": []
      },
      {
        "id": "1230",
        "parent": "0",
        "text": "- Unión a proteínas no\nclínicamente significativa",
        "guid": "",
        "children": []
      },
      {
        "id": "1231",
        "parent": "0",
        "text": "- Metabolizado en hígado a\nmetabolitos inactivos",
        "guid": "",
        "children": []
      },
      {
        "id": "1232",
        "parent": "0",
        "text": "- Vida media:\n20-23 horas",
        "guid": "",
        "children": []
      },
      {
        "id": "1233",
        "parent": "0",
        "text": "- Interacciones:",
        "guid": "",
        "children": []
      },
      {
        "id": "1234",
        "parent": "0",
        "text": "- Inhibidor de CYP2C19,\nCYP1A2 y β-oxidación",
        "guid": "",
        "children": []
      },
      {
        "id": "1235",
        "parent": "0",
        "text": "- Inhibe metabolismo de fenobarbital, fenitoína,\nvalproato, epóxido de carbamazepina,\nN-desmetilclobazam y warfarina",
        "guid": "",
        "children": []
      },
      {
        "id": "1236",
        "parent": "0",
        "text": "- Inductor débil\nde CYP3A4",
        "guid": "",
        "children": []
      },
      {
        "id": "1237",
        "parent": "0",
        "text": "- Disminuye niveles de\ncarbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "1238",
        "parent": "0",
        "text": "- Reduce eficacia de\nanticonceptivos orales",
        "guid": "",
        "children": []
      },
      {
        "id": "1239",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1240",
        "parent": "0",
        "text": "- Agente de\namplio espectro",
        "guid": "",
        "children": []
      },
      {
        "id": "1241",
        "parent": "0",
        "text": "- Efectivo contra:",
        "guid": "",
        "children": []
      },
      {
        "id": "1242",
        "parent": "0",
        "text": "- Crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1243",
        "parent": "0",
        "text": "- Crisis generalizadas en\nsíndrome de Lennox-Gastaut",
        "guid": "",
        "children": []
      },
      {
        "id": "1244",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1245",
        "parent": "0",
        "text": "- Dosis inicial: 600\nmg 2 veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1246",
        "parent": "0",
        "text": "- Titulación: 600 mg/semana\na 1200 mg/semana",
        "guid": "",
        "children": []
      },
      {
        "id": "1247",
        "parent": "0",
        "text": "- Hasta 1200 mg 3\nveces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1248",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1249",
        "parent": "0",
        "text": "- Comunes:",
        "guid": "",
        "children": []
      },
      {
        "id": "1250",
        "parent": "0",
        "text": "- Irritación gastrointestinal con\nanorexia, náuseas y vómitos",
        "guid": "",
        "children": []
      },
      {
        "id": "1251",
        "parent": "0",
        "text": "- Mejora con\nadministración con\nalimentos",
        "guid": "",
        "children": []
      },
      {
        "id": "1252",
        "parent": "0",
        "text": "- Insomnio",
        "guid": "",
        "children": []
      },
      {
        "id": "1253",
        "parent": "0",
        "text": "- Irritabilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1254",
        "parent": "0",
        "text": "- Dolor de cabeza",
        "guid": "",
        "children": []
      },
      {
        "id": "1255",
        "parent": "0",
        "text": "- Pérdida de peso",
        "guid": "",
        "children": []
      },
      {
        "id": "1256",
        "parent": "0",
        "text": "- Toxicidades graves:",
        "guid": "",
        "children": []
      },
      {
        "id": "1257",
        "parent": "0",
        "text": "- Anemia aplásica",
        "guid": "",
        "children": []
      },
      {
        "id": "1258",
        "parent": "0",
        "text": "- Riesgo estimado: 1/5000\na 1/8000 pacientes",
        "guid": "",
        "children": []
      },
      {
        "id": "1259",
        "parent": "0",
        "text": "- Improbable después de 1\naño de tratamiento",
        "guid": "",
        "children": []
      },
      {
        "id": "1260",
        "parent": "0",
        "text": "- No reportada en\npacientes <13 años",
        "guid": "",
        "children": []
      },
      {
        "id": "1261",
        "parent": "0",
        "text": "- Insuficiencia hepática",
        "guid": "",
        "children": []
      },
      {
        "id": "1262",
        "parent": "0",
        "text": "- Riesgo estimado: 1/26,000\na 1/54,000 pacientes",
        "guid": "",
        "children": []
      },
      {
        "id": "1263",
        "parent": "0",
        "text": "- Advertencia especial por\nestos efectos graves",
        "guid": "",
        "children": []
      },
      {
        "id": "1264",
        "parent": "0",
        "text": "- Uso solo para epilepsia grave donde\nbeneficios superan riesgos",
        "guid": "",
        "children": []
      },
      {
        "id": "1265",
        "parent": "0",
        "text": "- Monitorización\nrecomendada:",
        "guid": "",
        "children": []
      },
      {
        "id": "1266",
        "parent": "0",
        "text": "- Hemograma completo y prueba\nfunción hepática antes de iniciar",
        "guid": "",
        "children": []
      },
      {
        "id": "1267",
        "parent": "0",
        "text": "- Repetir cada 2 semanas\nen primeros 6 meses",
        "guid": "",
        "children": []
      },
      {
        "id": "1268",
        "parent": "0",
        "text": "- Reducir frecuencia a cada 3\nmeses después de 1 año",
        "guid": "",
        "children": []
      },
      {
        "id": "1269",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1270",
        "parent": "0",
        "text": "- Aunque aprobado para\nmonoterapia, no indicado como\ntratamiento de primera línea",
        "guid": "",
        "children": []
      },
      {
        "id": "1271",
        "parent": "0",
        "text": "- Debido a potencial toxicidad\nidiosincrática grave",
        "guid": "",
        "children": []
      },
      {
        "id": "1272",
        "parent": "0",
        "text": "- Terapia adyuvante o monoterapia\nalternativa cuando otras opciones\napropiadas y más seguras han fallado",
        "guid": "",
        "children": []
      },
      {
        "id": "1273",
        "parent": "0",
        "text": "# GABAPENTINA",
        "guid": "cJU0iQNSEftRGqT9NzpchQ",
        "children": []
      },
      {
        "id": "1274",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1275",
        "parent": "0",
        "text": "- Se une a la subunidad α2δ de canales\nde sodio voltaje-dependientes",
        "guid": "",
        "children": []
      },
      {
        "id": "1276",
        "parent": "0",
        "text": "- Reduce el\ninflujo de calcio",
        "guid": "",
        "children": []
      },
      {
        "id": "1277",
        "parent": "0",
        "text": "- Disminuye liberación de\nneurotransmisores en\ncondiciones de\nhiperexcitabilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1278",
        "parent": "0",
        "text": "- Disponible únicamente\ncomo preparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "1279",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1280",
        "parent": "0",
        "text": "- Biodisponibilidad:",
        "guid": "",
        "children": []
      },
      {
        "id": "1281",
        "parent": "0",
        "text": "- Baja y variable entre sujetos e\nincluso en el mismo sujeto",
        "guid": "",
        "children": []
      },
      {
        "id": "1282",
        "parent": "0",
        "text": "- Disminuye con aumento de dosis\ndebido a sistema de transporte activo\nsaturable desde intestino",
        "guid": "",
        "children": []
      },
      {
        "id": "1283",
        "parent": "0",
        "text": "- 60% tras dosis\núnica de 300 mg",
        "guid": "",
        "children": []
      },
      {
        "id": "1284",
        "parent": "0",
        "text": "- 29% para 1600 mg\n3 veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1285",
        "parent": "0",
        "text": "- Unión a proteínas\ndespreciable",
        "guid": "",
        "children": []
      },
      {
        "id": "1286",
        "parent": "0",
        "text": "- Eliminada sin\ncambios en orina",
        "guid": "",
        "children": []
      },
      {
        "id": "1287",
        "parent": "0",
        "text": "- Vida media: 5-7 horas",
        "guid": "",
        "children": []
      },
      {
        "id": "1288",
        "parent": "0",
        "text": "- Interacciones:",
        "guid": "",
        "children": []
      },
      {
        "id": "1289",
        "parent": "0",
        "text": "- No conocidas, excepto\nposible interferencia de\nantiácidos con su absorción",
        "guid": "",
        "children": []
      },
      {
        "id": "1290",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1291",
        "parent": "0",
        "text": "- Agente de espectro estrecho\ncontra crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1292",
        "parent": "0",
        "text": "- Puede causar\nexacerbación de\nmioclonías",
        "guid": "",
        "children": []
      },
      {
        "id": "1293",
        "parent": "0",
        "text": "- Aprobaciones\nFDA adicionales:",
        "guid": "",
        "children": []
      },
      {
        "id": "1294",
        "parent": "0",
        "text": "- Tratamiento de\nneuralgia postherpética",
        "guid": "",
        "children": []
      },
      {
        "id": "1295",
        "parent": "0",
        "text": "- Preparación de liberación\nprolongada (gabapentina enacarbil):",
        "guid": "",
        "children": []
      },
      {
        "id": "1296",
        "parent": "0",
        "text": "- Síndrome de\npiernas inquietas",
        "guid": "",
        "children": []
      },
      {
        "id": "1297",
        "parent": "0",
        "text": "- Neuralgia\npostherpética",
        "guid": "",
        "children": []
      },
      {
        "id": "1298",
        "parent": "0",
        "text": "- Otra forma de\ndosificación\ngastrorretentiva:",
        "guid": "",
        "children": []
      },
      {
        "id": "1299",
        "parent": "0",
        "text": "- Manejo de\nneuralgia\npostherpética",
        "guid": "",
        "children": []
      },
      {
        "id": "1300",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1301",
        "parent": "0",
        "text": "- Dosis inicial:\n300-400 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1302",
        "parent": "0",
        "text": "- Incremento:\n300-400 mg cada\ndía",
        "guid": "",
        "children": []
      },
      {
        "id": "1303",
        "parent": "0",
        "text": "- Hasta 300-400 mg\n3 veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1304",
        "parent": "0",
        "text": "- Posibilidad de aumentar según\nnecesidad hasta 4800 mg/día en\n3 dosis divididas",
        "guid": "",
        "children": []
      },
      {
        "id": "1305",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1306",
        "parent": "0",
        "text": "- Posibles efectos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1307",
        "parent": "0",
        "text": "- Somnolencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1308",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "1309",
        "parent": "0",
        "text": "- Ataxia",
        "guid": "",
        "children": []
      },
      {
        "id": "1310",
        "parent": "0",
        "text": "- Cansancio",
        "guid": "",
        "children": []
      },
      {
        "id": "1311",
        "parent": "0",
        "text": "- Aumento de peso",
        "guid": "",
        "children": []
      },
      {
        "id": "1312",
        "parent": "0",
        "text": "- Puede causar\nmioclonías",
        "guid": "",
        "children": []
      },
      {
        "id": "1313",
        "parent": "0",
        "text": "- Puede provocar:",
        "guid": "",
        "children": []
      },
      {
        "id": "1314",
        "parent": "0",
        "text": "- Enlentecimiento cognitivo\nen adultos mayores",
        "guid": "",
        "children": []
      },
      {
        "id": "1315",
        "parent": "0",
        "text": "- Labilidad\nemocional en\nniños",
        "guid": "",
        "children": []
      },
      {
        "id": "1316",
        "parent": "0",
        "text": "- Edema periférico más probable\ncon aumento de edad",
        "guid": "",
        "children": []
      },
      {
        "id": "1317",
        "parent": "0",
        "text": "- Reclasificada como sustancia\ncontrolada en algunos estados",
        "guid": "",
        "children": []
      },
      {
        "id": "1318",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1319",
        "parent": "0",
        "text": "- Puede usarse como tratamiento\nadyuvante para crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1320",
        "parent": "0",
        "text": "- A menudo elegida por:",
        "guid": "",
        "children": []
      },
      {
        "id": "1321",
        "parent": "0",
        "text": "- Beneficio anecdótico en tratamiento\nde cefalea y otros dolores",
        "guid": "",
        "children": []
      },
      {
        "id": "1322",
        "parent": "0",
        "text": "- Beneficio\npara el sueño",
        "guid": "",
        "children": []
      },
      {
        "id": "1323",
        "parent": "0",
        "text": "- Aunque aprobada en Europa\ncomo monoterapia inicial:",
        "guid": "",
        "children": []
      },
      {
        "id": "1324",
        "parent": "0",
        "text": "- Gran ensayo comparativo\naleatorizado la encontró menos\nefectiva que lamotrigina",
        "guid": "",
        "children": []
      },
      {
        "id": "1325",
        "parent": "0",
        "text": "# PREGABALINA",
        "guid": "NLJhjCjlsL87dWYEJDl99A",
        "children": []
      },
      {
        "id": "1326",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1327",
        "parent": "0",
        "text": "- Estructuralmente\nrelacionada con\ngabapentina",
        "guid": "",
        "children": []
      },
      {
        "id": "1328",
        "parent": "0",
        "text": "- Mecanismo de\nacción similar",
        "guid": "",
        "children": []
      },
      {
        "id": "1329",
        "parent": "0",
        "text": "- Disponible únicamente\ncomo preparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "1330",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1331",
        "parent": "0",
        "text": "- A diferencia de\ngabapentina:",
        "guid": "",
        "children": []
      },
      {
        "id": "1332",
        "parent": "0",
        "text": "- Muy buena\nbiodisponibilidad\noral",
        "guid": "",
        "children": []
      },
      {
        "id": "1333",
        "parent": "0",
        "text": "- Independiente\nde la dosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1334",
        "parent": "0",
        "text": "- Sin unión a proteínas",
        "guid": "",
        "children": []
      },
      {
        "id": "1335",
        "parent": "0",
        "text": "- No metabolizada\nen humanos",
        "guid": "",
        "children": []
      },
      {
        "id": "1336",
        "parent": "0",
        "text": "- Sin\ninteracciones\nconocidas",
        "guid": "",
        "children": []
      },
      {
        "id": "1337",
        "parent": "0",
        "text": "- Excretada sin\ncambios en orina",
        "guid": "",
        "children": []
      },
      {
        "id": "1338",
        "parent": "0",
        "text": "- Vida media:\naproximadamente 6\nhoras",
        "guid": "",
        "children": []
      },
      {
        "id": "1339",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1340",
        "parent": "0",
        "text": "- Fármaco de espectro\nestrecho contra crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1341",
        "parent": "0",
        "text": "- Indicación FDA oficial\npara epilepsia:",
        "guid": "",
        "children": []
      },
      {
        "id": "1342",
        "parent": "0",
        "text": "- Terapia adyuvante para pacientes\nadultos con crisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "1343",
        "parent": "0",
        "text": "- Como gabapentina:",
        "guid": "",
        "children": []
      },
      {
        "id": "1344",
        "parent": "0",
        "text": "- Espectro estrecho de\neficacia contra crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1345",
        "parent": "0",
        "text": "- Puede exacerbar crisis mioclónicas y\nde ausencia generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1346",
        "parent": "0",
        "text": "- Indicaciones\nFDA adicionales:",
        "guid": "",
        "children": []
      },
      {
        "id": "1347",
        "parent": "0",
        "text": "- Dolor neuropático asociado con\nneuropatía periférica diabética",
        "guid": "",
        "children": []
      },
      {
        "id": "1348",
        "parent": "0",
        "text": "- Neuralgia\npostherpética",
        "guid": "",
        "children": []
      },
      {
        "id": "1349",
        "parent": "0",
        "text": "- Fibromialgia",
        "guid": "",
        "children": []
      },
      {
        "id": "1350",
        "parent": "0",
        "text": "- Dolor neuropático asociado\ncon lesión medular",
        "guid": "",
        "children": []
      },
      {
        "id": "1351",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1352",
        "parent": "0",
        "text": "- Dosis inicial: 75 mg una vez (al\nacostarse) o dos veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1353",
        "parent": "0",
        "text": "- Incremento: 75-150 mg cada\nsemana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1354",
        "parent": "0",
        "text": "- Hasta control de crisis, aparición de\nefectos adversos o dosis máxima de\n300 mg 2 veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1355",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1356",
        "parent": "0",
        "text": "- Posibles efectos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1357",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "1358",
        "parent": "0",
        "text": "- Somnolencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1359",
        "parent": "0",
        "text": "- Aumento del apetito",
        "guid": "",
        "children": []
      },
      {
        "id": "1360",
        "parent": "0",
        "text": "- Aumento de peso",
        "guid": "",
        "children": []
      },
      {
        "id": "1361",
        "parent": "0",
        "text": "- Edema periférico",
        "guid": "",
        "children": []
      },
      {
        "id": "1362",
        "parent": "0",
        "text": "- Mioclonías posibles con dosis más\naltas en algunos individuos",
        "guid": "",
        "children": []
      },
      {
        "id": "1363",
        "parent": "0",
        "text": "- Es una\nsustancia\ncontrolada",
        "guid": "",
        "children": []
      },
      {
        "id": "1364",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1365",
        "parent": "0",
        "text": "- Indicada como terapia\nadyuvante para crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1366",
        "parent": "0",
        "text": "- Inferior a lamotrigina como\nterapia de primera línea",
        "guid": "",
        "children": []
      },
      {
        "id": "1367",
        "parent": "0",
        "text": "- Probablemente no debe usarse como\ntratamiento de primera línea",
        "guid": "",
        "children": []
      },
      {
        "id": "1368",
        "parent": "0",
        "text": "- Sin embargo, un estudio de\nconversión a monoterapia fue exitoso",
        "guid": "",
        "children": []
      },
      {
        "id": "1369",
        "parent": "0",
        "text": "# LAMOTRIGINA",
        "guid": "C5oXzEd1Glwl1JJKMFX0Eg",
        "children": []
      },
      {
        "id": "1370",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1371",
        "parent": "0",
        "text": "- Bloquea canales de sodio como\nfenitoína y carbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "1372",
        "parent": "0",
        "text": "- Se cree que tiene otras acciones no\nreconocidas que explican eficacia\ncontra crisis de ausencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1373",
        "parent": "0",
        "text": "- Disponible únicamente\ncomo preparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "1374",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1375",
        "parent": "0",
        "text": "- Excelente\nbiodisponibilidad\noral",
        "guid": "",
        "children": []
      },
      {
        "id": "1376",
        "parent": "0",
        "text": "- Unión a proteínas no\nclínicamente significativa",
        "guid": "",
        "children": []
      },
      {
        "id": "1377",
        "parent": "0",
        "text": "- Metabolismo\nextenso en hígado:",
        "guid": "",
        "children": []
      },
      {
        "id": "1378",
        "parent": "0",
        "text": "- Predominantemente\npor glucuronidación",
        "guid": "",
        "children": []
      },
      {
        "id": "1379",
        "parent": "0",
        "text": "- Eliminación en orina",
        "guid": "",
        "children": []
      },
      {
        "id": "1380",
        "parent": "0",
        "text": "- Vida media:",
        "guid": "",
        "children": []
      },
      {
        "id": "1381",
        "parent": "0",
        "text": "- Aproximadamente 24\nhoras en monoterapia",
        "guid": "",
        "children": []
      },
      {
        "id": "1382",
        "parent": "0",
        "text": "- Al menos el doble cuando\nse usa con valproato",
        "guid": "",
        "children": []
      },
      {
        "id": "1383",
        "parent": "0",
        "text": "- Aproximadamente la mitad cuando se\nusa con inductor enzimático",
        "guid": "",
        "children": []
      },
      {
        "id": "1384",
        "parent": "0",
        "text": "- Estrógenos y embarazo aumentan\naclaramiento de lamotrigina",
        "guid": "",
        "children": []
      },
      {
        "id": "1385",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1386",
        "parent": "0",
        "text": "- Antiepiléptico de\namplio espectro",
        "guid": "",
        "children": []
      },
      {
        "id": "1387",
        "parent": "0",
        "text": "- Indicaciones\nFDA limitadas a:",
        "guid": "",
        "children": []
      },
      {
        "id": "1388",
        "parent": "0",
        "text": "- Crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1389",
        "parent": "0",
        "text": "- Crisis\ntónico-clónicas\ngeneralizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1390",
        "parent": "0",
        "text": "- Síndrome de\nLennox-Gastaut",
        "guid": "",
        "children": []
      },
      {
        "id": "1391",
        "parent": "0",
        "text": "- Menos efectiva contra crisis de\nausencia generalizadas que\nvalproato y etosuximida",
        "guid": "",
        "children": []
      },
      {
        "id": "1392",
        "parent": "0",
        "text": "- Puede ser efectiva contra crisis\nmioclónicas en algunos pacientes, pero\npuede exacerbarlas en otros",
        "guid": "",
        "children": []
      },
      {
        "id": "1393",
        "parent": "0",
        "text": "- Indicación FDA adicional:\ntratamiento de mantenimiento\nen trastorno bipolar I",
        "guid": "",
        "children": []
      },
      {
        "id": "1394",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1395",
        "parent": "0",
        "text": "- Requiere titulación muy\nlenta para evitar desarrollo\nde erupción cutánea",
        "guid": "",
        "children": []
      },
      {
        "id": "1396",
        "parent": "0",
        "text": "- En monoterapia:",
        "guid": "",
        "children": []
      },
      {
        "id": "1397",
        "parent": "0",
        "text": "- Inicio: 25 mg/día\ndurante 2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "1398",
        "parent": "0",
        "text": "- Seguido por 50 mg/día\ndurante 2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "1399",
        "parent": "0",
        "text": "- Luego 100 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1400",
        "parent": "0",
        "text": "- Incrementos según necesidad:\n100 mg cada 2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "1401",
        "parent": "0",
        "text": "- Velocidad de titulación:",
        "guid": "",
        "children": []
      },
      {
        "id": "1402",
        "parent": "0",
        "text": "- Mitad de rápida con ácido\nvalproico adyuvante",
        "guid": "",
        "children": []
      },
      {
        "id": "1403",
        "parent": "0",
        "text": "- Doble de rápida en presencia\nde inductor enzimático y\nausencia de ácido valproico",
        "guid": "",
        "children": []
      },
      {
        "id": "1404",
        "parent": "0",
        "text": "- Concentración sérica útil para guiar\ntitulación adicional si crisis no\ncontroladas a 600 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1405",
        "parent": "0",
        "text": "- Rango terapéutico\nsugerido: 2-20 μg/mL",
        "guid": "",
        "children": []
      },
      {
        "id": "1406",
        "parent": "0",
        "text": "- Preparación de\nliberación prolongada:",
        "guid": "",
        "children": []
      },
      {
        "id": "1407",
        "parent": "0",
        "text": "- Permite dosificación\nuna vez al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1408",
        "parent": "0",
        "text": "- Reduce toxicidad\npor niveles pico",
        "guid": "",
        "children": []
      },
      {
        "id": "1409",
        "parent": "0",
        "text": "- Puede mejorar eficacia\ncuando se usa 2 veces al día\nen pacientes resistentes",
        "guid": "",
        "children": []
      },
      {
        "id": "1410",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1411",
        "parent": "0",
        "text": "- Relacionados\ncon dosis:",
        "guid": "",
        "children": []
      },
      {
        "id": "1412",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "1413",
        "parent": "0",
        "text": "- Visión borrosa",
        "guid": "",
        "children": []
      },
      {
        "id": "1414",
        "parent": "0",
        "text": "- Diplopía",
        "guid": "",
        "children": []
      },
      {
        "id": "1415",
        "parent": "0",
        "text": "- Inestabilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1416",
        "parent": "0",
        "text": "- Náuseas y vómitos",
        "guid": "",
        "children": []
      },
      {
        "id": "1417",
        "parent": "0",
        "text": "- Dolor de cabeza",
        "guid": "",
        "children": []
      },
      {
        "id": "1418",
        "parent": "0",
        "text": "- Temblor",
        "guid": "",
        "children": []
      },
      {
        "id": "1419",
        "parent": "0",
        "text": "- Concentración sérica\nindicada para síntomas\ncompatibles con toxicidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1420",
        "parent": "0",
        "text": "- Particularmente si\nconcentración basal >10\nμg/mL",
        "guid": "",
        "children": []
      },
      {
        "id": "1421",
        "parent": "0",
        "text": "- Erupción cutánea:",
        "guid": "",
        "children": []
      },
      {
        "id": "1422",
        "parent": "0",
        "text": "- En aproximadamente\n3% de pacientes",
        "guid": "",
        "children": []
      },
      {
        "id": "1423",
        "parent": "0",
        "text": "- Mayor\nincidencia en\nniños",
        "guid": "",
        "children": []
      },
      {
        "id": "1424",
        "parent": "0",
        "text": "- Mayor con\ncoadministración de ácido\nvalproico",
        "guid": "",
        "children": []
      },
      {
        "id": "1425",
        "parent": "0",
        "text": "- Mayor con titulación más\nrápida y dosis más altas",
        "guid": "",
        "children": []
      },
      {
        "id": "1426",
        "parent": "0",
        "text": "- Riesgo aumentado en pacientes\ncon erupción previa por\ncarbamazepina o fenitoína",
        "guid": "",
        "children": []
      },
      {
        "id": "1427",
        "parent": "0",
        "text": "- Efectos adversos\nidiosincráticos graves\n(raros):",
        "guid": "",
        "children": []
      },
      {
        "id": "1428",
        "parent": "0",
        "text": "- Síndrome de\nStevens-Johnson",
        "guid": "",
        "children": []
      },
      {
        "id": "1429",
        "parent": "0",
        "text": "- Necrólisis\nepidérmica tóxica",
        "guid": "",
        "children": []
      },
      {
        "id": "1430",
        "parent": "0",
        "text": "- Síndrome de\nhipersensibilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1431",
        "parent": "0",
        "text": "- Linfohistiocitosis\nhemofagocítica",
        "guid": "",
        "children": []
      },
      {
        "id": "1432",
        "parent": "0",
        "text": "- Advertencia 2023 sobre anomalías de\nritmo y conducción cardíaca:",
        "guid": "",
        "children": []
      },
      {
        "id": "1433",
        "parent": "0",
        "text": "- Basada en\nhallazgos in vitro",
        "guid": "",
        "children": []
      },
      {
        "id": "1434",
        "parent": "0",
        "text": "- Sin relevancia\nclínica definitiva",
        "guid": "",
        "children": []
      },
      {
        "id": "1435",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1436",
        "parent": "0",
        "text": "- Antiepiléptico importante de\nprimera línea para:",
        "guid": "",
        "children": []
      },
      {
        "id": "1437",
        "parent": "0",
        "text": "- Crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1438",
        "parent": "0",
        "text": "- Crisis\ntónico-clónicas\ngeneralizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1439",
        "parent": "0",
        "text": "- Varios ensayos comparativos la favorecen sobre\notros antiepilépticos para crisis focales en balance\nde tolerabilidad y eficacia",
        "guid": "",
        "children": []
      },
      {
        "id": "1440",
        "parent": "0",
        "text": "- Inferior a:",
        "guid": "",
        "children": []
      },
      {
        "id": "1441",
        "parent": "0",
        "text": "- Ácido valproico para epilepsia\ngeneralizada idiopática",
        "guid": "",
        "children": []
      },
      {
        "id": "1442",
        "parent": "0",
        "text": "- Etosuximida para crisis de\nausencia generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1443",
        "parent": "0",
        "text": "- Menos sedante y menos efectos\ncognitivos adversos que\nantiepilépticos tradicionales",
        "guid": "",
        "children": []
      },
      {
        "id": "1444",
        "parent": "0",
        "text": "- Uso en monoterapia asociado\ncon una de las tasas más bajas\nde teratogenicidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1445",
        "parent": "0",
        "text": "- Favorable para uso en pacientes\nfemeninas en edad fértil",
        "guid": "",
        "children": []
      },
      {
        "id": "1446",
        "parent": "0",
        "text": "- Puede tener interacciones\nfarmacodinámicas con otros\nbloqueadores clásicos de canales de\nsodio",
        "guid": "",
        "children": []
      },
      {
        "id": "1447",
        "parent": "0",
        "text": "- Resulta en efectos adversos a\nconcentraciones séricas\nmenores de lo esperado",
        "guid": "",
        "children": []
      },
      {
        "id": "1448",
        "parent": "0",
        "text": "- Combinación con valproato\npuede ser sinérgica",
        "guid": "",
        "children": []
      },
      {
        "id": "1449",
        "parent": "0",
        "text": "- Mayor eficacia\nque la predicha",
        "guid": "",
        "children": []
      },
      {
        "id": "1450",
        "parent": "0",
        "text": "# TOPIRAMATO",
        "guid": "QBoDnGYL8olVFQ4KXRdXFA",
        "children": []
      },
      {
        "id": "1451",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1452",
        "parent": "0",
        "text": "- Múltiples\nmecanismos de\nacción:",
        "guid": "",
        "children": []
      },
      {
        "id": "1453",
        "parent": "0",
        "text": "- Antagonismo de\nreceptores AMPA/kainato",
        "guid": "",
        "children": []
      },
      {
        "id": "1454",
        "parent": "0",
        "text": "- Aumento de\nactividad GABA",
        "guid": "",
        "children": []
      },
      {
        "id": "1455",
        "parent": "0",
        "text": "- Bloqueo de canales de sodio\nvoltaje-dependientes",
        "guid": "",
        "children": []
      },
      {
        "id": "1456",
        "parent": "0",
        "text": "- Inhibidor débil de anhidrasa\ncarbónica (no contribuye\nsignificativamente a eficacia)",
        "guid": "",
        "children": []
      },
      {
        "id": "1457",
        "parent": "0",
        "text": "- Disponible como\npreparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "1458",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1459",
        "parent": "0",
        "text": "- Excelente\nbiodisponibilidad\noral",
        "guid": "",
        "children": []
      },
      {
        "id": "1460",
        "parent": "0",
        "text": "- Unión a proteínas no\nclínicamente significativa",
        "guid": "",
        "children": []
      },
      {
        "id": "1461",
        "parent": "0",
        "text": "- Parcialmente\nmetabolizado en\nhígado",
        "guid": "",
        "children": []
      },
      {
        "id": "1462",
        "parent": "0",
        "text": "- Aproximadamente 70%\neliminado sin cambios en orina",
        "guid": "",
        "children": []
      },
      {
        "id": "1463",
        "parent": "0",
        "text": "- Vida media:\naproximadamente 21\nhoras",
        "guid": "",
        "children": []
      },
      {
        "id": "1464",
        "parent": "0",
        "text": "- Interacciones:",
        "guid": "",
        "children": []
      },
      {
        "id": "1465",
        "parent": "0",
        "text": "- Inductor leve\nde CYP3A4",
        "guid": "",
        "children": []
      },
      {
        "id": "1466",
        "parent": "0",
        "text": "- Reduce eficacia de anticonceptivos\norales a dosis ≥200 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1467",
        "parent": "0",
        "text": "- Inhibidor leve\nde CYP2C19",
        "guid": "",
        "children": []
      },
      {
        "id": "1468",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1469",
        "parent": "0",
        "text": "- Antiepiléptico de\namplio espectro",
        "guid": "",
        "children": []
      },
      {
        "id": "1470",
        "parent": "0",
        "text": "- Efectivo contra crisis focales y\ntónico-clónicas generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1471",
        "parent": "0",
        "text": "- Ensayo piloto sugiere no\nefectividad para crisis de\nausencia generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1472",
        "parent": "0",
        "text": "- Aprobaciones\nFDA adicionales:",
        "guid": "",
        "children": []
      },
      {
        "id": "1473",
        "parent": "0",
        "text": "- Profilaxis de migraña",
        "guid": "",
        "children": []
      },
      {
        "id": "1474",
        "parent": "0",
        "text": "- Preparación para pérdida de peso en\ncombinación con fentermina",
        "guid": "",
        "children": []
      },
      {
        "id": "1475",
        "parent": "0",
        "text": "- Uso frecuente fuera de\nindicación para trastorno bipolar",
        "guid": "",
        "children": []
      },
      {
        "id": "1476",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1477",
        "parent": "0",
        "text": "- Requiere titulación gradual para manejar\nefectos adversos cognitivos",
        "guid": "",
        "children": []
      },
      {
        "id": "1478",
        "parent": "0",
        "text": "- Inicio\nsugerido: 25\nmg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1479",
        "parent": "0",
        "text": "- Incremento: 25 mg cada semana hasta\ndosis diaria total de 100 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1480",
        "parent": "0",
        "text": "- Titulación adicional: 25-50 mg cada\nsemana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1481",
        "parent": "0",
        "text": "- Hasta dosis diaria total de 400\nmg/día en 2 dosis divididas",
        "guid": "",
        "children": []
      },
      {
        "id": "1482",
        "parent": "0",
        "text": "- Preparaciones de liberación\nprolongada (dosificación una vez al\ndía) pueden mejorar tolerabilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1483",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1484",
        "parent": "0",
        "text": "- Menos bien tolerado\nque lamotrigina",
        "guid": "",
        "children": []
      },
      {
        "id": "1485",
        "parent": "0",
        "text": "- Principal problema de\ntolerabilidad: posibles efectos\nadversos cognitivos",
        "guid": "",
        "children": []
      },
      {
        "id": "1486",
        "parent": "0",
        "text": "- Enlentecimiento\ncognitivo",
        "guid": "",
        "children": []
      },
      {
        "id": "1487",
        "parent": "0",
        "text": "- Disminución de\natención y memoria",
        "guid": "",
        "children": []
      },
      {
        "id": "1488",
        "parent": "0",
        "text": "- Deterioro de\nfunción ejecutiva",
        "guid": "",
        "children": []
      },
      {
        "id": "1489",
        "parent": "0",
        "text": "- Dificultad para\nencontrar palabras",
        "guid": "",
        "children": []
      },
      {
        "id": "1490",
        "parent": "0",
        "text": "- Reducción de\nfluidez verbal",
        "guid": "",
        "children": []
      },
      {
        "id": "1491",
        "parent": "0",
        "text": "- Pacientes pueden no ser\nconscientes de estas dificultades",
        "guid": "",
        "children": []
      },
      {
        "id": "1492",
        "parent": "0",
        "text": "- Otros posibles efectos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1493",
        "parent": "0",
        "text": "- Sedación",
        "guid": "",
        "children": []
      },
      {
        "id": "1494",
        "parent": "0",
        "text": "- Fatiga",
        "guid": "",
        "children": []
      },
      {
        "id": "1495",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "1496",
        "parent": "0",
        "text": "- Ataxia",
        "guid": "",
        "children": []
      },
      {
        "id": "1497",
        "parent": "0",
        "text": "- Depresión",
        "guid": "",
        "children": []
      },
      {
        "id": "1498",
        "parent": "0",
        "text": "- Cálculos renales en\naproximadamente 1.5% de\nindividuos",
        "guid": "",
        "children": []
      },
      {
        "id": "1499",
        "parent": "0",
        "text": "- Disminución del apetito\ny pérdida de peso",
        "guid": "",
        "children": []
      },
      {
        "id": "1500",
        "parent": "0",
        "text": "- Parestesias en\nmanos y pies:",
        "guid": "",
        "children": []
      },
      {
        "id": "1501",
        "parent": "0",
        "text": "- Pueden ocurrir con inicio\ny aumento de dosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1502",
        "parent": "0",
        "text": "- Generalmente\nse resuelven",
        "guid": "",
        "children": []
      },
      {
        "id": "1503",
        "parent": "0",
        "text": "- Efecto debido a actividad\ninhibidora de anhidrasa carbónica",
        "guid": "",
        "children": []
      },
      {
        "id": "1504",
        "parent": "0",
        "text": "- Más\ncomunes en\nniños:",
        "guid": "",
        "children": []
      },
      {
        "id": "1505",
        "parent": "0",
        "text": "- Oligohidrosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1506",
        "parent": "0",
        "text": "- Hipertermia",
        "guid": "",
        "children": []
      },
      {
        "id": "1507",
        "parent": "0",
        "text": "- Acidosis metabólica",
        "guid": "",
        "children": []
      },
      {
        "id": "1508",
        "parent": "0",
        "text": "- Raramente reportados:",
        "guid": "",
        "children": []
      },
      {
        "id": "1509",
        "parent": "0",
        "text": "- Miopía aguda",
        "guid": "",
        "children": []
      },
      {
        "id": "1510",
        "parent": "0",
        "text": "- Glaucoma secundario\nde ángulo cerrado",
        "guid": "",
        "children": []
      },
      {
        "id": "1511",
        "parent": "0",
        "text": "- Hiperamonemia posible cuando\nse usa junto con valproato",
        "guid": "",
        "children": []
      },
      {
        "id": "1512",
        "parent": "0",
        "text": "- Exposición in utero\nasociada con:",
        "guid": "",
        "children": []
      },
      {
        "id": "1513",
        "parent": "0",
        "text": "- Bajo peso al nacer",
        "guid": "",
        "children": []
      },
      {
        "id": "1514",
        "parent": "0",
        "text": "- Aumento de defectos de\nnacimiento (aproximadamente 4%),\nparticularmente fisuras orales",
        "guid": "",
        "children": []
      },
      {
        "id": "1515",
        "parent": "0",
        "text": "- Mayor riesgo de trastorno\ndel espectro autista y\ndiscapacidad intelectual",
        "guid": "",
        "children": []
      },
      {
        "id": "1516",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1517",
        "parent": "0",
        "text": "- Aunque aprobado por FDA para\nmonoterapia inicial de crisis focales y\ntónico-clónicas generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1518",
        "parent": "0",
        "text": "- No es fármaco de primera\nelección debido a efectos\nadversos cognitivos",
        "guid": "",
        "children": []
      },
      {
        "id": "1519",
        "parent": "0",
        "text": "- A menos que su uso esté\njustificado por comorbilidad\n(migraña u obesidad)",
        "guid": "",
        "children": []
      },
      {
        "id": "1520",
        "parent": "0",
        "text": "- Efectivo como terapia adyuvante para\ncrisis focales y generalizadas en\nsíndrome de Lennox-Gastaut",
        "guid": "",
        "children": []
      },
      {
        "id": "1521",
        "parent": "0",
        "text": "# TIAGABINA",
        "guid": "Hx4YcDudUNJWw_QeEwtu2A",
        "children": []
      },
      {
        "id": "1522",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1523",
        "parent": "0",
        "text": "- Inhibe la recaptación de\nGABA en la sinapsis",
        "guid": "",
        "children": []
      },
      {
        "id": "1524",
        "parent": "0",
        "text": "- Disponible únicamente\ncomo preparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "1525",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1526",
        "parent": "0",
        "text": "- Excelente\nbiodisponibilidad\noral",
        "guid": "",
        "children": []
      },
      {
        "id": "1527",
        "parent": "0",
        "text": "- 96% unida a proteínas",
        "guid": "",
        "children": []
      },
      {
        "id": "1528",
        "parent": "0",
        "text": "- De importancia\nlimitada ya que:",
        "guid": "",
        "children": []
      },
      {
        "id": "1529",
        "parent": "0",
        "text": "- Decisiones de dosificación\nno dependen del nivel",
        "guid": "",
        "children": []
      },
      {
        "id": "1530",
        "parent": "0",
        "text": "- Concentración sérica tan baja\nque no compite significativamente\npor unión a proteínas",
        "guid": "",
        "children": []
      },
      {
        "id": "1531",
        "parent": "0",
        "text": "- Metabolismo\nextenso en hígado",
        "guid": "",
        "children": []
      },
      {
        "id": "1532",
        "parent": "0",
        "text": "- Vida media:",
        "guid": "",
        "children": []
      },
      {
        "id": "1533",
        "parent": "0",
        "text": "- 7-9 horas en\nmonoterapia",
        "guid": "",
        "children": []
      },
      {
        "id": "1534",
        "parent": "0",
        "text": "- Acortada a 2-5 horas en\npresencia de inductor enzimático",
        "guid": "",
        "children": []
      },
      {
        "id": "1535",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1536",
        "parent": "0",
        "text": "- Espectro estrecho de eficacia contra\ncrisis focales únicamente",
        "guid": "",
        "children": []
      },
      {
        "id": "1537",
        "parent": "0",
        "text": "- Puede exacerbar crisis de ausencia y\nmioclónicas generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1538",
        "parent": "0",
        "text": "- Usos fuera de\nindicación:",
        "guid": "",
        "children": []
      },
      {
        "id": "1539",
        "parent": "0",
        "text": "- Manejo de espasticidad en\nesclerosis múltiple",
        "guid": "",
        "children": []
      },
      {
        "id": "1540",
        "parent": "0",
        "text": "- Tratamiento de\nadicciones",
        "guid": "",
        "children": []
      },
      {
        "id": "1541",
        "parent": "0",
        "text": "- Aumento de proporción\nde sueño profundo",
        "guid": "",
        "children": []
      },
      {
        "id": "1542",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1543",
        "parent": "0",
        "text": "- Inicio: 4 mg al\nacostarse",
        "guid": "",
        "children": []
      },
      {
        "id": "1544",
        "parent": "0",
        "text": "- Incremento: 4 mg\ncada semana",
        "guid": "",
        "children": []
      },
      {
        "id": "1545",
        "parent": "0",
        "text": "- Dosis objetivo inicial: 8\nmg 3 veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1546",
        "parent": "0",
        "text": "- Incremento adicional: 4 mg cada\nsemana según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1547",
        "parent": "0",
        "text": "- Hasta 12-16 mg\n3 veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1548",
        "parent": "0",
        "text": "- Dosis más alta posible en\npresencia de inductor enzimático",
        "guid": "",
        "children": []
      },
      {
        "id": "1549",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1550",
        "parent": "0",
        "text": "- Efectos más comunes (más\nfrecuentes durante titulación):",
        "guid": "",
        "children": []
      },
      {
        "id": "1551",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "1552",
        "parent": "0",
        "text": "- Astenia",
        "guid": "",
        "children": []
      },
      {
        "id": "1553",
        "parent": "0",
        "text": "- Nerviosismo",
        "guid": "",
        "children": []
      },
      {
        "id": "1554",
        "parent": "0",
        "text": "- Temblor",
        "guid": "",
        "children": []
      },
      {
        "id": "1555",
        "parent": "0",
        "text": "- Depresión",
        "guid": "",
        "children": []
      },
      {
        "id": "1556",
        "parent": "0",
        "text": "- Labilidad emocional",
        "guid": "",
        "children": []
      },
      {
        "id": "1557",
        "parent": "0",
        "text": "- Puede asociarse con episodios\nrelacionados con dosis:",
        "guid": "",
        "children": []
      },
      {
        "id": "1558",
        "parent": "0",
        "text": "- Estatus epiléptico\nno convulsivo",
        "guid": "",
        "children": []
      },
      {
        "id": "1559",
        "parent": "0",
        "text": "- Encefalopatía",
        "guid": "",
        "children": []
      },
      {
        "id": "1560",
        "parent": "0",
        "text": "- Pueden ocurrir incluso en\nausencia de epilepsia",
        "guid": "",
        "children": []
      },
      {
        "id": "1561",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1562",
        "parent": "0",
        "text": "- Debe reservarse para uso como terapia\nadyuvante para crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1563",
        "parent": "0",
        "text": "# LEVETIRACETAM",
        "guid": "LwTZJVCd5xdcPe_xLVfK0Q",
        "children": []
      },
      {
        "id": "1564",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1565",
        "parent": "0",
        "text": "- Mecanismo de acción\nprincipal: unión a proteína\nvesicular sináptica SV2A",
        "guid": "",
        "children": []
      },
      {
        "id": "1566",
        "parent": "0",
        "text": "- Resulta en disminución no específica de\nliberación de neurotransmisores en estado\nde hiperactivación neuronal",
        "guid": "",
        "children": []
      },
      {
        "id": "1567",
        "parent": "0",
        "text": "- Disponible en\nformulaciones oral e IV",
        "guid": "",
        "children": []
      },
      {
        "id": "1568",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1569",
        "parent": "0",
        "text": "- Excelente\nbiodisponibilidad\noral",
        "guid": "",
        "children": []
      },
      {
        "id": "1570",
        "parent": "0",
        "text": "- Unión a\nproteínas muy\nbaja",
        "guid": "",
        "children": []
      },
      {
        "id": "1571",
        "parent": "0",
        "text": "- Sin\nmetabolismo\nhepático:",
        "guid": "",
        "children": []
      },
      {
        "id": "1572",
        "parent": "0",
        "text": "- 66% excretado sin\ncambios en orina",
        "guid": "",
        "children": []
      },
      {
        "id": "1573",
        "parent": "0",
        "text": "- Resto hidrolizado a\ncompuestos inactivos",
        "guid": "",
        "children": []
      },
      {
        "id": "1574",
        "parent": "0",
        "text": "- Vida media: 6-8 horas",
        "guid": "",
        "children": []
      },
      {
        "id": "1575",
        "parent": "0",
        "text": "- Sin interacciones farmacocinéticas\nsignificativas conocidas",
        "guid": "",
        "children": []
      },
      {
        "id": "1576",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1577",
        "parent": "0",
        "text": "- Fármaco de\namplio espectro",
        "guid": "",
        "children": []
      },
      {
        "id": "1578",
        "parent": "0",
        "text": "- Efectivo contra:",
        "guid": "",
        "children": []
      },
      {
        "id": "1579",
        "parent": "0",
        "text": "- Crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1580",
        "parent": "0",
        "text": "- Crisis\ntónico-clónicas\ngeneralizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1581",
        "parent": "0",
        "text": "- Crisis mioclónicas\ngeneralizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1582",
        "parent": "0",
        "text": "- Único antiepiléptico con\nevidencia Clase I para eficacia\ncontra crisis mioclónicas",
        "guid": "",
        "children": []
      },
      {
        "id": "1583",
        "parent": "0",
        "text": "- Puede ser más efectivo que lamotrigina en\nniñas y mujeres jóvenes con epilepsia\nmioclónica juvenil (para quienes valproato no\nes opción recomendada)",
        "guid": "",
        "children": []
      },
      {
        "id": "1584",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1585",
        "parent": "0",
        "text": "- Inicio: 500 mg/día en 2 dosis divididas o\nuna vez al acostarse con preparación de\nliberación prolongada",
        "guid": "",
        "children": []
      },
      {
        "id": "1586",
        "parent": "0",
        "text": "- Incremento según\nnecesidad y tolerancia",
        "guid": "",
        "children": []
      },
      {
        "id": "1587",
        "parent": "0",
        "text": "- Hasta dosis diaria total de\n3000-4000 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1588",
        "parent": "0",
        "text": "- Análisis post hoc de\nensayos clínicos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1589",
        "parent": "0",
        "text": "- Eficacia ya máxima en\ndosis de titulación inicial",
        "guid": "",
        "children": []
      },
      {
        "id": "1590",
        "parent": "0",
        "text": "- Ajustes de dosis al alza deben limitarse\ncuando no se observa beneficio adicional\ndespués de uno o dos incrementos",
        "guid": "",
        "children": []
      },
      {
        "id": "1591",
        "parent": "0",
        "text": "- Considerar entonces terapia\nalternativa o adyuvante",
        "guid": "",
        "children": []
      },
      {
        "id": "1592",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1593",
        "parent": "0",
        "text": "- Efectos\nadversos\ncomunes:",
        "guid": "",
        "children": []
      },
      {
        "id": "1594",
        "parent": "0",
        "text": "- Somnolencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1595",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "1596",
        "parent": "0",
        "text": "- Astenia",
        "guid": "",
        "children": []
      },
      {
        "id": "1597",
        "parent": "0",
        "text": "- Irritabilidad y hostilidad posibles\n(más frecuentes en niños)",
        "guid": "",
        "children": []
      },
      {
        "id": "1598",
        "parent": "0",
        "text": "- Depresión, ansiedad y, raramente,\npsicosis también posibles",
        "guid": "",
        "children": []
      },
      {
        "id": "1599",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1600",
        "parent": "0",
        "text": "- Aunque no aprobado por FDA para\nmonoterapia en Estados Unidos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1601",
        "parent": "0",
        "text": "- Ampliamente utilizado como tratamiento\nde primera línea para crisis focales y\ntónico-clónicas generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1602",
        "parent": "0",
        "text": "- Aprobado para\nmonoterapia inicial en\nEuropa",
        "guid": "",
        "children": []
      },
      {
        "id": "1603",
        "parent": "0",
        "text": "- Excelente\ntratamiento\nadyuvante:",
        "guid": "",
        "children": []
      },
      {
        "id": "1604",
        "parent": "0",
        "text": "- Debido a su seguridad",
        "guid": "",
        "children": []
      },
      {
        "id": "1605",
        "parent": "0",
        "text": "- Ausencia de\ninteracciones",
        "guid": "",
        "children": []
      },
      {
        "id": "1606",
        "parent": "0",
        "text": "- Preparación IV utilizada como\nagente de segunda línea en\ntratamiento de estatus epiléptico",
        "guid": "",
        "children": []
      },
      {
        "id": "1607",
        "parent": "0",
        "text": "# BRIVARACETAM",
        "guid": "WzCP5SIAw4MeXyGYONvIkw",
        "children": []
      },
      {
        "id": "1608",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1609",
        "parent": "0",
        "text": "- Estructuralmente\nrelacionado con\nlevetiracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "1610",
        "parent": "0",
        "text": "- Mecanismo de acción\nsimilar: unión a SV2A",
        "guid": "",
        "children": []
      },
      {
        "id": "1611",
        "parent": "0",
        "text": "- Aproximadamente 20\nveces mayor afinidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1612",
        "parent": "0",
        "text": "- Mayor selectividad",
        "guid": "",
        "children": []
      },
      {
        "id": "1613",
        "parent": "0",
        "text": "- Mayor permeabilidad\ncerebral que levetiracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "1614",
        "parent": "0",
        "text": "- Disponible en\nformulaciones oral e IV",
        "guid": "",
        "children": []
      },
      {
        "id": "1615",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1616",
        "parent": "0",
        "text": "- Excelente biodisponibilidad\ntras administración oral",
        "guid": "",
        "children": []
      },
      {
        "id": "1617",
        "parent": "0",
        "text": "- Débilmente unido a\nproteínas plasmáticas",
        "guid": "",
        "children": []
      },
      {
        "id": "1618",
        "parent": "0",
        "text": "- Vida media:\naproximadamente 7-8\nhoras",
        "guid": "",
        "children": []
      },
      {
        "id": "1619",
        "parent": "0",
        "text": "- Excreción renal tras\nmetabolismo extenso:",
        "guid": "",
        "children": []
      },
      {
        "id": "1620",
        "parent": "0",
        "text": "- Principalmente\npor hidrólisis",
        "guid": "",
        "children": []
      },
      {
        "id": "1621",
        "parent": "0",
        "text": "- En menor medida por hidroxilación\n(principalmente vía CYP2C19)",
        "guid": "",
        "children": []
      },
      {
        "id": "1622",
        "parent": "0",
        "text": "- Más interacciones\nque levetiracetam:",
        "guid": "",
        "children": []
      },
      {
        "id": "1623",
        "parent": "0",
        "text": "- Aclaramiento aumentado por\ninductores enzimáticos",
        "guid": "",
        "children": []
      },
      {
        "id": "1624",
        "parent": "0",
        "text": "- Puede aumentar epóxido\nde carbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "1625",
        "parent": "0",
        "text": "- Puede aumentar concentración\nde fenitoína hasta 20%",
        "guid": "",
        "children": []
      },
      {
        "id": "1626",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1627",
        "parent": "0",
        "text": "- Amplio espectro de eficacia\nen modelos preclínicos",
        "guid": "",
        "children": []
      },
      {
        "id": "1628",
        "parent": "0",
        "text": "- Ensayos humanos con\nevidencia Clase I solo en\npacientes con crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1629",
        "parent": "0",
        "text": "- Datos de estudios abiertos\napoyan eficacia para tipos de\ncrisis generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1630",
        "parent": "0",
        "text": "- Particularmente en pacientes con\nepilepsia mioclónica juvenil",
        "guid": "",
        "children": []
      },
      {
        "id": "1631",
        "parent": "0",
        "text": "- Análisis agrupados demostraron\neficacia superior a placebo:",
        "guid": "",
        "children": []
      },
      {
        "id": "1632",
        "parent": "0",
        "text": "- 50 mg/día, 100 mg/día y 200 mg/día\nadministrados en 2 dosis divididas\ncomo terapia adyuvante",
        "guid": "",
        "children": []
      },
      {
        "id": "1633",
        "parent": "0",
        "text": "- Análisis post hoc de\ndatos agrupados:",
        "guid": "",
        "children": []
      },
      {
        "id": "1634",
        "parent": "0",
        "text": "- Mayoría de respondedores\n(75-100%) respondieron desde\ninicio de tratamiento",
        "guid": "",
        "children": []
      },
      {
        "id": "1635",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1636",
        "parent": "0",
        "text": "- Dosis inicial recomendada:\n50 mg 2 veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1637",
        "parent": "0",
        "text": "- Ajuste basado en\nrespuesta y tolerabilidad:",
        "guid": "",
        "children": []
      },
      {
        "id": "1638",
        "parent": "0",
        "text": "- Reducción a 25 mg 2\nveces al día, o",
        "guid": "",
        "children": []
      },
      {
        "id": "1639",
        "parent": "0",
        "text": "- Aumento hasta 100\nmg 2 veces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1640",
        "parent": "0",
        "text": "- Razonable iniciar con 25\nmg 2 veces al día en:",
        "guid": "",
        "children": []
      },
      {
        "id": "1641",
        "parent": "0",
        "text": "- Pacientes mayores",
        "guid": "",
        "children": []
      },
      {
        "id": "1642",
        "parent": "0",
        "text": "- Personas con mayor riesgo\nde efectos adversos",
        "guid": "",
        "children": []
      },
      {
        "id": "1643",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1644",
        "parent": "0",
        "text": "- Efectos más comunes (más\nfrecuentes que placebo):",
        "guid": "",
        "children": []
      },
      {
        "id": "1645",
        "parent": "0",
        "text": "- Somnolencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1646",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "1647",
        "parent": "0",
        "text": "- Fatiga",
        "guid": "",
        "children": []
      },
      {
        "id": "1648",
        "parent": "0",
        "text": "- Irritabilidad reportada solo en 3.2% de\npacientes (vs 1.1% con placebo)",
        "guid": "",
        "children": []
      },
      {
        "id": "1649",
        "parent": "0",
        "text": "- Es una\nsustancia\ncontrolada",
        "guid": "",
        "children": []
      },
      {
        "id": "1650",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1651",
        "parent": "0",
        "text": "- Aprobado por FDA para\ntratamiento de crisis de inicio\nparcial en pacientes ≥4 años",
        "guid": "",
        "children": []
      },
      {
        "id": "1652",
        "parent": "0",
        "text": "- Incluye monoterapia\ny uso adyuvante",
        "guid": "",
        "children": []
      },
      {
        "id": "1653",
        "parent": "0",
        "text": "- No ha sido sometido específicamente a\nensayos de monoterapia inicial",
        "guid": "",
        "children": []
      },
      {
        "id": "1654",
        "parent": "0",
        "text": "- No efectivo cuando se\nañade a levetiracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "1655",
        "parent": "0",
        "text": "- Estudios\nabiertos\nsugieren:",
        "guid": "",
        "children": []
      },
      {
        "id": "1656",
        "parent": "0",
        "text": "- Efectos adversos conductuales de\nlevetiracetam pueden mejorar tras\ncambio a brivaracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "1657",
        "parent": "0",
        "text": "- Indicado en pacientes:",
        "guid": "",
        "children": []
      },
      {
        "id": "1658",
        "parent": "0",
        "text": "- Incapaces de tolerar levetiracetam por\nefectos adversos conductuales",
        "guid": "",
        "children": []
      },
      {
        "id": "1659",
        "parent": "0",
        "text": "- Con riesgo de efectos adversos\nconductuales de levetiracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "1660",
        "parent": "0",
        "text": "- Preparación IV explorada en\ntratamiento de estatus epiléptico por su\nsuperior permeabilidad cerebral",
        "guid": "",
        "children": []
      },
      {
        "id": "1661",
        "parent": "0",
        "text": "# ZONISAMIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "1662",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1663",
        "parent": "0",
        "text": "- Estructuralmente\nrelacionada con\nsulfonamidas",
        "guid": "",
        "children": []
      },
      {
        "id": "1664",
        "parent": "0",
        "text": "- Múltiples\nmecanismos de\nacción:",
        "guid": "",
        "children": []
      },
      {
        "id": "1665",
        "parent": "0",
        "text": "- Bloqueo de canales de calcio\ntipo T (predictivo de eficacia\ncontra crisis de ausencia)",
        "guid": "",
        "children": []
      },
      {
        "id": "1666",
        "parent": "0",
        "text": "- Bloqueo de\ncanales de sodio",
        "guid": "",
        "children": []
      },
      {
        "id": "1667",
        "parent": "0",
        "text": "- Inhibición débil de actividad\nde anhidrasa carbónica",
        "guid": "",
        "children": []
      },
      {
        "id": "1668",
        "parent": "0",
        "text": "- Disponible únicamente\ncomo preparación oral",
        "guid": "",
        "children": []
      },
      {
        "id": "1669",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1670",
        "parent": "0",
        "text": "- Excelente\nbiodisponibilidad\noral",
        "guid": "",
        "children": []
      },
      {
        "id": "1671",
        "parent": "0",
        "text": "- Unión a proteínas no\nclínicamente significativa",
        "guid": "",
        "children": []
      },
      {
        "id": "1672",
        "parent": "0",
        "text": "- Metabolizada en hígado a\nmetabolitos inactivos",
        "guid": "",
        "children": []
      },
      {
        "id": "1673",
        "parent": "0",
        "text": "- Vida media larga:\naproximadamente 60 horas",
        "guid": "",
        "children": []
      },
      {
        "id": "1674",
        "parent": "0",
        "text": "- No es inductor ni inhibidor\nenzimático hepático",
        "guid": "",
        "children": []
      },
      {
        "id": "1675",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1676",
        "parent": "0",
        "text": "- Considerada antiepiléptico\nde amplio espectro",
        "guid": "",
        "children": []
      },
      {
        "id": "1677",
        "parent": "0",
        "text": "- Ensayos Clase I solo realizados en\npacientes con crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1678",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1679",
        "parent": "0",
        "text": "- Dosis inicial: 100 mg al\nacostarse durante 2 semanas,\nluego 200 mg al acostarse",
        "guid": "",
        "children": []
      },
      {
        "id": "1680",
        "parent": "0",
        "text": "- Incremento: 100 mg cada 2\nsemanas según necesidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1681",
        "parent": "0",
        "text": "- Hasta 600 mg/día una vez al\nacostarse o en dos dosis divididas",
        "guid": "",
        "children": []
      },
      {
        "id": "1682",
        "parent": "0",
        "text": "- Rango terapéutico sugerido\npara concentración\nplasmática: 10-40 μg/mL",
        "guid": "",
        "children": []
      },
      {
        "id": "1683",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1684",
        "parent": "0",
        "text": "- Posibles efectos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1685",
        "parent": "0",
        "text": "- Sedación",
        "guid": "",
        "children": []
      },
      {
        "id": "1686",
        "parent": "0",
        "text": "- Ataxia",
        "guid": "",
        "children": []
      },
      {
        "id": "1687",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "1688",
        "parent": "0",
        "text": "- Náuseas",
        "guid": "",
        "children": []
      },
      {
        "id": "1689",
        "parent": "0",
        "text": "- Fatiga",
        "guid": "",
        "children": []
      },
      {
        "id": "1690",
        "parent": "0",
        "text": "- Agitación",
        "guid": "",
        "children": []
      },
      {
        "id": "1691",
        "parent": "0",
        "text": "- Irritabilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1692",
        "parent": "0",
        "text": "- Anorexia",
        "guid": "",
        "children": []
      },
      {
        "id": "1693",
        "parent": "0",
        "text": "- Pérdida de\npeso posible",
        "guid": "",
        "children": []
      },
      {
        "id": "1694",
        "parent": "0",
        "text": "- Enlentecimiento cognitivo y\ndificultad con concentración:",
        "guid": "",
        "children": []
      },
      {
        "id": "1695",
        "parent": "0",
        "text": "- Particularmente a\ndosis más altas",
        "guid": "",
        "children": []
      },
      {
        "id": "1696",
        "parent": "0",
        "text": "- Menos pronunciados\nque con topiramato",
        "guid": "",
        "children": []
      },
      {
        "id": "1697",
        "parent": "0",
        "text": "- Raramente:\ndepresión y psicosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1698",
        "parent": "0",
        "text": "- Raramente: erupción grave\n(síndrome de Stevens-Johnson y\nnecrólisis epidérmica tóxica)",
        "guid": "",
        "children": []
      },
      {
        "id": "1699",
        "parent": "0",
        "text": "- Cálculos renales en hasta 4%\nde pacientes (prevención con\nhidratación adecuada)",
        "guid": "",
        "children": []
      },
      {
        "id": "1700",
        "parent": "0",
        "text": "- Raramente, más\nfrecuente en niños:",
        "guid": "",
        "children": []
      },
      {
        "id": "1701",
        "parent": "0",
        "text": "- Oligohidrosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1702",
        "parent": "0",
        "text": "- Hipertermia",
        "guid": "",
        "children": []
      },
      {
        "id": "1703",
        "parent": "0",
        "text": "- Acidosis metabólica",
        "guid": "",
        "children": []
      },
      {
        "id": "1704",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1705",
        "parent": "0",
        "text": "- Aprobada como monoterapia inicial\npara crisis focales en Europa",
        "guid": "",
        "children": []
      },
      {
        "id": "1706",
        "parent": "0",
        "text": "- En Japón, también\naprobada como monoterapia\npara crisis generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1707",
        "parent": "0",
        "text": "- Indicación FDA oficial: terapia adyuvante\npara crisis focales en adultos",
        "guid": "",
        "children": []
      },
      {
        "id": "1708",
        "parent": "0",
        "text": "- Raramente agente de primera\nelección para monoterapia inicial por\nefectos adversos cognitivos",
        "guid": "",
        "children": []
      },
      {
        "id": "1709",
        "parent": "0",
        "text": "- Gran ensayo aleatorizado SANAD II favorece\nlamotrigina sobre zonisamida como tratamiento de\nprimera línea para epilepsia focal",
        "guid": "",
        "children": []
      },
      {
        "id": "1710",
        "parent": "0",
        "text": "- Ventaja: vida media larga reduce\nimpacto de dosis olvidada",
        "guid": "",
        "children": []
      },
      {
        "id": "1711",
        "parent": "0",
        "text": "# LACOSAMIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "1712",
        "parent": "0",
        "text": "## MECANISMOS Y\nCARACTERÍSTICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1713",
        "parent": "0",
        "text": "- Bloquea canales de sodio,\nmejorando inactivación lenta",
        "guid": "",
        "children": []
      },
      {
        "id": "1714",
        "parent": "0",
        "text": "- A diferencia de bloqueadores\nclásicos de canales de sodio que\nmejoran inactivación rápida",
        "guid": "",
        "children": []
      },
      {
        "id": "1715",
        "parent": "0",
        "text": "- Disponible en\nformulaciones oral y\nparenteral",
        "guid": "",
        "children": []
      },
      {
        "id": "1716",
        "parent": "0",
        "text": "##\nFARMACOCINÉTICA",
        "guid": "",
        "children": []
      },
      {
        "id": "1717",
        "parent": "0",
        "text": "- Excelente\nbiodisponibilidad\noral",
        "guid": "",
        "children": []
      },
      {
        "id": "1718",
        "parent": "0",
        "text": "- Unión a proteínas no\nclínicamente significativa",
        "guid": "",
        "children": []
      },
      {
        "id": "1719",
        "parent": "0",
        "text": "- Convertida en hígado a\nmetabolitos inactivos",
        "guid": "",
        "children": []
      },
      {
        "id": "1720",
        "parent": "0",
        "text": "- Aproximadamente 40%\neliminada sin cambios en orina",
        "guid": "",
        "children": []
      },
      {
        "id": "1721",
        "parent": "0",
        "text": "- Vida media:\naproximadamente 13\nhoras",
        "guid": "",
        "children": []
      },
      {
        "id": "1722",
        "parent": "0",
        "text": "## EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1723",
        "parent": "0",
        "text": "- Efectiva contra:",
        "guid": "",
        "children": []
      },
      {
        "id": "1724",
        "parent": "0",
        "text": "- Crisis de inicio focal",
        "guid": "",
        "children": []
      },
      {
        "id": "1725",
        "parent": "0",
        "text": "- Crisis tónico-clónicas de\ninicio generalizado",
        "guid": "",
        "children": []
      },
      {
        "id": "1726",
        "parent": "0",
        "text": "- Generalmente no efectiva\ncontra crisis de ausencia o\nmioclónicas generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1727",
        "parent": "0",
        "text": "- Improbable que exacerbe estas\ncrisis en mayoría de pacientes",
        "guid": "",
        "children": []
      },
      {
        "id": "1728",
        "parent": "0",
        "text": "## DOSIFICACIÓN",
        "guid": "",
        "children": []
      },
      {
        "id": "1729",
        "parent": "0",
        "text": "- Dosis inicial: 100 mg/día (una vez\nal acostarse o en 2 dosis divididas)\ndurante 1 semana",
        "guid": "",
        "children": []
      },
      {
        "id": "1730",
        "parent": "0",
        "text": "- Luego 100 mg 2\nveces al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1731",
        "parent": "0",
        "text": "- Titulación según necesidad: 100\nmg cada 1-2 semanas",
        "guid": "",
        "children": []
      },
      {
        "id": "1732",
        "parent": "0",
        "text": "- Hasta control de crisis, aparición\nde efectos secundarios o dosis\ndiaria total de 600 mg/día",
        "guid": "",
        "children": []
      },
      {
        "id": "1733",
        "parent": "0",
        "text": "## EFECTOS\nADVERSOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1734",
        "parent": "0",
        "text": "- Efectos adversos comunes (más\nfrecuentes a dosis más altas):",
        "guid": "",
        "children": []
      },
      {
        "id": "1735",
        "parent": "0",
        "text": "- Mareos",
        "guid": "",
        "children": []
      },
      {
        "id": "1736",
        "parent": "0",
        "text": "- Náuseas",
        "guid": "",
        "children": []
      },
      {
        "id": "1737",
        "parent": "0",
        "text": "- Vómitos",
        "guid": "",
        "children": []
      },
      {
        "id": "1738",
        "parent": "0",
        "text": "- Diplopía",
        "guid": "",
        "children": []
      },
      {
        "id": "1739",
        "parent": "0",
        "text": "- Fatiga",
        "guid": "",
        "children": []
      },
      {
        "id": "1740",
        "parent": "0",
        "text": "- Sedación",
        "guid": "",
        "children": []
      },
      {
        "id": "1741",
        "parent": "0",
        "text": "- Efectos adversos más probables\ncuando se usa junto con otros\nbloqueadores de canales de sodio",
        "guid": "",
        "children": []
      },
      {
        "id": "1742",
        "parent": "0",
        "text": "- Puede producir prolongación del\nintervalo PR dependiente de dosis:",
        "guid": "",
        "children": []
      },
      {
        "id": "1743",
        "parent": "0",
        "text": "- Potencialmente significativa en\npacientes con problemas de\nconducción cardíaca conocidos",
        "guid": "",
        "children": []
      },
      {
        "id": "1744",
        "parent": "0",
        "text": "- O combinada con otros\nfármacos con efecto similar",
        "guid": "",
        "children": []
      },
      {
        "id": "1745",
        "parent": "0",
        "text": "- Es una\nsustancia\ncontrolada",
        "guid": "",
        "children": []
      },
      {
        "id": "1746",
        "parent": "0",
        "text": "## LUGAR EN\nLA TERAPIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1747",
        "parent": "0",
        "text": "- Indicada como monoterapia o terapia\nadyuvante para crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1748",
        "parent": "0",
        "text": "- Indicada como terapia adyuvante en\ntratamiento de crisis tónico-clónicas\ngeneralizadas en pacientes ≥4 años",
        "guid": "",
        "children": []
      },
      {
        "id": "1749",
        "parent": "0",
        "text": "- Perfil farmacocinético favorable y titulación\nrápida la hacen agente adecuado de primera\nlínea para epilepsia focal",
        "guid": "",
        "children": []
      },
      {
        "id": "1750",
        "parent": "0",
        "text": "- Formulación\nparenteral:",
        "guid": "",
        "children": []
      },
      {
        "id": "1751",
        "parent": "0",
        "text": "- Indicada como reemplazo a\ncorto plazo cuando\nadministración oral no es\nfactible",
        "guid": "",
        "children": []
      },
      {
        "id": "1752",
        "parent": "0",
        "text": "- Eficaz contra crisis no convulsivas en\npacientes críticamente enfermos",
        "guid": "",
        "children": []
      },
      {
        "id": "1753",
        "parent": "0",
        "text": "- Varios reportes apoyan\neficacia en estatus epiléptico",
        "guid": "",
        "children": []
      },
      {
        "id": "1754",
        "parent": "0",
        "text": "- Como terapia\nadyuvante:",
        "guid": "",
        "children": []
      },
      {
        "id": "1755",
        "parent": "0",
        "text": "- Mayor eficacia y mejor tolerabilidad si\nse combina con fármaco no bloqueador\nde canales de sodio",
        "guid": "",
        "children": []
      },
      {
        "id": "1756",
        "parent": "0",
        "text": "# TRATAMIENTO MÉDICO DE EPILEPSIA\nTRAS FALLO DEL PRIMER\nMEDICAMENTO ANTIEPILÉPTICO",
        "guid": "YQOoewfBSzwDPR8VUZjdBQ",
        "children": []
      },
      {
        "id": "1757",
        "parent": "0",
        "text": "## ESTABLECER VERDADERO\nFRACASO DE EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1758",
        "parent": "0",
        "text": "- Descartar pseudorresistencia\nantes del siguiente paso:",
        "guid": "",
        "children": []
      },
      {
        "id": "1759",
        "parent": "0",
        "text": "- Mala adherencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1760",
        "parent": "0",
        "text": "- Eventos no epilépticos",
        "guid": "",
        "children": []
      },
      {
        "id": "1761",
        "parent": "0",
        "text": "- Diagnóstico\nincorrecto de\nepilepsia",
        "guid": "",
        "children": []
      },
      {
        "id": "1762",
        "parent": "0",
        "text": "- Elección inapropiada\nde medicamento",
        "guid": "",
        "children": []
      },
      {
        "id": "1763",
        "parent": "0",
        "text": "- Incumplimiento de\nrequisitos de estilo de vida:",
        "guid": "",
        "children": []
      },
      {
        "id": "1764",
        "parent": "0",
        "text": "- Privación de sueño",
        "guid": "",
        "children": []
      },
      {
        "id": "1765",
        "parent": "0",
        "text": "- Consumo episódico\nintenso de alcohol",
        "guid": "",
        "children": []
      },
      {
        "id": "1766",
        "parent": "0",
        "text": "- Más problemático en pacientes con\nepilepsia generalizada idiopática",
        "guid": "",
        "children": []
      },
      {
        "id": "1767",
        "parent": "0",
        "text": "- Características focales en crisis de inicio\ngeneralizado pueden llevar a:",
        "guid": "",
        "children": []
      },
      {
        "id": "1768",
        "parent": "0",
        "text": "- Diagnóstico incorrecto\nde epilepsia focal",
        "guid": "",
        "children": []
      },
      {
        "id": "1769",
        "parent": "0",
        "text": "- Administración de medicamentos de\nespectro estrecho inapropiados",
        "guid": "",
        "children": []
      },
      {
        "id": "1770",
        "parent": "0",
        "text": "- Considerar dosis\ninsuficiente:",
        "guid": "",
        "children": []
      },
      {
        "id": "1771",
        "parent": "0",
        "text": "- Concentración sérica útil para explorar\nflexibilidad de dosificación",
        "guid": "",
        "children": []
      },
      {
        "id": "1772",
        "parent": "0",
        "text": "- Ejemplo: lamotrigina\nindicada hasta 500 mg/día\n(concentración <10 μg/mL)",
        "guid": "",
        "children": []
      },
      {
        "id": "1773",
        "parent": "0",
        "text": "- En práctica clínica, control de\ncrisis reportado con dosis más\naltas (10-20 μg/mL)",
        "guid": "",
        "children": []
      },
      {
        "id": "1774",
        "parent": "0",
        "text": "## ELECCIÓN DEL\nSIGUIENTE MEDICAMENTO",
        "guid": "",
        "children": []
      },
      {
        "id": "1775",
        "parent": "0",
        "text": "- Criterios generales:",
        "guid": "",
        "children": []
      },
      {
        "id": "1776",
        "parent": "0",
        "text": "- Efectivo contra tipos de\ncrisis del paciente",
        "guid": "",
        "children": []
      },
      {
        "id": "1777",
        "parent": "0",
        "text": "- Casi todos efectivos contra crisis\nfocales excepto etosuximida",
        "guid": "",
        "children": []
      },
      {
        "id": "1778",
        "parent": "0",
        "text": "- Menor número efectivos contra\ncrisis de inicio generalizado",
        "guid": "",
        "children": []
      },
      {
        "id": "1779",
        "parent": "0",
        "text": "- Si clasificación incierta: preferir\nagente de amplio espectro",
        "guid": "",
        "children": []
      },
      {
        "id": "1780",
        "parent": "0",
        "text": "- Evitar agentes de espectro estrecho\n(gabapentina, oxcarbazepina)",
        "guid": "",
        "children": []
      },
      {
        "id": "1781",
        "parent": "0",
        "text": "- Pueden precipitar\ncrisis mioclónicas",
        "guid": "",
        "children": []
      },
      {
        "id": "1782",
        "parent": "0",
        "text": "- Con múltiples tipos de crisis:\nabordar las más incapacitantes",
        "guid": "",
        "children": []
      },
      {
        "id": "1783",
        "parent": "0",
        "text": "- Perfil de seguridad:",
        "guid": "",
        "children": []
      },
      {
        "id": "1784",
        "parent": "0",
        "text": "- Sin efectos adversos relacionados con\ncomorbilidades del paciente",
        "guid": "",
        "children": []
      },
      {
        "id": "1785",
        "parent": "0",
        "text": "- Ejemplo: levetiracetam, topiramato,\nzonisamida y perampanel",
        "guid": "",
        "children": []
      },
      {
        "id": "1786",
        "parent": "0",
        "text": "- No ideales para pacientes con\ntrastorno bipolar o depresión",
        "guid": "",
        "children": []
      },
      {
        "id": "1787",
        "parent": "0",
        "text": "- Efectividad contra\ncomorbilidades:",
        "guid": "",
        "children": []
      },
      {
        "id": "1788",
        "parent": "0",
        "text": "- Topiramato: buena opción con\nmigrañas frecuentes",
        "guid": "",
        "children": []
      },
      {
        "id": "1789",
        "parent": "0",
        "text": "- Lamotrigina: estabilizador del\nánimo con trastorno bipolar I",
        "guid": "",
        "children": []
      },
      {
        "id": "1790",
        "parent": "0",
        "text": "- Consideraciones\nadicionales:",
        "guid": "",
        "children": []
      },
      {
        "id": "1791",
        "parent": "0",
        "text": "- Velocidad de titulación:",
        "guid": "",
        "children": []
      },
      {
        "id": "1792",
        "parent": "0",
        "text": "- Titulación lenta inapropiada con\nnecesidad urgente de control",
        "guid": "",
        "children": []
      },
      {
        "id": "1793",
        "parent": "0",
        "text": "- En mujeres en\nedad fértil evitar:",
        "guid": "",
        "children": []
      },
      {
        "id": "1794",
        "parent": "0",
        "text": "- Medicamentos que reducen eficacia\nde anticonceptivos orales",
        "guid": "",
        "children": []
      },
      {
        "id": "1795",
        "parent": "0",
        "text": "- Medicamentos con teratogenicidad\nconocida (valproato, topiramato)",
        "guid": "",
        "children": []
      },
      {
        "id": "1796",
        "parent": "0",
        "text": "- Pacientes con\nproblemas de\nadherencia:",
        "guid": "",
        "children": []
      },
      {
        "id": "1797",
        "parent": "0",
        "text": "- Beneficio con medicamentos\nde vida media larga",
        "guid": "",
        "children": []
      },
      {
        "id": "1798",
        "parent": "0",
        "text": "- Administración\nuna vez al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1799",
        "parent": "0",
        "text": "- Más indulgentes con\ndosis olvidadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1800",
        "parent": "0",
        "text": "- Carbamazepina o\noxcarbazepina:",
        "guid": "",
        "children": []
      },
      {
        "id": "1801",
        "parent": "0",
        "text": "- Olvidar dosis puede precipitar\ncrisis de rebote graves",
        "guid": "",
        "children": []
      },
      {
        "id": "1802",
        "parent": "0",
        "text": "## FALLO POR\nINTOLERABILIDAD",
        "guid": "",
        "children": []
      },
      {
        "id": "1803",
        "parent": "0",
        "text": "- Reemplazar con\nmonoterapia alternativa si:",
        "guid": "",
        "children": []
      },
      {
        "id": "1804",
        "parent": "0",
        "text": "- Fallo por falta de\ntolerabilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1805",
        "parent": "0",
        "text": "- Fallo por falta tanto de\ntolerabilidad como de eficacia",
        "guid": "",
        "children": []
      },
      {
        "id": "1806",
        "parent": "0",
        "text": "- A menos que intolerabilidad\nrelacionada con dosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1807",
        "parent": "0",
        "text": "- Siguiente medicamento no debe\nasociarse con mismo efecto adverso",
        "guid": "",
        "children": []
      },
      {
        "id": "1808",
        "parent": "0",
        "text": "- Recomendación de\nconsenso de expertos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1809",
        "parent": "0",
        "text": "- Preferible medicamento con\nmecanismo de acción diferente",
        "guid": "",
        "children": []
      },
      {
        "id": "1810",
        "parent": "0",
        "text": "- Si primer\nmedicamento fue\nefectivo:",
        "guid": "",
        "children": []
      },
      {
        "id": "1811",
        "parent": "0",
        "text": "- Considerar medicamento con mismo\nmecanismo pero menor probabilidad de\ncausar efecto adverso",
        "guid": "",
        "children": []
      },
      {
        "id": "1812",
        "parent": "0",
        "text": "- Ejemplo: si levetiracetam\ncontrola crisis pero falla por\nefectos conductuales",
        "guid": "",
        "children": []
      },
      {
        "id": "1813",
        "parent": "0",
        "text": "- Brivaracetam puede ser\nreemplazo apropiado",
        "guid": "",
        "children": []
      },
      {
        "id": "1814",
        "parent": "0",
        "text": "- Mejoría o resolución de efectos\nconductuales reportada en\nmayoría de pacientes",
        "guid": "",
        "children": []
      },
      {
        "id": "1815",
        "parent": "0",
        "text": "## FALLO POR\nFALTA DE EFICACIA",
        "guid": "",
        "children": []
      },
      {
        "id": "1816",
        "parent": "0",
        "text": "- Opciones\nigualmente\nefectivas:",
        "guid": "",
        "children": []
      },
      {
        "id": "1817",
        "parent": "0",
        "text": "- Monoterapia\nde reemplazo",
        "guid": "",
        "children": []
      },
      {
        "id": "1818",
        "parent": "0",
        "text": "- Terapia adyuvante",
        "guid": "",
        "children": []
      },
      {
        "id": "1819",
        "parent": "0",
        "text": "- Monoterapia de sustitución\nfavorecida cuando:",
        "guid": "",
        "children": []
      },
      {
        "id": "1820",
        "parent": "0",
        "text": "- Primer medicamento no bien\ntolerado o totalmente ineficaz",
        "guid": "",
        "children": []
      },
      {
        "id": "1821",
        "parent": "0",
        "text": "- Adultos mayores con\notros medicamentos",
        "guid": "",
        "children": []
      },
      {
        "id": "1822",
        "parent": "0",
        "text": "- Mujeres en edad fértil\ncontemplando embarazo",
        "guid": "",
        "children": []
      },
      {
        "id": "1823",
        "parent": "0",
        "text": "- Pacientes con\nproblemas de\nadherencia",
        "guid": "",
        "children": []
      },
      {
        "id": "1824",
        "parent": "0",
        "text": "- Restricciones\nfinancieras",
        "guid": "",
        "children": []
      },
      {
        "id": "1825",
        "parent": "0",
        "text": "- Proceso habitual\nde sustitución:",
        "guid": "",
        "children": []
      },
      {
        "id": "1826",
        "parent": "0",
        "text": "- Periodo de terapia combinada\nhasta que nuevo medicamento\nalcance dosis efectiva",
        "guid": "",
        "children": []
      },
      {
        "id": "1827",
        "parent": "0",
        "text": "- Primer medicamento retirado\ngradualmente después",
        "guid": "",
        "children": []
      },
      {
        "id": "1828",
        "parent": "0",
        "text": "- Excepciones (cambio\ninmediato posible):",
        "guid": "",
        "children": []
      },
      {
        "id": "1829",
        "parent": "0",
        "text": "- Cambio entre\nmedicamentos de misma\nfamilia:",
        "guid": "",
        "children": []
      },
      {
        "id": "1830",
        "parent": "0",
        "text": "- Carbamazepina, oxcarbazepina,\neslicarbazepina acetato",
        "guid": "",
        "children": []
      },
      {
        "id": "1831",
        "parent": "0",
        "text": "- Gabapentina y\npregabalina",
        "guid": "",
        "children": []
      },
      {
        "id": "1832",
        "parent": "0",
        "text": "- Levetiracetam y\nbrivaracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "1833",
        "parent": "0",
        "text": "- Un estudio sugiere factibilidad\nde cambio inmediato de:",
        "guid": "",
        "children": []
      },
      {
        "id": "1834",
        "parent": "0",
        "text": "- Bloqueadores de canales de sodio\n(fenitoína, carbamazepina,\noxcarbazepina) a lacosamida",
        "guid": "",
        "children": []
      },
      {
        "id": "1835",
        "parent": "0",
        "text": "- Opinión de\nexpertos\nrecomienda:",
        "guid": "",
        "children": []
      },
      {
        "id": "1836",
        "parent": "0",
        "text": "- Segundo agente en monoterapia\ndebería tener mecanismo diferente",
        "guid": "",
        "children": []
      },
      {
        "id": "1837",
        "parent": "0",
        "text": "## TERAPIA AÑADIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "1838",
        "parent": "0",
        "text": "- Preferida cuando:",
        "guid": "",
        "children": []
      },
      {
        "id": "1839",
        "parent": "0",
        "text": "- Primer medicamento bien\ntolerado y parcialmente efectivo",
        "guid": "",
        "children": []
      },
      {
        "id": "1840",
        "parent": "0",
        "text": "- Agente adicional no\nprobado en monoterapia",
        "guid": "",
        "children": []
      },
      {
        "id": "1841",
        "parent": "0",
        "text": "- Primer medicamento\nparcialmente efectivo y bien\ntolerado hasta dosis alta",
        "guid": "",
        "children": []
      },
      {
        "id": "1842",
        "parent": "0",
        "text": "- Posibilidad de reducir dosis\ndel primer medicamento",
        "guid": "",
        "children": []
      },
      {
        "id": "1843",
        "parent": "0",
        "text": "- Tendencia a mayor uso de terapia\ncombinada respecto a monoterapia\nalternativa (2005-2015)",
        "guid": "",
        "children": []
      },
      {
        "id": "1844",
        "parent": "0",
        "text": "- Consideraciones para\nterapia añadida:",
        "guid": "",
        "children": []
      },
      {
        "id": "1845",
        "parent": "0",
        "text": "- Evitar interacciones\nfarmacocinéticas negativas",
        "guid": "",
        "children": []
      },
      {
        "id": "1846",
        "parent": "0",
        "text": "- Inducción enzimática\npuede reducir eficacia",
        "guid": "",
        "children": []
      },
      {
        "id": "1847",
        "parent": "0",
        "text": "- Ejemplo: eficacia de perampanel\nreducida con inductor enzimático",
        "guid": "",
        "children": []
      },
      {
        "id": "1848",
        "parent": "0",
        "text": "- Inhibición enzimática menos\nproblemática con ajustes de dosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1849",
        "parent": "0",
        "text": "- Combinación de\nmedicamentos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1850",
        "parent": "0",
        "text": "- Mayor eficacia y tolerabilidad con\nmecanismos de acción diferentes",
        "guid": "",
        "children": []
      },
      {
        "id": "1851",
        "parent": "0",
        "text": "- Cohorte de Glasgow: bloqueador de\ncanales de sodio + levetiracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "1852",
        "parent": "0",
        "text": "- Mayor probabilidad de control de\ncrisis que otras combinaciones",
        "guid": "",
        "children": []
      },
      {
        "id": "1853",
        "parent": "0",
        "text": "- Brivaracetam con bloqueador\nde canales de sodio:",
        "guid": "",
        "children": []
      },
      {
        "id": "1854",
        "parent": "0",
        "text": "- Mayor tasa de respuesta que\notras combinaciones",
        "guid": "",
        "children": []
      },
      {
        "id": "1855",
        "parent": "0",
        "text": "- Favorable: incluir medicamento\ncon múltiples mecanismos",
        "guid": "",
        "children": []
      },
      {
        "id": "1856",
        "parent": "0",
        "text": "- Medicamentos con\nmecanismos similares:",
        "guid": "",
        "children": []
      },
      {
        "id": "1857",
        "parent": "0",
        "text": "- Posibles mayores efectos\nadversos y menor eficacia",
        "guid": "",
        "children": []
      },
      {
        "id": "1858",
        "parent": "0",
        "text": "- Combinación de dos\nbloqueadores de canales de\nsodio:",
        "guid": "",
        "children": []
      },
      {
        "id": "1859",
        "parent": "0",
        "text": "- Efectos adversos incluso con\nconcentraciones terapéuticas",
        "guid": "",
        "children": []
      },
      {
        "id": "1860",
        "parent": "0",
        "text": "- Ejemplo: lacosamida inferior en\neficacia y tolerabilidad combinada\ncon otro bloqueador",
        "guid": "",
        "children": []
      },
      {
        "id": "1861",
        "parent": "0",
        "text": "- Ejemplo notable: brivaracetam inefectivo\ncombinado con levetiracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "1862",
        "parent": "0",
        "text": "- Manejo de efectos\nadversos en combinación:",
        "guid": "",
        "children": []
      },
      {
        "id": "1863",
        "parent": "0",
        "text": "- Umbral bajo para reducir dosis\ndel primer medicamento",
        "guid": "",
        "children": []
      },
      {
        "id": "1864",
        "parent": "0",
        "text": "- Efectos no específicos\n(fatiga, sedación):",
        "guid": "",
        "children": []
      },
      {
        "id": "1865",
        "parent": "0",
        "text": "- Relacionados con carga\ntotal de fármacos",
        "guid": "",
        "children": []
      },
      {
        "id": "1866",
        "parent": "0",
        "text": "- Mitigados reduciendo dosis\ndel primer medicamento",
        "guid": "",
        "children": []
      },
      {
        "id": "1867",
        "parent": "0",
        "text": "##\nCOMBINACIONES\nSINÉRGICAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1868",
        "parent": "0",
        "text": "- Varias combinaciones con eficacia\nsinérgica en modelos animales",
        "guid": "",
        "children": []
      },
      {
        "id": "1869",
        "parent": "0",
        "text": "- Combinación ideal:",
        "guid": "",
        "children": []
      },
      {
        "id": "1870",
        "parent": "0",
        "text": "- Eficacia supra-aditiva",
        "guid": "",
        "children": []
      },
      {
        "id": "1871",
        "parent": "0",
        "text": "- Toxicidad infra-aditiva",
        "guid": "",
        "children": []
      },
      {
        "id": "1872",
        "parent": "0",
        "text": "- Pocas combinaciones\ndemostradas sinérgicas en\nhumanos",
        "guid": "",
        "children": []
      },
      {
        "id": "1873",
        "parent": "0",
        "text": "- Evidencia más sólida:\nlamotrigina + valproato",
        "guid": "",
        "children": []
      },
      {
        "id": "1874",
        "parent": "0",
        "text": "- Otras combinaciones\npotencialmente favorables:",
        "guid": "",
        "children": []
      },
      {
        "id": "1875",
        "parent": "0",
        "text": "- Lamotrigina +\nlevetiracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "1876",
        "parent": "0",
        "text": "- Cannabidiol +\nclobazam",
        "guid": "",
        "children": []
      },
      {
        "id": "1877",
        "parent": "0",
        "text": "- Lamotrigina +\ntopiramato",
        "guid": "",
        "children": []
      },
      {
        "id": "1878",
        "parent": "0",
        "text": "- Cenobamate\n+ clobazam",
        "guid": "",
        "children": []
      },
      {
        "id": "1879",
        "parent": "0",
        "text": "## OPTIMIZACIÓN EN EPILEPSIA\nRESISTENTE A FÁRMACOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1880",
        "parent": "0",
        "text": "- Aunque disminuye\nprobabilidad de control con\ncada medicamento fallido:",
        "guid": "",
        "children": []
      },
      {
        "id": "1881",
        "parent": "0",
        "text": "- Remisiones prolongadas reportadas\nen hasta 25% de pacientes",
        "guid": "",
        "children": []
      },
      {
        "id": "1882",
        "parent": "0",
        "text": "- Concentraciones plasmáticas ayudan a\ndeterminar dosis insuficiente",
        "guid": "",
        "children": []
      },
      {
        "id": "1883",
        "parent": "0",
        "text": "- Optimización de dosis\nparticularmente efectiva:",
        "guid": "",
        "children": []
      },
      {
        "id": "1884",
        "parent": "0",
        "text": "- Medicamentos que actúan\nsobre canal de sodio",
        "guid": "",
        "children": []
      },
      {
        "id": "1885",
        "parent": "0",
        "text": "- Fenitoína, carbamazepina,\noxcarbazepina, lamotrigina, lacosamida",
        "guid": "",
        "children": []
      },
      {
        "id": "1886",
        "parent": "0",
        "text": "- Consideraciones\nsobre concentración:",
        "guid": "",
        "children": []
      },
      {
        "id": "1887",
        "parent": "0",
        "text": "- Mayoría de medicamentos\ntienen rango terapéutico de\nreferencia sugerido",
        "guid": "",
        "children": []
      },
      {
        "id": "1888",
        "parent": "0",
        "text": "- Concentración necesaria varía\nenormemente entre individuos",
        "guid": "",
        "children": []
      },
      {
        "id": "1889",
        "parent": "0",
        "text": "- Algunos pacientes: control con\nconcentraciones menores al rango",
        "guid": "",
        "children": []
      },
      {
        "id": "1890",
        "parent": "0",
        "text": "- Otros requieren concentración\nmayor sin efectos tóxicos",
        "guid": "",
        "children": []
      },
      {
        "id": "1891",
        "parent": "0",
        "text": "- \"Concentraciones\nterapéuticas individuales\":\nreferencia para el paciente",
        "guid": "",
        "children": []
      },
      {
        "id": "1892",
        "parent": "0",
        "text": "- Formulaciones de\nliberación prolongada:",
        "guid": "",
        "children": []
      },
      {
        "id": "1893",
        "parent": "0",
        "text": "- Carbamazepina: evidencia de\nmejor eficacia y tolerabilidad",
        "guid": "",
        "children": []
      },
      {
        "id": "1894",
        "parent": "0",
        "text": "- Un reporte de mejor control con\nlamotrigina de liberación prolongada",
        "guid": "",
        "children": []
      },
      {
        "id": "1895",
        "parent": "0",
        "text": "- Administración 2 veces al día\nproduce concentración\nplasmática más estable:",
        "guid": "",
        "children": []
      },
      {
        "id": "1896",
        "parent": "0",
        "text": "- Reduce niveles valle asociados con\ndisminución del umbral convulsivo",
        "guid": "",
        "children": []
      },
      {
        "id": "1897",
        "parent": "0",
        "text": "- Reduce concentración pico\nasociada con efectos tóxicos",
        "guid": "",
        "children": []
      },
      {
        "id": "1898",
        "parent": "0",
        "text": "- En combinaciones de\ndos medicamentos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1899",
        "parent": "0",
        "text": "- Medicamento ineficaz debe ser\nreemplazado por uno nuevo",
        "guid": "",
        "children": []
      },
      {
        "id": "1900",
        "parent": "0",
        "text": "- Combinación de tres\nmedicamentos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1901",
        "parent": "0",
        "text": "- Preferible evitarla (riesgo\nde interacciones)",
        "guid": "",
        "children": []
      },
      {
        "id": "1902",
        "parent": "0",
        "text": "- Puede ser inevitable cuando\ncada medicamento ha tenido\neficacia parcial",
        "guid": "",
        "children": []
      },
      {
        "id": "1903",
        "parent": "0",
        "text": "- Cenobamate:",
        "guid": "",
        "children": []
      },
      {
        "id": "1904",
        "parent": "0",
        "text": "- Medicamento\nintroducido\nrecientemente",
        "guid": "",
        "children": []
      },
      {
        "id": "1905",
        "parent": "0",
        "text": "- Tasas excepcionales de control\nen epilepsia resistente",
        "guid": "",
        "children": []
      },
      {
        "id": "1906",
        "parent": "0",
        "text": "- Considerar antes de cirugía\npara pacientes no ideales para\nintervención quirúrgica",
        "guid": "",
        "children": []
      },
      {
        "id": "1907",
        "parent": "0",
        "text": "# CONCLUSIÓN SOBRE\nMEDICAMENTOS ANTIEPILÉPTICOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1908",
        "parent": "0",
        "text": "## PUNTOS CLAVE",
        "guid": "",
        "children": []
      },
      {
        "id": "1909",
        "parent": "0",
        "text": "### PRINCIPIOS\nGENERALES",
        "guid": "",
        "children": []
      },
      {
        "id": "1910",
        "parent": "0",
        "text": "- Muchos medicamentos\nantiepilépticos disponibles con\nventajas y desventajas específicas",
        "guid": "",
        "children": []
      },
      {
        "id": "1911",
        "parent": "0",
        "text": "- Algunos tienen eficacia adicional en\ntratamiento de comorbilidades:",
        "guid": "",
        "children": []
      },
      {
        "id": "1912",
        "parent": "0",
        "text": "- Migraña",
        "guid": "",
        "children": []
      },
      {
        "id": "1913",
        "parent": "0",
        "text": "- Trastorno bipolar",
        "guid": "",
        "children": []
      },
      {
        "id": "1914",
        "parent": "0",
        "text": "- Elección basada en:",
        "guid": "",
        "children": []
      },
      {
        "id": "1915",
        "parent": "0",
        "text": "- Perfil de eficacia\ndel medicamento",
        "guid": "",
        "children": []
      },
      {
        "id": "1916",
        "parent": "0",
        "text": "- Factores\nespecíficos del\npaciente",
        "guid": "",
        "children": []
      },
      {
        "id": "1917",
        "parent": "0",
        "text": "- Combinaciones deben evitar\ninteracciones farmacocinéticas y\nfarmacodinámicas desfavorables",
        "guid": "",
        "children": []
      },
      {
        "id": "1918",
        "parent": "0",
        "text": "### AVANCES\nRECIENTES",
        "guid": "",
        "children": []
      },
      {
        "id": "1919",
        "parent": "0",
        "text": "- Aprobación FDA de ganaxolona\n(indicación muy estrecha)",
        "guid": "",
        "children": []
      },
      {
        "id": "1920",
        "parent": "0",
        "text": "- Expansión de indicaciones de\nalgunos medicamentos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1921",
        "parent": "0",
        "text": "- Cannabidiol para\nesclerosis tuberosa",
        "guid": "",
        "children": []
      },
      {
        "id": "1922",
        "parent": "0",
        "text": "- Mayor conciencia de fisiopatología\nautoinmune subyacente",
        "guid": "",
        "children": []
      },
      {
        "id": "1923",
        "parent": "0",
        "text": "- Requiere inmunoterapia\npara manejo óptimo",
        "guid": "",
        "children": []
      },
      {
        "id": "1924",
        "parent": "0",
        "text": "- Mejor comprensión de\nfisiopatología permitirá terapia\nmás específica en el futuro",
        "guid": "",
        "children": []
      },
      {
        "id": "1925",
        "parent": "0",
        "text": "### FENOBARBITAL\nY PRIMIDONA",
        "guid": "",
        "children": []
      },
      {
        "id": "1926",
        "parent": "0",
        "text": "- Primidona: posible reacción\ntóxica aguda no relacionada\ncon fenobarbital",
        "guid": "",
        "children": []
      },
      {
        "id": "1927",
        "parent": "0",
        "text": "- Fenobarbital, primidona, fenitoína y\ncarbamazepina: potentes inductores\nenzimáticos hepáticos",
        "guid": "",
        "children": []
      },
      {
        "id": "1928",
        "parent": "0",
        "text": "- Uso prolongado de\nfenobarbital asociado con:",
        "guid": "",
        "children": []
      },
      {
        "id": "1929",
        "parent": "0",
        "text": "- Disminución de\ndensidad ósea",
        "guid": "",
        "children": []
      },
      {
        "id": "1930",
        "parent": "0",
        "text": "- Contracturas\nde Dupuytren",
        "guid": "",
        "children": []
      },
      {
        "id": "1931",
        "parent": "0",
        "text": "- Fibromatosis plantar",
        "guid": "",
        "children": []
      },
      {
        "id": "1932",
        "parent": "0",
        "text": "- Hombro congelado",
        "guid": "",
        "children": []
      },
      {
        "id": "1933",
        "parent": "0",
        "text": "### FENITOÍNA Y\nDERIVADOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1934",
        "parent": "0",
        "text": "- Cinética no\nlineal saturable:",
        "guid": "",
        "children": []
      },
      {
        "id": "1935",
        "parent": "0",
        "text": "- Concentración aumenta\ndesproporcionadamente con\nincrementos de dosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1936",
        "parent": "0",
        "text": "- Pequeños incrementos\nnecesarios cuando concentración\nestá en rango terapéutico",
        "guid": "",
        "children": []
      },
      {
        "id": "1937",
        "parent": "0",
        "text": "- Fosfenitoína (profármaco) puede\nadministrarse intramuscularmente\ncon absorción confiable",
        "guid": "",
        "children": []
      },
      {
        "id": "1938",
        "parent": "0",
        "text": "### BLOQUEADORES DE\nCANALES DE SODIO Y\nCRISIS GENERALIZADAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1939",
        "parent": "0",
        "text": "- Bloqueadores tradicionales pueden\nexacerbar crisis de ausencia y\nmioclónicas generalizadas:",
        "guid": "",
        "children": []
      },
      {
        "id": "1940",
        "parent": "0",
        "text": "- Fenitoína",
        "guid": "",
        "children": []
      },
      {
        "id": "1941",
        "parent": "0",
        "text": "- Carbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "1942",
        "parent": "0",
        "text": "- Oxcarbazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "1943",
        "parent": "0",
        "text": "- Evitar en epilepsia\ngeneralizada idiopática",
        "guid": "",
        "children": []
      },
      {
        "id": "1944",
        "parent": "0",
        "text": "- Otros medicamentos\ncon potencial similar:",
        "guid": "",
        "children": []
      },
      {
        "id": "1945",
        "parent": "0",
        "text": "- Gabapentina",
        "guid": "",
        "children": []
      },
      {
        "id": "1946",
        "parent": "0",
        "text": "- Pregabalina",
        "guid": "",
        "children": []
      },
      {
        "id": "1947",
        "parent": "0",
        "text": "- Tiagabina",
        "guid": "",
        "children": []
      },
      {
        "id": "1948",
        "parent": "0",
        "text": "- Vigabatrina",
        "guid": "",
        "children": []
      },
      {
        "id": "1949",
        "parent": "0",
        "text": "###\nCARBAMAZEPINA Y\nDERIVADOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1950",
        "parent": "0",
        "text": "- Carbamazepina induce su propio\nmetabolismo (titulación gradual)",
        "guid": "",
        "children": []
      },
      {
        "id": "1951",
        "parent": "0",
        "text": "- Alelo HLA-B1502 predictivo de\nerupción grave en personas de\nascendencia asiática",
        "guid": "",
        "children": []
      },
      {
        "id": "1952",
        "parent": "0",
        "text": "- Oxcarbazepina más\npropensa a causar\nhiponatremia que\ncarbamazepina",
        "guid": "",
        "children": []
      },
      {
        "id": "1953",
        "parent": "0",
        "text": "- Mayor riesgo en personas\nmayores con diuréticos",
        "guid": "",
        "children": []
      },
      {
        "id": "1954",
        "parent": "0",
        "text": "- Eslicarbazepina: vida media\nlarga en LCR (dosificación\noral una vez al día)",
        "guid": "",
        "children": []
      },
      {
        "id": "1955",
        "parent": "0",
        "text": "### VALPROATO Y\nETOSUXIMIDA",
        "guid": "",
        "children": []
      },
      {
        "id": "1956",
        "parent": "0",
        "text": "- Valproato: amplio espectro\ncontra todos los tipos de crisis\nfocales y generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1957",
        "parent": "0",
        "text": "- Mayor tasa de\nteratogenicidad entre\nantiepilépticos",
        "guid": "",
        "children": []
      },
      {
        "id": "1958",
        "parent": "0",
        "text": "- Evitar en mujeres\nen edad fértil",
        "guid": "",
        "children": []
      },
      {
        "id": "1959",
        "parent": "0",
        "text": "- Etosuximida: medicamento de elección\npara crisis de ausencia típicas",
        "guid": "",
        "children": []
      },
      {
        "id": "1960",
        "parent": "0",
        "text": "- Valproato igualmente\nefectivo pero con más\nefectos cognitivos adversos",
        "guid": "",
        "children": []
      },
      {
        "id": "1961",
        "parent": "0",
        "text": "###\nBENZODIAZEPINAS",
        "guid": "",
        "children": []
      },
      {
        "id": "1962",
        "parent": "0",
        "text": "- Posible desarrollo de\ntolerancia al efecto terapéutico",
        "guid": "",
        "children": []
      },
      {
        "id": "1963",
        "parent": "0",
        "text": "- Menos probable con clobazam\nque con clonazepam",
        "guid": "",
        "children": []
      },
      {
        "id": "1964",
        "parent": "0",
        "text": "### OTROS\nMEDICAMENTOS",
        "guid": "",
        "children": []
      },
      {
        "id": "1965",
        "parent": "0",
        "text": "- Felbamato: anemia aplásica e\ninsuficiencia hepática\nimprobables después de 1 año",
        "guid": "",
        "children": []
      },
      {
        "id": "1966",
        "parent": "0",
        "text": "- Gabapentina: baja\nbiodisponibilidad que\ndisminuye con dosis\ncrecientes",
        "guid": "",
        "children": []
      },
      {
        "id": "1967",
        "parent": "0",
        "text": "- Pregabalina: espectro\nestrecho contra crisis focales",
        "guid": "",
        "children": []
      },
      {
        "id": "1968",
        "parent": "0",
        "text": "- Puede exacerbar crisis mioclónicas y\nde ausencia generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1969",
        "parent": "0",
        "text": "- Lamotrigina:",
        "guid": "",
        "children": []
      },
      {
        "id": "1970",
        "parent": "0",
        "text": "- Aclaramiento\ndisminuido por\nvalproato",
        "guid": "",
        "children": []
      },
      {
        "id": "1971",
        "parent": "0",
        "text": "- Aclaramiento aumentado por\nestrógenos, embarazo e\ninductores enzimáticos",
        "guid": "",
        "children": []
      },
      {
        "id": "1972",
        "parent": "0",
        "text": "- Tiagabina: posibles episodios\nde estatus epiléptico no\nconvulsivo o encefalopatía",
        "guid": "",
        "children": []
      },
      {
        "id": "1973",
        "parent": "0",
        "text": "- Levetiracetam: único antiepiléptico\ncon evidencia Clase I para crisis\nmioclónicas generalizadas",
        "guid": "",
        "children": []
      },
      {
        "id": "1974",
        "parent": "0",
        "text": "- Brivaracetam: posiblemente\nmenos efectos secundarios\nconductuales que levetiracetam",
        "guid": "",
        "children": []
      },
      {
        "id": "1975",
        "parent": "0",
        "text": "- Zonisamida: vida media\nlarga (60 horas) reduce\nimpacto de dosis olvidada",
        "guid": "",
        "children": []
      },
      {
        "id": "1976",
        "parent": "0",
        "text": "- Lacosamida: posible\nprolongación del intervalo PR\ndependiente de dosis",
        "guid": "",
        "children": []
      },
      {
        "id": "1977",
        "parent": "0",
        "text": "- Vigabatrina: uso prolongado\nasociado con constricción\nirreversible del campo visual",
        "guid": "",
        "children": []
      },
      {
        "id": "1978",
        "parent": "0",
        "text": "- Rufinamida: valproato\nreduce su aclaramiento\n(iniciar a dosis más baja)",
        "guid": "",
        "children": []
      },
      {
        "id": "1979",
        "parent": "0",
        "text": "- Perampanel: vida media muy larga\njustifica dosificación una vez al día",
        "guid": "",
        "children": []
      },
      {
        "id": "1980",
        "parent": "0",
        "text": "- Cannabidiol: reduce aclaramiento del\nmetabolito activo de clobazam",
        "guid": "",
        "children": []
      },
      {
        "id": "1981",
        "parent": "0",
        "text": "- Cenobamate: requiere titulación\nmuy lenta para evitar reacciones\ncutáneas alérgicas",
        "guid": "",
        "children": []
      },
      {
        "id": "1982",
        "parent": "0",
        "text": "- Fenfluramina: actúa vía\nmecanismos serotoninérgicos",
        "guid": "",
        "children": []
      },
      {
        "id": "1983",
        "parent": "0",
        "text": "- Ganaxolona: esteroide neuroactivo para crisis\nasociadas con trastorno por deficiencia de quinasa\ntipo 5 dependiente de ciclina",
        "guid": "",
        "children": []
      },
      {
        "id": "1984",
        "parent": "0",
        "text": "### MANEJO DE\nFRACASO\nTERAPÉUTICO",
        "guid": "",
        "children": []
      },
      {
        "id": "1985",
        "parent": "0",
        "text": "- Privación de sueño y factores de estilo de vida:\ncausas comunes de fracaso aparente en\nepilepsia generalizada idiopática",
        "guid": "",
        "children": []
      },
      {
        "id": "1986",
        "parent": "0",
        "text": "- Tras fallo por\nefectos adversos:",
        "guid": "",
        "children": []
      },
      {
        "id": "1987",
        "parent": "0",
        "text": "- Reemplazo no debe asociarse con\nmismos efectos adversos",
        "guid": "",
        "children": []
      },
      {
        "id": "1988",
        "parent": "0",
        "text": "- Tras fallo por falta de\neficacia confirmada:",
        "guid": "",
        "children": []
      },
      {
        "id": "1989",
        "parent": "0",
        "text": "- Monoterapia de reemplazo y terapia\nadyuvante igualmente efectivas",
        "guid": "",
        "children": []
      },
      {
        "id": "1990",
        "parent": "0",
        "text": "- Monoterapia de\nsustitución:",
        "guid": "",
        "children": []
      },
      {
        "id": "1991",
        "parent": "0",
        "text": "- Requiere período de terapia combinada\nhasta alcanzar dosis efectiva",
        "guid": "",
        "children": []
      },
      {
        "id": "1992",
        "parent": "0",
        "text": "- Terapia adyuvante:",
        "guid": "",
        "children": []
      },
      {
        "id": "1993",
        "parent": "0",
        "text": "- Preferible si primer medicamento\nparcialmente efectivo y bien tolerado",
        "guid": "",
        "children": []
      },
      {
        "id": "1994",
        "parent": "0",
        "text": "- Combinaciones con diferentes\nmecanismos de acción:",
        "guid": "",
        "children": []
      },
      {
        "id": "1995",
        "parent": "0",
        "text": "- Mayor\nprobabilidad de\néxito",
        "guid": "",
        "children": []
      },
      {
        "id": "1996",
        "parent": "0",
        "text": "- Optimización de dosis:",
        "guid": "",
        "children": []
      },
      {
        "id": "1997",
        "parent": "0",
        "text": "- Particularmente efectiva para\nmedicamentos que actúan\nsobre canal de sodio",
        "guid": "",
        "children": []
      },
      {
        "id": "1998",
        "parent": "0",
        "text": "- En combinaciones:",
        "guid": "",
        "children": []
      },
      {
        "id": "1999",
        "parent": "0",
        "text": "- Medicamento ineficaz debe ser\nreemplazado para evitar polifarmacia",
        "guid": "",
        "children": []
      }
    ]
  },
  "node_count": 2000,
  "relations": [],
  "cross_references": [],
  "specialty": "Continuum",
  "folder": "- Entidades clínicas/Neurología",
  "filename": "Continuum. Actualización sobre medicamentos anticonvulsivos-2025",
  "id": "map_1643",
  "resolved_references": []
}